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ABSTRACT 
 
Carbamazepine (CBZ) is a first-line drug used for the treatment of partial and tonic-clonic 
seizures.  It is also the drug of choice for use during pregnancy and recommended for the 
treatment of seizure disorders in children.  CBZ possesses the ability to induce metabolism of 
drugs that are transformed in the liver and has the unique ability to induce its own metabolism by 
a phenomenon known as ‘auto-induction’, where its biological half-life is significantly reduced 
during chronic administration.  Large doses of CBZ are often prescribed as daily divided doses 
and this often adversely affects patient compliance, with the result that therapy is ineffective. 
 
A sustained-release dosage form containing CBZ is currently marketed as Tegretol® CR and the 
development of a generic product would provide patients with an equivalent product with a 
similar dosing frequency, at a reduced cost.  Therefore, the development of a polymer-based 
matrix tablet was undertaken to produce a sustained-release dosage form of CBZ, since these 
dosage forms are relatively simple and cheap to produce when compared to other, more 
sophisticated forms of sustained-release technology. 
 
Preformulation studies were conducted to assess moisture content of excipients and dosage forms 
and to identify possible incompatibilities between CBZ and potential formulation excipients.  
Furthermore, studies were conducted to assess the potential for polymorphic transitions to occur 
during manufacture.  Stability testing was conducted to assess the behaviour of the dosage forms 
under storage conditions that the product may be exposed to.  Dissolution testing was undertaken 
using USP Apparatus 3, which allowed for a more realistic assessment and prediction of in vivo 
drug release rates.  Samples were analysed using a high performance liquid chromatographic 
method that was developed and validated for the determination of CBZ. 
 
Tablets were manufactured by wet granulation and direct compression techniques, and the 
resultant drug release profiles were evaluated statistically by means of the f1 and f2 difference and 
similarity factors.  The f2 factor was incorporated as an assessment criterion in the design of an 
artificial neural network that was used to predict drug release profiles and formulation 
composition.  
A direct compression tablet formulation was successfully adapted from a prototype wet 
granulation matrix formulation and a number of formulation variables were assessed to establish 
their effect(s) on the dissolution rate profile of CBZ that resulted from testing of the dosage 
forms.  The particle size grade of CBZ was also investigated and it was ascertained that fine 
particle size grade CBZ showed improved drug release profiles when compared to the coarse 
grade CBZ which was desirable, since CBZ is a highly water insoluble compound.  Furthermore, 
the impact of the viscosity grade and proportion of rate-controlling polymer, viz., hydroxypropyl 
methylcellulose was also investigated for its effect on drug release rates.  The lower viscosity 
grade was found to be more appropriate for use with CBZ.  The type of anti-frictional agent used 
in the formulations did not appear to affect drug release from the polymeric matrix tablets, 
however specific compounds may have an effect on the physical characteristics of the polymeric 
tablets.   
 
The resultant formulations did not display zero-order drug release kinetics and a first-order 
mathematical model was developed to provide an additional resource for mathematical analysis 
of dissolution profiles.  An artificial neural network was designed, developed and applied to 
predict dissolution rate profiles for formulation.  Furthermore, the network was used to predict 
formulation compositions that would produce drug release profiles comparable to the reference 
product, Tegretol® CR.  The formulation composition predicted by the network to match the 
dissolution profile of the innovator product was manufactured and tested in vitro. The 
formulation was further manipulated, empirically, so as to match the in vitro dissolution rate 
profile of Tegretol® CR, more completely. 
 
The test tablets that were produced were tested in two health male volunteers using Tegretol® CR 
400mg as the reference product.  The batch used for this “proof of concept” biostudy was 
produced in accordance with cGMP guidelines and the protocol in accordance with ICH 
guidelines.  The test matrix tablets revealed in vivo bioavailability profiles for CBZ, however, 
bioequivalence between the test and reference product could not be established. It can be 
concluded that the polymeric matrix CBZ tablets have the potential to be used as a twice-daily 
dosage form for the treatment of relevant seizure disorders. 
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STUDY OBJECTIVES 
 
Carbamazepine is the drug of choice for the treatment of partial and tonic-clonic seizure 
disorders and is pharmacologically active within a narrow therapeutic range. 
Consequently, chronic drug therapy in epileptic patients requires steady-state plasma 
concentrations with minimal fluctuations below the minimum effective concentration or 
above the maximum toxic concentration, in order to prevent seizure relapse or the 
occurrence of adverse side effects. Sustained release delivery systems of carbamazepine 
with controlled and predictable release kinetics, when compared to conventional dosage 
forms are likely to result in improved drug therapy. The use of a sustained-release dosage 
form for the delivery of carbamazepine may therefore be appropriate and desirable to 
enhance patient adherence with the added advantage of minimal fluctuations in plasma 
carbamazepine levels.  Furthermore, the use of simple controlled release technology may 
result in the availability of a more cost-effective therapeutic option for epileptic patients 
stabilized on carbamazepine.  
 
The study objectives were: 
 
1. To develop and validate an isocratic high performance liquid chromatography 
(HPLC) system for the accurate and precise quantitation of carbamazepine. 
2. To develop a generic sustained-release dosage form of carbamazepine (400mg). 
3. To develop and assess the feasibility of using a direct compression manufacturing 
procedure for large-scale production of carbamazepine matrix tablets. 
4. To assess the key components that affect drug release from dosage forms 
produced by direct compression and therefore empirically optimise dosage form 
performance. 
5. To elucidate the mechanisms of drug release using mathematical descriptors. 
6. To develop and apply a neural network to the prediction of drug release profiles 
from general data and to predict formulation compositions for specific profiles. 
7. To investigate the in vivo performance of an optimised formulation in human 
subjects. 
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CHAPTER ONE 
CARBAMAZEPINE MONOGRAPH 
 
1. Carbamazepine (CBZ) 
1.1 Introduction 
 
A seizure can be defined as any interruption of consciousness that may be accompanied by 
changes in motor, sensory, or behavioral activity [1] or alternately as a recurrent paroxysmal 
disorder of cerebral function that is characterized by sudden, brief attacks of altered 
consciousness, motor activity, sensory phenomena, or inappropriate behavior caused by an 
abnormal excessive discharge of cerebral neurons [2].   
 
Seizures can be classified according to several different criteria and the specific symptom or 
set of symptoms, reflect the affected part of the cerebral hemisphere in which the seizure 
originates [2].  Approximately 1 to 2% of the world population is affected by some type of 
seizure disorder [2, 3], and seizures are the second most common neurological disorder after 
stroke that occurs in humans [3]. 
 
The principal mechanisms of action of 1 have been found to involve voltage-operated ion 
channels and/or inhibitory and excitatory synaptic function [3].  Following each action 
potential, voltage-dependant Na+ channels enter an inactive state, and antiepileptic 
compounds are thought to prolong the inactive state [3].  CBZ is an effective anti-convulsant 
agent, used for the control of major motor and psychomotor epilepsy [4] and is used in the 
treatment of simple and complex partial seizures, tonic-clonic seizures as well as partial with 
secondarily generalized tonic-clonic seizures [6]. In addition, CBZ is used in the treatment of 
trigeminal neuralgia and for the treatment of generalized as well as complex partial seizures 
[7].   
 
CBZ is most frequently prescribed for patients who have failed to respond to first-line anti-
convulsant therapy or for those who develop significant side-effects from other 
anticonvulsant agents [7].  Adult doses of up to 2g per day in divided doses may be 
prescribed [3,5,6,7] to patients receiving CBZ therapy.  Large doses often ensue as treatment 
progresses and this is principally due to the auto-inducing properties of CBZ [1,3,5,6]. CBZ 
therefore potentiates its own metabolism through the induction of hepatic cytochrome P450 
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hepatic enzymes, specifically the CYP3A4 system [1,6]. Up regulation of the CYP3A4 
system may also occur in the gut wall epithelial cells resulting in altered absorption in some 
patients. 
 
Sustained-release formulations allow for the prolonged action of an overall reduced dose and 
this is seen as beneficial from a patient compliance perspective.  Furthermore, the side-effect 
profile is improved through the constant delivery of drug throughout the gastro-intestinal 
tract.  Currently there are several commercially available sustained-release dosage forms and 
Tegretol® CR is the trade name of the product available in South Africa. 
 
CBZ exhibits anti-diuretic activity through increased levels of the anti-diuretic hormone and 
is not as effective in the treatment of absence seizures associated with a 3 second spike and 
wave in electroencephalograms or in myonclonic seizures of childhood or adolescence [5]. 
 
 
1.2 Physico-Chemical Properties 
1.2.1 Description 
 
Carbamazepine is an iminostilbene derivative that is structurally related to the tri-cyclic anti-
depressants [5, 7, 8] and contains the dibenzazepine ring system of the psychotherapeutic 
drug, imipramine (4).   
 
CBZ is known as 5-carbamyl-5H-dibenzo[b,f]azepine [1,5], 5H-dibenzo[b,f]azepine-5-
carboxamide [1,4,9, 10, 11), 5-carbamoyl-5H-dibenz[b,f]azepine [5, 12] or 2,3:6,7-
dibenzazepine-1-carboxylicacid,amide [13]. 
 
 
The chemical structure of CBZ and its metabolites are depicted in Figure 1.1. It has an 
empirical formula of C15H12N2O and possesses a molecular weight of 236.26 g/mol [1,5,9, 
10,12].   
 
 3
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Figure 1.1 The chemical structure of CBZ and the metabolic products of 
                         Biotransformation. 
 
 
The elemental composition of CBZ is approximately 76.25% carbon, 5.12% hydrogen, 
11.86% nitrogen and 6.77% oxygen [13].  CBZ is a white, yellowish white or off-white 
crystalline compound or powder which is odourless and either tasteless or possesses a slightly 
bitter taste [1,5,9,10,12,13,14] 
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1.2.2 Synthesis 
 
CBZ can be synthesized by treating iminodibenzyl in toluene with carbonyl chloride (COCl2) 
to give 95% of 5-chlorocarbonyl iminodibenzyl, which can be dissolved in carbon 
tetrachloride (CCl4).  The solution is further treated with 1,3-dibromo-5,5-dimethyl hydantoin 
and (PhCO2)2 to give 90% 5-chloro-carbonyl-10-bromoimino-dibenzyl.  The latter compound 
is dissolved in xylene and heated at about 100°C in an autoclave with the introduction of 
gaseous ammonia (NH3) to produce  85% 5-carbamoyl-5H-dibenzo[b,f]zepine [1,13].  A 
schematic representation of this process is shown in Figure 1.2 
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H
+
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Cl Cl N
C
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N
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Br
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NH3
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1,3-dibromo-5,5-dimethyl hydantoin / 
 (PhCOO)2
 
Figure 1.2  A schematic diagram showing the synthesis of CBZ. 
 
 
1.2.3 Dissociation Constant and Solubility data 
 
CBZ is highly insoluble in water at 25ºC [10,12,13,14] with a solubility of 170mg/l.  CBZ is 
a neutral molecule [5] and consequently, does not possess a dissociation constant and 
therefore is unlikely to be affected by variations in pH during dissolution testing, HPLC 
analysis and following oral administration in humans.  CBZ is readily soluble in non-polar 
solvents [12] and in propylene glycol [4,12,13] and is sparingly soluble in alcohol and in 
 5
acetone [10,12,13,14].  Knowledge of the solubility characteristics of CBZ, become pertinent 
during formulation development when selecting a granulating fluid for wet granulation (WG), 
as well as provides alternatives to modify the formulation composition and enables the 
formulator to assess dissolution profile data appropriately.  
 
1.3 Identifcation 
1.3.1 X-Ray Diffraction (XRD) 
 
XRD reveals that in the three dimensional structure of CBZ, the angle of flexure of α is 53º, 
the angle of annelation, β is 30º and the angle of torsion γ is 3º [1].  The centres between the 
benzene rings measured at 4.85Å is characteristic or typical of the tricyclic psychoactive 
drugs [1].  CBZ exhibits polymorphism and four polymorphic forms have been isolated with 
the β form or form III being the polymorph used in commercial pharmaceutical formulations 
[14-17].  Other polymorphic forms have been reported but appear to be extremely unstable. 
The properties of two major stable forms of CBZ and the dihydrate form are summarized in 
Table 1.1.  An example of an X-ray diffractogram is depicted in Figure 1.3. 
 
 
 
 
 
Figure 1.3 X-ray diffractogram of CBZ (β form) [62]. 
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Table 1.1 Properties of the polymorphic forms of CBZ 
Property  CBZ α Form CBZ β Form CBZ Dihydrate 
Behaviour on heating Melting point 
190 - 191°C 
Transition at 176°C 
to alpha form 
Dehydration from 30 to 85°C  
Transition into alpha form 
Water Content 
(Karl Fischer) 
<0.20% <0.20% 13.2%  
Shape of particles Narrow needles Ground crystals Needles 
 
 
1.3.2 Infrared Spectrum (IR) 
 
The characteristic absorption bands in the infrared absorption spectrum of CBZ are shown in 
Figure 1.4 [10, 13] and a summary of the description of the characteristic IR bands for CBZ 
are described in Table 1.2 [13] 
 
 
 
        Figure 1.4 IR absorption spectrum for CBZ [9]. 
                     
 
                    Table 1.2 IR band frequencies for CBZ. 
Frequency (cm-1) Assignments 
3470 NH2 
1680 C = O 
1600 shoulder and 1590 Aromatic C = C 
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Characteristic principal peaks for CBZ when determined in potassium bromide occur at 1678, 
1388 and 1594 cm-1. 
 
 
1.3.3 Colour Test 
 
CBZ can be identified using a colorimetric test in which ammonium molybdate is the reagent 
of choice and  yields a faint blue colour, with an analytical sensitivity of 1.0µg [13].  An 
additional colorimetric test procedure has been described, in which 0.1g of the drug is treated 
with 2mL nitric acid in a water bath for three minutes after which an orange colour becomes 
apparent [10].  
 
 
1.3.4 Crystal Test 
 
CBZ can also be identified using a crystallization test, where needle-shaped crystals are 
formed when CBZ is dissolved in a lead iodide solution [13]. 
 
 
1.3.5 Melting Range 
 
CBZ melts within a range between 187° and 193ºC [1,10,13]. 
 
 
1.3.6 Ultraviolet Absorption Spectrum 
 
The wavelength of maximum absorption  (λmax) of CBZ in a neutral methanolic solution is 
212nm with inflections at 236nm, 283nm and a minimum at 256nm [13]. A typical UV 
absorption spectrum of CBZ is shown in Figure 1.5.  A major peak has been reported to occur 
at 220nm and a smaller peak at 280-290nm [1].  The solvent in which the UV spectrum is 
developed may affect the specific UV absorbance of CBZ slightly.  For example, in ethanol a 
λmax  of 215nm was observed and a minimum at 257nm, when compared to the UV spectrum 
developed in a methanolic solution [13].   
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CBZ also exhibits an intense blue fluorescence when it is radiated with ultraviolet light at 
366nm [13]. 
 
 
 
                            Figure 1.5 UV absorption spectrum of CBZ in methanol [13]. 
 
 
1.4 Stability 
 
CBZ is a relatively stable compound when stored in the solid state at controlled room 
temperature [9,13].  CBZ should be stored in airtight containers [9,13,14] and protected from 
light [9,13].   
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1.5 Pharmacokinetics 
1.5.1 Absorption  
 
The absorption of CBZ following oral administration has been shown to be slow, erratic, 
unpredictable [1,3,6,12,18] but almost complete [3,20] with approximately 80 - 90% 
bioavailability [7,12,19]. CBZ is lipid soluble compound, which is slowly and variably 
absorbed from the GIT [7].  The slow and discontinuous absorption of CBZ from the gastro-
intestinal tract (GIT), and subsequent variable plasma concentrations, has been attributed in 
part to the slow dissolution rate of CBZ in GIT fluids [1,20] or through a rapid GIT transit 
time through the anti-cholinergic effects of CBZ [1].  It is therefore likely, that the absorption 
of CBZ is primarily dissolution-rate limited [12,18].   
 
It has been reported that concomitant administration of CBZ with food improves the 
absorption profile of CBZ [1,21] and food has been shown to assist patients to tolerate larger 
daily doses of CBZ [3].  Peak plasma concentrations are usually observed between 4 to 8 
hours following oral administration of CBZ [1,3,6,13].  However, peak levels can usually be 
reached approximately  3-6 hours after dosing but may be delayed by up to 24 hours after 
administration [7,12].  The amount of drug administered may also play a role in the 
bioavailability of CBZ [1].  A consistent delay in the time to reach Cmax, in addition to an 
apparent reduced absorption, has been reported when daily doses higher than 20-25 mg/kg 
were administered to either healthy volunteers or patients [1].  This may be a result of 
incomplete dissolution of CBZ in the GIT fluids [1]. As a result doses administered 3 or 4 
times daily may provide more effective and appropriate therapy as dissolution rates would 
not be the rate controlling step in absorption when the drug is delivered in divided doses [1]. 
 
 
1.5.2 Distribution 
 
CBZ is rapidly distributed into all tissues and fluids throughout the body [6,14] and is 
reported to have an apparent volume of distribution of approximately 1 to 2 L/kg [3, 7,12,18].   
 
Plasma protein binding has been reported to be approximately, 70 to 80% [1,3,5-7,12,14,18] 
when plasma concentrations of CBZ are between 5 – 30 µg/ml [1].  Albumin and α-1-acid-
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glycoprotein in plasma are the proteins implicated in protein binding of CBZ [5,18].  No 
significant displacement interactions of CBZ with other drugs have been reported [3].   
 
The concentration of CBZ in the cerebro-spinal fluid (CSF) appears to correspond to the 
concentration of unbound drug in plasma (6, 1, 22, 20), which is approximately 17 to 31% of 
the concentration in plasma [1, 5].   
 
CBZ distributes into amniotic fluid and the concentration has been reported to correspond to 
the free fraction of the drug in plasma [1,5]. CBZ concentrations in breast milk and saliva 
were found to be 60% and between 20-30%, respectively, of that found in plasma following 
oral dosing in healthy subjects [1,12].  A number of studies have shown that a correlation 
exists between the concentrations of CBZ found in plasma/serum and in saliva, where the 
reported correlation coefficient, r was 0.84 – 0.99 [1,20,22]. The salivary concentration of 
CBZ appears to accurately reflect the free fraction of CBZ in plasma/serum [1,22].  CBZ 
appears to enter red blood cells in only limited amounts [1] where erythrocyte/plasma ratios 
of 0.15 to 0.38 have been reported [1].  
 
 
1.5.3 Metabolism and Elimination 
 
The mammalian body does not possess a mechanism for the removal of unchanged 
exogenous lipophilic compounds, especially those of a neutral character [1].  Consequently 
biotransformation by hepatic metabolizing enzymes impart a more hydrophilic character to 
these lipophilic compounds so as to facilitate their excretion from the human body, via either 
the renal or hepatic-biliary system [1]. 
 
The potential sites for metabolic reactions of CBZ are the tricyclic skeleton and the 
carbamoyl side chain [1].  CBZ is extensively metabolized in the liver with only 1 – 3% of 
the administered dose excreted unchanged in the urine [1,5,12,24].  The clearance of CBZ is 
very much affected by changes in hepatic enzyme activity and plasma protein binding where 
concomitant treatment with compounds such as phenytoin, phenobarbital, primidone, 
ethosuximide and methsuximide accelerate the elimination of CBZ [1, 22] through hepatic 
enzyme induction, following prolonged exposure to CBZ.  However, changes in hepatic 
blood flow may not significantly affect CBZ clearance.  Four main metabolic pathways that 
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have been identified for the biotransformation of CBZ have been reported [1,5]. The primary 
metabolic pathway involves epoxidation of the 10,11 double bond at the azepine ring, which 
is the predominant pathway of metabolism in humans [6,18] and accounts for approximately 
20-40% of the removal of CBZ [11]. The other metabolic pathways include hydroxylation of 
the six-membered aromatic rings, N-glucuronidation of CBZ at the carbamoyl side-chain and 
substitution of the six-membered rings with a sulfur-containing group, that account for 
approximately 25%, 15% and 5% of the metabolic products respectively. 
 
Approximately 98 to 99% of an administered dose of CBZ is metabolized in the liver, mainly 
to the active metabolite CBZ 10,11-epoxide which possesses pharmacological activity 
comparable to the parent compound [1,7,12] and the  ratio of the of the active metabolite to 
the parent CBZ remains relatively constant [1].   
 
The elimination half-life of CBZ following a single oral dose of 200mg is reported to be 
between 30 to 40 hours, whereas after multiple dosing of the half-life is reduced to between 
10 to 20 hours [3,5,7,11,13,14,23].  The shorter reported elimination half-life may be 
attributed to the auto-induction of hepatic enzymes, a phenomenon confirmed for CBZ 
[6,13,14,18,22-24].  
 
The hepatic clearance of drugs that exhibit auto-inducing properties progressively increases 
with continued long term or chronic therapy [1,12].  The average clearance values reported 
for patients receiving CBZ chronically have been reported to be 0.064L/hr/kg [7] and 1.4 
ml/min/kg [5].    Single dose studies suggest that CBZ has a clearance value that is one-half 
to one-third that observed for patients on chronic therapy [7].  The induction of hepatic 
enzymes occurs within 3 to 5 days after initiation of therapy and continues for up to between 
21 to 28 days following the cessation of treatment.   
 
The hepatic cytochrome P450 isoforms  primarily responsible for the biotransformation of 
CBZ are CYP3A4  and CYP2C8 [6,18,24].  CYP3A4 present in the gut epithelial wall also 
plays an important role in drug metabolism [18,24].  In addition CBZ induces the metabolism 
of other drug molecules, metabolized by this isoform, such as the oral contraceptives [5,6,14].  
CBZ is also known to induce the CYP2C, CYP3A isoforms and also UDP-glucuronyl 
transferases [6]. Consequently CBZ also affects the metabolism of other drugs that utilize 
these enzymatic pathways, which is especially significant when considering therapy with 
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other anti-convulsant agents such as phenytoin [7].  The use of a controlled-release dosage 
form can overcome CYP3A4 heterogeneity issues in the gastro-intestinal tract and this may 
improve drug therapy.  
 
The metabolism of CBZ in children appears to be faster than in adults [14,22] and therefore 
larger and more frequent doses are required to achieve comparable therapeutic serum levels 
of the parent drug [22]. During pregnancy, serum levels of anticonvulsants tend to decrease 
where clearance may increase two-fold [25], thus necessitating dosage adjustment in order to 
keep patients seizure free, during gestation. 
 
 
1.5.4 Mode of Action (MOA) 
 
CBZ has a similar mechanism of action to phenytoin [3,11] and shows maximal activity 
against electroshock seizures when compared to chemically induced seizures [3,5].  CBZ has 
been shown to limit the repetitive firing of action potentials evoked by a sustained 
depolarization of mouse spinal cord or cortical neurons in culture [3,6].  This activity appears 
to be mediated by a slowing down of the rate of recovery of voltage-activated Na+ channels, 
from inactivation [6]. These effects are observed when CBZ concentrations are within 
therapeutic levels of between 6 and 12µg/ml in the cerebro-spinal fluid in humans [6].   
 
CBZ is presumed to suppress abnormal neuronal excitability [5], a mode of action postulated 
for the observed analgesia during the treatment of trigeminal neuralgia [5].  CBZ acts 
presynaptically to decrease synaptic transmission [3] and these effects probably account for 
its anti-convulsant activity.  CBZ is also thought to block cyclic-AMP mediated calcium 
influx associated with transmitter release [5] and is known to act as an adenosine receptor 
antagonist [3,5].   
 
Studies in animals have shown that CBZ has inhibitory effects on hippocampal discharges 
and inhibits the reticulo-thalamic and thalamo-cortical projections, which are implicated in 
tonic-clonic seizures [5]. 
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1.5.5 Clinical Indications 
 
CBZ was originally used for the treatment of trigeminal neuralgia [6,26] and is still employed 
for this purpose [5,14].  CBZ has been shown to be particularly effective for the treatment of 
complex partial psychomotor or temporal lobeseizures, as well as generalized convulsive or 
tonic-clonic seizures [5,6,11,26].  CBZ is one of the major anti-convulsant drugs and 
considered by many clinicians as the drug of first choice in the treatment of focal seizures and 
has been shown to be as effective as an anti-convulsant in the treatment of partial and grand-
mal seizures [5,22]. 
 
 
1.5.6 Therapeutic Levels and Dosing 
 
Divided daily doses of CBZ of 10 – 40 mg/kg/day are effective in children [5,14]. The dose 
of CBZ should be adjusted to the needs of the individual patient, when treating epilepsy, to 
achieve adequate control of seizure activity [14]. The effective total plasma concentration of 
CBZ is approximately 4 - 12µg/ml or 16 – 50 µmol/l for daily doses of 400 to 1200mg 
[11,12,14,22].   
 
Treatment of patients should begin with an initial low dose, to minimize side effects, after 
which the dose is gradually titrated upwards in increments of 100 to 200mg, every two weeks 
to a usual maintenance dose of between 0.8 – 1.2g per day, in divided does [11,14].  In adults, 
daily doses of between 1 – 2g may be required to control patients [3,14]. 
 
Control of seizures has been demonstrated with CBZ concentrations of between 20 - 
40µmol/l or 4.7-9.5μg/ml [5].  However there is a general agreement that the therapeutic 
level is usually 4 - 8µg/ml [3,5,6,14,26] although the overlap with both sub-therapeutic and 
toxic levels may be considerable [22]. In such cases some patients may complain of diplopia 
at drug levels above 7µg/ml whilst others can tolerate levels above 10µg/ml [3].   
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The frequent difficulty of finding a clear relationship between serum CBZ levels and clinical 
response is possibly explained by the presence of the active epoxide metabolite, which 
accumulates in serum to a variable extent depending on whether the patient is receiving 
single or multiple drug therapy [22].   
 
For the initial treatment of trigeminal neuralgia and pain syndromes administration of 100mg 
twice daily is recommended and this may be increased by 100mg every 12 hours until the 
pain is relieved, up to a maximum daily dose of 1.2g [25]. 
 
 
1.5.7 Drug Interactions 
 
CBZ induces its own metabolism as well as that of several other drugs thereby increasing the 
total body clearance of these compounds.  Drug interactions, in which CBZ is implicated, are 
almost exclusively related to the enzyme-inducing properties of the compound [3,11,12]  
 
Furthermore, CBZ metabolism is affected by the enzyme inducing or inhibitory effects of 
other drugs.  A list of some of the drugs for which clearance is increased as a result of the 
induction of metabolism due to CBZ administration is shown in Table 1.3 [3,5,6,14,25] 
 
 
      Table 1.3 Drug interactions with CBZ. 
Increased Metabolism due to CBZ 
inducing effect 
Drugs that decrease CBZ 
metabolism 
Phenytoin Valproic acid, Lamotrigine 
Ethosuximide Primidone 
Valproate Phenobarbitone 
Clonazepam Propoxyphene 
Clobazam Cimetidine 
Warfarin Diltiazem 
Theophylline Verapamil 
Doxycycline Isoniazid 
Cyclosporin Erythromycin 
Oestrogen Fluoxetine 
Haloperidol Triacetyloleandomycin 
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Phenobarbital, phenytoin and valproate may increase the metabolism of CBZ by inducing the 
enzyme, CYP3A4 [6], whereas propoxyphene is known to inhibit the metabolism and 
clearance of CBZ [3,5,6]. A list of some of the drugs that induce or inhibit the metabolism of 
CBZ is listed in Table 1.3 [6,3,5,6,14,25].   
 
Inhibition of CBZ metabolism can lead to increased plasma levels of CBZ such that 
concentrations rise into the toxic range and thus, these combinations are best avoided.  Of 
primary importance is the fact that therapeutic levels of CBZ may be reduced through 
enzyme induction into the sub-therapeutic range, which may lead to an increased seizure 
frequency in patients.   
 
CBZ may also decrease the ability of a patient to tolerate alcohol [5] and the concomitant 
administration of anti-depressant compounds may antagonize the anti-epileptic activity of 
CBZ by lowering the convulsive threshold [14]. 
 
 
1.5.8 Adverse Effects and Toxicity 
 
Dose dependant side-effects of CBZ, particularly in the initial stages of therapy are of a 
neurosensory nature and include drowsiness, general obtundity, ataxia, nystagmus, diplopia, 
headache [3,7,14,22]. Such side effects tend to become prominent at serum concentrations 
above 9µg/ml or 38µmol/l [7,22].   
 
Acute intoxication with CBZ may result in stupor or coma, hyperirritability, convulsions and 
respiratory depression [6].  Symptoms of overdosage with CBZ include erythema of the face, 
tremor, ataxia, psychomotor restlessness, changes in blood pressure, muscle hypotonia, 
dilatation of the pupils, unconsciousness and convulsions [3,5,14,25]. 
 
Gastro-intestinal side effects are usually mild and transient and include dry mouth, nausea 
and vomiting, abdominal pain, anorexia, diarrhea or constipation [5,14,25]. 
 
Hyponatraemia and water intoxication have been reported [3,5,14] due to an increased 
circulating anti-diuretic hormone level caused by CBZ [5]. 
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Occasional reports of blood disorders include agranulocytosis, aplastic anaemia, eosinophilia, 
persistant reversible leucopaenia , leucocytosis, thrombocytopaenia, splenomegaly, 
pneumonitis, abnormalities of liver and kidney function and cholestatic jaundice have been 
reported and are rare [14].   
 
Serious and even irreversible skin disorders including erythroderma, exfoliative dermatitis, 
Stevens-Johnson syndrome, systemic lupus erythematosus-like syndromehave been reported 
[5,6,14]. 
 
Severe over-dosage may result in adverse events primarily associated with the CNS and may 
result in stupor, coma, convulsions (at very high doses), respiratory depression and death. 
 
CBZ should not be prescribed to patients with atrioventricular heart block, blood disorders or 
bone marrow depression and porphyria [25] and should be used with caution in patients with 
a history of liver or renal disease and in the elderly [25].  Cross-hypersensitivity may occur in 
those patients who are allergic to the tricyclic anti-depressants [25]. 
 
 
1.6 CONCLUSION 
 
CBZ is prescribed in large doses especially during chronic therapy as a result of the auto-
inducing effect of CBZ on liver enzyme that result in decreased plasma levels, with the 
subsequent need to dose as much as 1.2g on a daily basis in some patients.  The need for 
large daily doses requires that patients receiving CBZ chronically must use dosage regimens 
with frequent dosing intervals.  From a practical and patient-compliance perspective, this is 
not desirable since chronic therapy relies on the maintenance of a steady state plasma 
concentration and the omission of doses may disrupt plasma levels, which may manifest as a 
seizure episode in patients.  The application and use of sustained-release dosage forms, 
decreases the dosing frequency and has the potential to enhance patient compliance and 
adherence to the dosage regimen. 
 
CBZ can exhibit slow and erratic absorption leading to fluctuating systemic drug levels.  The 
use of a sustained-release delivery dosage form would reduce the peak to trough fluctuations 
usually associated when conventional immediate release dosage forms are administered 
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chronically and where sharp increases and decreases in blood levels are observed.  
Conventional dosage forms deliver large quantities of API immediately in the GIT resulting 
in the initial spike and decline of blood drug levels that can be observed with conventional 
therapy.   
 
Furthermore the rapid increase and decrease in blood levels of CBZ can result in 
concentration levels superceding the maximum therapeutic or minimum toxic concentration 
of a particular drug.  This can result in undesirable adverse drug-related events where the 
plasma concentrations may fall below the minimum effective concentration, resulting in 
ineffective therapy.    
 
The clinical use of sustained-release dosage forms can enhance anti-epileptic therapy through 
a combination of improving patient compliance by reducing the dosing frequency and 
optimizing drug delivery through controlled and predictable release of CBZ. Therefore, 
attempts were made to develop and assess a generic CBZ sustained release dosage form that 
was equivalent to a commercially available sustained release CBZ dosage form, viz., 
Tegretol® CR. 
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CHAPTER TWO 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC (HPLC) ANALYSIS OF CBZ 
 
2.1 Method Development 
2.1.1 Introduction 
 
High performance liquid chromatography (HPLC) is an analytical tool used for the separation 
and quantitation of compounds based on their physico-chemical properties [27-30].  HPLC can 
be used for the analysis of compounds such as macromolecules or thermolabile substances that 
cannot be analysed using gas chromatography (GC) since HPLC analysis can be conducted at 
room temperature [31].  Liquid chromatographic techniques that have been developed and that 
are currently used include reversed-phase, ion-exchange, hydrophilic interaction, hydrophobic-
interaction and size-exclusion chromatography [32].  Reversed-phase HPLC (RP-HPLC) allows 
for the separation of compounds according to their polarity, with relatively non-polar molecules 
having a high affinity for a non-polar stationary phase. Therefore, these compounds are retained 
for longer periods on a column, whereas compounds of high polarity will elute more rapidly 
from the column in the mobile phase [31,50].  HPLC makes use of the fact that a particular 
solute will display unique retention characteristics under specified conditions.  Therefore, an 
analyte will elute at a specific time depending on the type of column used, the nature of the 
mobile phase in addition to the flow rate of the mobile phase.  In validated systems used for 
quantitation, these unique characteristics provide a means of identifying a compound of interest 
under specified conditions.  Consequently different HPLC methods exist for the analyses of 
pharmaceutical compounds and the ultimate method adopted for analysis will depend on the 
physico-chemical properties of the analyte of interest. RP-HPLC is the most widely used liquid 
chromatographic procedure for the analysis of drug molecules [33]. 
 
During analysis, the sample components partition to differing degrees between a stationary and 
mobile phase, based on their inherent physico-chemical properties [39].  The nature of the 
physico-chemical interaction between the mobile and stationary phase allows solute molecules to 
emerge from the column in individual component zones or bands, which are then monitored as a 
function of an appropriate detector response versus time [39]. 
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HPLC stationary phases include adsorbent materials such as silica, polymeric substrates, 
alumina, styrene-divinylbenzene, methacrylate and graphitized carbon, of which silica is the 
most commonly used for analytes of molecular weight < 1000 g/mol [32].  The physical structure 
of the stationary phase comprises molecules that are covalently bound to the surface of the silica 
particles forming a uniform monomolecular layer, which is chemically stable [31-33].  This 
binding process, called silanisation, results in a variety of stationary bonded phases and produces 
long chain aliphatic silane groups, of which several derivatives are possible [31,32].  The variety 
of stationary phases provides the analyst with a range of options to solve potentially challenging 
analytical problems [31,32]. 
 
The quantitative analysis of carbamazepine (CBZ) in plasma has been achieved using a variety 
of techniques and methods including ultraviolet spectrophotometry following extraction [28,30], 
visible spectrophotometry, TLC and fluorometry, derivatised and underivatised gas-liquid 
chromatograpy, selected ion monitoring as well as HPLC [28,30].  Analytical methods that have 
been reported for the determination of CBZ in pharmaceutical dosage forms include HPLC with 
UV detection and UV spectrophotometry [34-37]. 
 
Based on the analytical methods described in the literature as well as the availability of 
equipment in our laboratory, HPLC with UV detection was selected as a potential method of 
analysis for carbamazepine in dosage forms.  Analytical methods reported in the literature for the 
determination of CBZ, either alone or in combination with related compounds such as other anti-
convulsants, metabolites or structural analogues are summarized in Table 2.1.   
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Table 2.1 Published HPLC methods used for the analysis of carbamazepine (CBZ) in 
biological fluids and dosage forms 
Stationary Phase Mobile Phase λ 
(nm) 
Internal 
Standard 
Reference 
Spherix® C18 MeOH:Water  45:55 254 * 34 
Spherisorb® ODS 
2 
MeCN:MeOH:potassium phosphate 
(0.05M; pH6.9) 
* * 41 
C18 MeOH:Water 50:50 * * 45 
Chrompak® 
column packed 
with LiChrosorb 
 
* 
 
* 
 
* 
46 
Partisil® C18 MeOH:Water 55:45 254 5-(-p-
methylphenyl)-5-
Phenylhydantoin 
35 
Lichrocart® C18 MeCN:Water 30:70 * * 47 
Bondsphere® MeCN:Ammonium acetate buffer 
(0.05M) 20:80 
* * 48 
Bondapak® C18 MeCN:EtOH:Water 25:25:50 285 * 36 
Nucleosil® C8 MeOH:Water 75:25 285 * 37 
Bondapak® C18 
MeOH (450ml) diluted to 1L with 
phosphate buffer (0.002M, pH 7.8), then 
filtered (0.5 µm pore size) and degassed 
under vacuum. 
 
* 
 
* 
49 
* Not Reported   MeOH: Methanol, EtOH: Ethanol, MeCN: Acetonitrile
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2.1.2 High Performance Liquid Chromatography (HPLC) 
 
HPLC is a technique most commonly used for the quantitation of drugs in pharmaceutical 
formulations [38].  HPLC involves the simultaneous separation and quantitation of compounds 
in a sample matrix that has been introduced onto a chromatographic column, packed with a 
stationary phase [39].  Separation is achieved by the use of a stationary phase and a solvent, 
termed the mobile phase, that is allowed to flow through the stationary phase [38,39] at a set 
flow rate, for isocratic chromatography.   
 
During analysis, the sample components partition to differing degrees between a stationary and 
mobile phase, based on their inherent physico-chemical properties [39].  The nature of the 
physico-chemical interaction between the mobile and stationary phase allows solute molecules to 
emerge from the column in individual component zones or bands, which are then monitored as a 
function of an appropriate detector response versus time [39]. 
 
 HPLC separations, to a large extent, include liquid-liquid chromatography (LLC), liquid-solid 
chromatography (LSC), size exclusion chromatography, normal, RP-HPLC, ion exchange and 
affinity chromatography.  In reversed-phase chromatography, the stationary phase is usually a 
hydrophobic bonded phase, such as an octadecylsilane or octylsilane and the mobile phases are 
usually polar solvents such as water or mixtures of water and water-miscible organic solvents 
such as methanol, acetonitrile, THF or isopropanol [40].  Nonionic, ionic and ionisable 
compounds can be separated using a single column and mobile phase, with or without added 
buffer salts, using bonded-phase columns that are reproducible and relatively stable [40].   
 
Only one solute was being investigated, thus the use of an isocratic system was deemed 
appropriate for the development of an HPLC analytical method.  For samples in which different 
solutes are present, it may be advantageous to use gradient elution where the composition of the 
mobile phase is altered during the separation, usually by blending two or more solvents with 
different eluting powers in continually changing proportions [41] whereas in isocratic systems, a 
mobile phase of constant composition is used to effect a separation. 
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In the case of an HPLC system that may not be accurate or precise, the use of an internal 
standard improves accuracy, by correcting for variable injection volumes of a test solution.  A 
solution containing a fixed amount of internal standard is added to the sample in a precisely 
measured volume.  Any subsequent losses of the analyte sample are accounted for, since losses 
of the analyte will be mirrored by losses of the internal standard [50].  A chemical substance may 
be used as an internal standard if it is related to the analyte of interest, is stable and elutes as 
close as possible to the analyte of interest whilst is still adequately resolved from the analyte and 
any possible excipients that may be present in the sample matrix being analysed [50].   
 
 
2.2 Experimental 
2.2.1 Reagents                                                
 
All chemicals used were at least of analytical reagent grade.  Acetonitrile (HPLC grade, distilled 
in glass) was purchased from Burdick and Jackson (Muskegon, MI,  USA) and Romil 
(Cambridge, IL, USA).  Analytical or reagent grade sodium hydroxide pellets (BDH Chemicals, 
Poole, UK) and ortho-phosphoric acid (85% w/w) (Pal Chemicals, Johannesburg, South Africa 
and Merck Industries, Johannesburg, South Africa) were used to prepare buffers for the mobile 
phase preparation. 
  
Two grades of CBZ, a coarse grade (CG) and fine grade (FG) were generously donated by 
Noveon Pharma (Raubling, Germany).  HPLC grade water was used for the preparation of all 
relevant solutions.  Water was purified using  a Milli-Ro® - 15 Water Purification System 
(Millipore, Bedford, MA, USA), which consists of a Super-C® carbon cartridge, two Ion-X® 
ion-exchange cartridges and an Organex-Q® cartridge.  The water was filtered through a 0.22µm 
Millipak® stack filter prior to use.   
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2.2.2 Preparation of Stock Solutions 
 
All stock solutions were prepared using a standard procedure.  Approximately 250mg of CBZ 
was accurately weighed transferred into a 1L A-grade volumetric flask.  CBZ was dissolved in 
approximately 30 to 50 ml of acetonitrile and the solution was made up to volume with HPLC 
grade water.  Calibration standards spanning the concentration range of 10, 20, 30, 40, 60, 80 and 
180 µg/mL were prepared by appropriate dilution of the stock solution, where aliquots were 
withdrawn from the stock solution using A-grade bulb pipettes, according to the concentration 
required, and made up to volume in a 50 ml volumetric flask.  A stock solution of the internal 
standard, protriptyline (PRO) was prepared by accurately weighing 250mg of the compound.  
PRO was quantitatively transferred to a 1L A-grade volumetric flask and was made up to volume 
with HPLC grade water.  Calibration and test samples were spiked with 1 ml of PRO at a 
concentration level of 250µg/ml prior to sample manipulation and analysis. 
 
2.2.3 Preparation of Buffer Solution 
 
0.05 M buffer solutions were prepared by pipetting 3.42ml of 85% v/v phosphoric acid into a 1L 
A-grade volumetric flask and making up to volume with HPLC grade water.  The pH of the 
solution was adjusted to pH 3 using sodium hydroxide pellets. A model GLP 21 Crison pH meter 
(Crison, LASEC, South Africa) was used to monitor the pH. 
 
2.3 HPLC System 
2.3.1 Chromatographic Hardware 
 
The modular HPLC system comprised of a Waters Model 6000A (Waters Associates, Milford, 
MA, USA) solvent delivery system module, a Waters Intelligent Sample Processor (WISP) 
Model 710B autosampler (Waters Associates, Milford, MA, USA), a Spectrochrom UV-100 UV 
detector (Linear instruments Corporation) and a Perkin Elmer 561 strip chart recorder (Hitachi, 
Japan).  
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2.3.2 Column Selection 
 
Silica gel and ODS silica gel are two of the most commonly used stationary phase packing 
materials used for normal and reversed-phase chromatographic applications, respectively.  
However, there are a variety of normal and reversed-phase packings available, most of which are 
based on chemical modification of the silica gel surface, although in recent years stationary 
phases which have organic polymeric backbones have also become available [50].   
 
For a neutral compound such as CBZ, the balance between the polarity of the mobile phase and 
lipophilicity of the molecule will determine the retention time on an HPLC column.  The pH of 
the mobile phase will theoretically, have no effect on retention times [50] except, perhaps in the 
case, where use of an internal standard becomes necessary and where the retention time of the 
internal standard may be affected by pH, depending on the specific physico-chemical properties 
of the molecule selected.  The reversed-phase retention mechanism is still not completely 
understood [41] and a possible explanation  is that the hydrophobic surface of the bonded phase 
extracts the less polar constituent of the mobile phase to form a layer at the silica-mobile phase 
interface [41].  However, it has been proposed that there may be several different mechanisms 
operating simultaneously [41].    Normally, in reversed-phase chromatography more polar 
solutes will elute at shorter retention times with lipophilic compounds being retained for longer 
periods and manipulation of the mobile phase polarity by using modifiers such as methanol and 
acetonitrile, can allow manipulation of retention times of the analytes of interest, thus effecting a 
separation.   
 
Silica gel is an adsorbent stationary phase and most frequently used for HPLC applications.  It is 
sold under a variety of brand names such as Lichrosorb®, LiChrospher®, Nucleosil® and Partisil® 
amongst others.  Silica gels with a relatively large specific surface area 950-450m2/g, a large 
pore volume of 0.7-1.2 ml/g, and a moderate mean pore diameter, of 50-250Å are generally used 
[42].  Many types of columns are commercially available and factors such as silica particle size, 
surface area and shape become important in terms of their application for the analysis of APIs. 
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Reversed-phase C18 columns have been most frequently used for the analysis of CBZ owing to 
their high degree of lipophilicity.  Therefore, a reversed-phase C18 column was chosen as the 
preferred stationary phase for these analytical studies.  Many C18 columns were assessed for their 
suitability for the analysis of CBZ, and a Prodigy® 250 x 4.6mm-i.d column (Phenomenex, 
Torrance, CA, USA) with 5µm-particle packing was adopted as the stationary of choice phase 
for analysis.  The separation of the analytes of interest on this stationary phase was efficient and 
resulted in well-resolved peaks. 
 
2.4 Mobile Phase Selection 
2.4.1 Factors Affecting the Choice of Mobile Phase 
 
In addition to the stationary phase, the mobile phase composition plays a significant role in the 
elution or retention of the compounds of interest.  HPLC is a multi-faceted process with the 
appropriate interplay of various parameters being vital during analysis, to produce a desired 
separation.  Parameters such as the physico-chemical properties of an analyte of interest, the type 
of stationary phase chosen in addition to the mobile phase selected for analysis play a combined 
role in effecting a suitable separation, and manipulation of one or all of these factors to optimize 
a separation and improve the chromatographic behaviour of the compound under investigation, 
may be necessary.    
 
The important characteristics of solvents for use in HPLC analysis include the need for high 
purity, immiscibility with the stationary phase, absence of reactivity towards an adsorbent, low 
boiling point and low viscosity [43].  Mobile phases of extreme pH must also be avoided, i.e., 
pH<3 and pH>9, as these may damage the bonded phase of the silica backbone or lead to 
dissolution of the silica [41]. However newer stationary phases are reported to be more resilient 
to extreme pH conditions [41].  The eluents used in reversed-phase chromatography with bonded 
non-polar stationary phases are generally polar solvents or mixtures of polar solvents, such as 
acetonitrile, methanol and/or water [42].  Of particular importance, is the fact that the mobile 
phase should be pure and free from impurities, dust, particulate matter and dissolved air [41,43].  
Particulate matter can interfere with the pumping action of the solvent delivery module or pump 
and this can cause damage to the seals and/or check valves, collect on the top of the column 
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causing subsequent column blockages thereby promoting chromatographic anomalies such as 
changes in retention time and poor peak resolution [44].   
 
All potential interference can be successfully avoided by adequate filtration of solutions prior to 
use in HPLC systems.  Dissolved air may collect in the pump or the detector cell and cause an 
erratic response in the detector or an irregular pumping action, which may result in an unstable 
flow rate, once again resulting in chromatographic anomalies.  The effect of dissolved gases can 
be prevented by degassing of solvents under vacuum prior to use or by use of an online 
degassing unit, which use ultrasonic vibrations or helium sparges to remove dissolved air or 
suspended air bubbles in a mobile phase [43]. 
 
Furthermore, an important factor to consider is the UV absorbance and UV cut-off values for 
solvents to be used in HPLC mobile phases [43], where it becomes unacceptable to use solvents 
with a similar absorbance as the solute that is to be analysed.  Acetonitrile and methanol products 
have UV cut-off values at 210nm and some acetonitrile products have UV cut-off at 190nm [43] 
and are commonly used solvents in the mobile phases that have been used for the analysis of 
CBZ and that are summarized in Table 2.1.     
 
 
2.4.2 Mobile Phase Analysis 
 
The initial mobile phase selected for evaluation was based on the methods in the literature and 
summarized in Table 2.1.  The mobile phase consisted of acetonitrile and phosphate buffer (pH 
3; 0.05M).  Since CBZ is a neutral drug, pH and molarity effects of the mobile phase are unlikely 
to have an effect with respect to its retention time.  However, the effect of pH and molarity 
becomes relevant when selecting an internal standard and optimizing the separation of the 
internal standard relative to the analyte of interest.   
 
The intended use for the analytical method was to analyse samples collected from dissolution 
studies conducted during formulation development of a sustained release CBZ dosage form.  
Consequently, the retention times of CBZ and the IS would have to be fairly short, yet provide 
 27
an effective separation of CBZ and the IS with adequate resolution, for purposes of quantitation 
of CBZ that had been released from the dosage form. 
  
Therefore, the effects of buffer molarity, pH and type as well as amount of organic modifier used 
in the mobile phase, were assessed for their effects on retention time and resolution of the 
compounds of interest.  The wavelength selected for these studies was 224nm and the detector 
sensitivity was set at an AUFS setting of 0.1.  The mobile phase flow rate was set at 1.0ml/min.   
                   
 
2.4.3 Buffer Molarity 
 
The effect of buffer molarity was investigated at five different molar concentrations ranging in 
strength from 0.01M to 0.1M.  The primary objective of these studies was to investigate the 
effect of buffer molarity on the retention time (RT) of potential internal standards such as 
protriptyline HCl (PRO), imipramine HCl (IMP) and cyclizine HCl  (CYZ) since the retention 
time of CBZ is unaffected by the molarity of the buffer as shown in Figure 2.1.  In general, an 
increase in buffer molarity resulted in longer retention times for the internal standards tested, 
whereas a constant retention time of approximately 4.6 minutes was observed for CBZ.   
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Figure 2.1 The effect of buffer molarity on the retention times of CBZ, PRO, 
                         IMP and CYZ. 
 
 
The peaks of interest were sharp, well-resolved and exhibited no tailing except for CYZ, which 
due to its basic nature produced broad peaks and thus was considered unacceptable for use as an 
internal standard for these studies.  Both PRO and IMP exhibited excellent  peak resolution and 
PRO was selected for further use.  The final buffer concentration selected for the analysis of 
CBZ was 0.05M due to the favourable retention time of both CBZ and the selected internal 
standard, PRO, and the resolution between these compounds.   
 
 
 2.4.4 Buffer pH 
 
The effect of buffer pH was investigated empirically over the pH range of 3 – 7 and more 
specifically at pH values of 3, 4, 5, 6 and 7.  The RT of CBZ was unaffected by buffer pH due to 
its neutral nature, however the RT for the tricyclic compounds considered for use as an IS 
showed a considerable increase in RT, with increasing pH.  Due to their basic nature, these 
compounds tend to become less ionized as pH increases, therefore they become less polar, thus 
exhibiting an increased preference for bonding to the stationary phase as shown in Figure 2.2.   
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Figure 2.2 The effect of buffer pH on the retention times of CBZ, PRO, IMP and 
                          CYZ. 
 
 
In addition, as the pH of the buffer increased from pH 4 to pH 7, the resolution between CBZ 
and the internal standards was compromised and considerable overlapping of peaks was 
observed, making quantitation difficult.  In contrast, when a buffer of pH = 3.0 was used, all 
peaks were well-resolved, sharp and symmetrical except for cyclizine which showed tailing due 
to its prolonged retention on the column.  It has been reported that compounds with a pKa > 8 
produce better peak shapes at pH 3.0, and thus this buffer pH was selected for further use in 
these studies. 
 
 
2.4.5 Organic Modifier 
 
Mobile phases for reversed-phase chromatography usually consist of an aqueous component, 
with or without a buffer in combination with an organic modifier such as methanol or 
acetonitrile.  As CBZ is lipophilic, the use of an organic modifier would affect its retention time 
and thus the effect of varying proportions of organic modifier, in the mobile phase, on retention 
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times were investigated.  The organic modifier used in these studies was acetonitrile and mobile 
phase compositions of 30% v/v, 35% v/v, 40% v/v and 45% v/v of acetonitrile were evaluated. 
 
An increase in acetonitrile content resulted in a decrease in the retention time for all compounds 
as shown in Figure 2.3.  As expected, mobile phase compositions of 30% v/v and 35% v/v 
acetonitrile revealed longer retention times than those containing 40% v/v and 45% v/v.  In 
addition, peak resolution was poor and thus quantitation was not effectively possible at mobile 
phase compositions of 30 and 35% v/v acetonitrile. 
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                 Figure 2.3  The effect of the organic modifier content on the retention 
                                                times of CBZ, PRO, IMP and CYZ. 
 
 
A summary of the effects of mobile phase composition on retention time, peak shape and 
resolution is shown in Table 2.2.  A mobile phase composition of 45% v/v: 55% acetonitrile: 
phosphate buffer (pH = 3; 0.05M) was selected for further studies.   
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Table 2.2 The effects of altering organic modifier content on retention time, peak shape   
                 and resolution. 
 RT (minutes) Resolution Peak Shape 
% Acetonitrile CBZ PRO IMP CYZ   
30  
10.24 
 
1.7 
 
12.6 
 
6.6 
Peaks were not distinctly 
resolved 
Peaks overlap.  
CYZ peak is broad 
and showed tailing 
35  
6.44 
 
5.8 
 
6.3 
 
3.8 
Peaks were not distinctly 
resolved 
Peaks overlap.  
CYZ peak is broad 
and showed tailing 
40  
4.44 
 
3.4 
 
3.6 
 
2.6 
Peaks were well resolved 
except for Cyclizine HCl 
Peaks were sharp, 
no tailing.  CYZ 
peak broad and 
showed tailing 
45     Peaks were well resolved Peaks were sharp, 
no tailing. 
 
 
2.4.6 Flow Rate Selection 
 
Flow rates ranging from 0.5-1.5 ml/min have been used for the analysis of CBZ a [34,35,47,48].  
Lower flow rates minimize any potential deleterious effects on the pump and column and 
conserve solvents.  A flow rate of 1.0ml/min was chosen for use in these studies since adequate 
peak resolution was observed at this flow rate without the extreme effects of high flow rates and 
associated high back pressures on equipment.  Furthermore, this flow rate enabled a compromise 
in terms of conserving solvents and retention time, as the slower the flow rate, the longer the 
resultant retention time. 
 
 
2.5 Detection 
2.5.1 Method of Detection 
  
To monitor the eluent emerging from an analytical column [41], variable wavelength UV 
detectors offer the best choice for a large range of solutes and are the most popular detectors 
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used in HPLC [41,44].  The principle of operation of these detectors is that a mobile phase is 
passed through a small flow cell located in the radiation beam of a UV/visible photometer or 
spectrophotometer [41] and consequently compounds that have been separated on the column 
absorb light, at the selected wavelength and will thus be detected.  A typical UV detector has a 
narrow flow cell about 1 mm in diameter with a 10mm path length, with a resultant internal 
volume of approximately 8µl [50].  The linear range of UV detectors is normally between 0.0001 
and 2 absorbance units and samples must be diluted sufficiently to fall within this range, to avoid 
deviations from the Beer-Lambert Law [50]. 
 
 
2.5.2 Detection Wavelength (λ) 
 
The UV absorption maxima (λmax) for CBZ occur at 212nm and 230nm whereas the λmax for 
PRO is at 256nm.  To optimize the detection of both compounds,a wavelength of 224nm was 
selected for use in these studies. 
 
 
2.5.3 Chromatographic Conditions Selected 
 
Following an evaluation of the impact of mobile phase composition, flow rate, buffer molarity 
and pH on the chromatographic separation of CBZ and PRO, the final chromatographic 
conditions were selected.  A summary of these conditions is listed in Table 2.3 and a typical 
separation achieved, using these conditions is depicted in Figure 2.4 
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Table 2.3 Optimal chromatographic conditions for the analysis of CBZ. 
Mobile Phase 0.05M phosphate buffer (pH 3.0): acetonitrile, 55:45 
Flow Rate 1.0 ml.min-1 
Detection Wavelength 224nm 
AUFS 0.1 
Injection Volume 1µl 
CBZ:IS 2:1 
Temperature Ambient 
Retention Time CBZ: 4.2 minutes 
PRO: 3.4 minutes 
 
 
A typical chromatogram obtained for the separation of CBZ and PRO is shown in Figure 2.4. 
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                   Figure 2.4 Typical chromatogram depicting CBZ and IS (60µg/ml). 
Time of Injection 
CBZ 
PRO 
TIME
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2.6 Method Validation 
2.6.1 Introduction 
 
Following the successful development of an analytical method for the quantitative analysis of 
an analyte, the method must be validated in order to verify that the results of any subsequent 
analysis are reliable and valid and that the method will perform in a consistent manner.  
Therefore, validation is the process whereby the performance of an analytical method is 
established as providing reliable and accurate data and proves that the method is suitable for 
its intended purpose [41,42,50].   
 
It is essential to use well-characterized and fully validated analytical methods in formulation 
development and assessment studies, in order to yield reliable results which can be 
satisfactorily interpreted [Shah].  Validation also forms an integral part of any quality-control 
system in the pharmaceutical industry and therefore HPLC method validation is a vital 
component of quality assurance [41,42,50]. 
 
Method validation includes all procedures that are required to demonstrate that a particular 
method for the quantitative determination of the concentration of an analyte, or series of 
analytes, in a particular biological or other matrix are reliable and valid for the intended 
application of the method [42].   
 
The parameters deemed essential to ensure that the performance of an analytical method is 
acceptable include linearity, accuracy, precision, sensitivity, specificity, selectivity, response 
function, reproducibility and stability of the analyte of interest under the study storage 
conditions [42]. 
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2.7 Results and Discussion 
2.7.1 Specificity 
 
The specificity or selectivity of an analytical method implies that the method can separate 
potential impurities arising from the synthetic process of the API, degradation products and 
structural analogues or polymorphs that may be present in a sample. More explicitly, the 
method has the ability to measure accurately and specifically the anlayte(s) of interest in the 
presence of other components that may be present in a sample matrix. [41,50-52].  In these 
studies, specificity was assessed by comparing the chromatograms produced from a standard 
aqueous sample to that of a sample mixture obtained by dissolving commercially available 
tablets or capsules containing 400mg or 200mg of CBZ respectively, in a selected dissolution 
medium.  The commercial products used for this assessment were Tegretol® CR (Novartis, 
Quebec, Canada) tablets and Carbatrol® (Shire Laboratories, Rockville, MD, USA) capsules.  
The resultant peaks were well resolved from the solvent front or void and from each other 
and no interference was observed at the retention times for CBZ and PRO, therefore, the 
method was considered specific for the analysis of CBZ in dosage forms. 
 
 
2.7.2 Linearity and Range 
 
Linearity of a method, is the ability of an analytical method to elicit test results that are 
proportional, either directly or by a well-defined mathematical transformation, to the 
concentration of anlayte in samples within a specific range [41,51,52]. 
 
The ICH guidelines specify that a minimum of five concentration levels must be used 
[42,52,53] and it is necessary that a minimum of twenty assays be performed for statistical 
validity [54].  Linearity was assessed by repeated measurements (n=6) of six concentration 
levels spanning a concentration range of 10 - 180 µg/ml for CBZ.  Peak height ratios of 
CBZ:PRO were measured for the purposes of confirming linearity of  response of the data.   
 
The coefficient of determination (R2) of the regression line for the peak height ratio response 
versus concentration plot, was used as an indicator of linearity, where an R2 value of greater 
than 0.9900 was considered to demonstrate the necessary linearity.  The calibration curve was 
linear over the concentration range studied, with an R2 value = 0.9998 for CBZ and an 
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equation for the line of y = 0.0129x – 0.0279. A typical calibration curve for the analysis of 
CBZ is shown in Figure 2.5. 
 
The range was chosen as the upper and lower concentration limits, of the analyte to be 
quantitated, that showed acceptable accuracy, precision and linearity.  The dissolution 
apparatus to be used and consequently,the expected concentration values are built into this 
range and the method was shown to be linear over the range 10-180µg/ml. 
 
 
             Figure 2.5 A typical calibration curve obtained for the analysis of CBZ. 
 
 
2.7.3 Precision 
 
The precision of an analytical method is the degree of agreement among individual test 
results when the procedure is applied repeatedly to multiple aliquots of an homogeneous 
sample [51].  Precision describes the closeness of replicate determinations of an analyte for 
an assay and can be further subdivided into intra-day or within-day precision and inter-day or 
inter-assay precision [42].   
 
According to the ICH guidelines, precision should be performed at a minimum of three 
different levels, viz., repeatability, intermediate precision, and reproducibility [52,53].  
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Precision is usually expressed as the percentage relative standard deviation (% RSD) (USP) 
and the tolerance for % RSD was set at ± 5%, for these studies. 
 
 
2.7.3.1 Repeatability 
 
The repeatability or reproducibility of an analytical method refers to inter-assay precision and 
is expressed as the degree of variation arising from consecutive and non-consecutive 
injections analysed on the same day [52].  Repeatability should be determined from a 
minimum of nine replicate determinations covering a specified range for an analytical 
procedure, for example, at three different concentration levels with three repetitions of each 
concentration [52].   
 
Consecutive and non-consecutive measurements were made, where consecutive 
measurements were obtained by repeated injections of the same concentrations taken from 
different vials placed sequentially in the auto-sampler, whereas non-consecutive 
measurements were obtained by injecting samples from successive vials that progressed from 
the lowest to highest concentration of calibration standard within each set of samples.   
 
The repeatability of the analytical method was assessed by repeated measurement (n=5) of 
calibration solutions containing 20µg/ml, 40µg/ml and 140µg/ml of CBZ, respectively.  
Standard deviations and %RSD values obtained for these assessments were all less than 3.5 
% for all solutions tested, indicating that the method demonstrated adequate repeatability for 
both consecutive, non-consecutive measurements of CBZ.  The results of these studies for 
both consecutive and non-consecutive measurements are summarized in Table 2.4. 
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Table 2.4 Repeatability data for CBZ analysis 
 Concentration (µg/ml) Standard Deviation % RSD 
Consecutive injections    
 20 0.21 1.08 
 40 0.18 0.44 
 140 0.05 2.61 
Non-consecutive injections    
 20 0.23 1.18 
 40 0.00 0.00 
 140 0.06 3.05 
 
 
2.7.3.2 Intermediate Precision 
 
Intermediate precision was used as an indicator of the day-to-day variance that could occur 
between individual measurements of CBZ.  Intermediate precision was determined using 
calibrators of the same concentrations prepared as described in Section 2.2.2 and samples 
were analysed daily, over a five-day period.  The results of these studies revealed that all 
standard deviation values were within the acceptable range, resulting in %RSD values ≤ to 
5%, which was the limit set for these studies in our laboratories.  The results of intermediate 
precision studies are depicted in Table 2.5. 
 
Table 2.5 Intermediate precision data for CBZ analysis 
Concentration 
µg/ml 
Mean (n= ) measured  
concentration  
µg/ml 
Standard Deviation  
% RSD 
20 19.78 0.3310 1.67 
40 40.39 0.5511 1.36 
140 139.27 2.1640 1.55 
 
 
2.7.3.3 Reproducibility 
 
Due to the intermediate precision data having been suitably validated, no reproducibility tests 
were performed.  Furthermore, ruggedness was not assessed, as only one analyst using one 
set of equipment would be using the previously developed and validated HPLC method. 
 
 
 
 
Formatted
Formatted
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2.7.4 Accuracy and Bias 
 
The accuracy of an analytical method is a measure of the closeness of an individual test result 
to a true test result value [9,52] and is thus a measure of the exactness of an analytical 
method.  Accuracy serves as a tool to ensure that the values measured are exactly the same as 
or as close to the theoretical value as possible.   
 
A tolerance of 2% was set for %RSD for accuracy, which complies with the limits set by a 
number of pharmaceutical industries.  The ICH guidelines on method validation recommend 
collecting data from a minimum of nine determinations over a minimum of three 
concentration levels covering a specified range for the assessment of accuracy [52,53].  
Accuracy studies were performed in triplicate on samples representative of low, medium and 
high concentrations that were expected during drug dissolution and formulation development 
studies.   
 
The results of accuracy studies are summarized in Table 2.6.  It can be seen that the largest 
value obtained for % bias was 5.23%, indicating that no value deviated by greater than 
approximately 6% of the stated value.  The resultant % RSD values for these analyses were 
all less than 1%, indicating that the method can be considered accurate for the determination 
of CBZ in formulation studies. 
 
Table 2.6 Accuracy and percent bias data for the analysis of CBZ 
Theoretical 
Concentration (µg/ml) 
Mean Concentration 
Determined (µg/ml) 
SD % RSD % Bias 
112 115.65 0.00 0.00 3.26 
140 139.48 0.01 0.01 -0.37 
168 159.21 0.01 0.02 -5.23 
 
 
2.7.5 Limit of Quantitation (LOQ) and Limit of Detection (LOD) 
 
The limit of quantitation (LOQ) of an analytical method is the lowest concentration of an 
analyte, in a sample, that can be determined precisely and accurately [52].  The limit of 
detection (LOD) of an analytical method is the lowest amount of an analyte in a sample that 
can be detected but not quantitated, as an exact value [51].   
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For chromatographic analysis, the LOD may be defined as that concentration giving a signal 
to noise ratio of 2:1 or 3:1 [9,51, 52] and the LOQ as that concentration that can be defined as 
having  a signal to noise ratio of 10:1.  Chromatographic conditions such as column type and 
age must be be considered, as they affect peak shape and response, which may result in 
higher LOQ and LOD values being determined with the result that a method may not have 
the necessary sensitivity for the determination of low concentrations of analyte [52]. 
Furthermore, changes in detector response due to deterioration of the UV source as a result of 
prolonged use, may also affect these values [54]. 
 
The LOD for these studies was determined at a signal to noise ratio of 3:1 and was found to 
be 4µg/ml with a resultant % RSD= 8.77.  The LOQ of the methods was determined using the 
method as described in the USP [Ref].  Six blank samples of acetonitrile were injected to 
establish the baseline noise after which decreasing sample concentrations (n=6) were 
injected.  An LOQ value of 10µg/ml with a resultant % RSD = 6.59 was obtained for CBZ.  
Although the %RSD values for the lower concentration levels were high, the values were less 
than 10%, which was considered acceptable for the purpose of these validation studies. 
 
 
2.7.6 Stability of the Analyte 
 
CBZ is known to exhibit polymorphism and form a water-insoluble dihydrate when stored in 
aqeuous solution.  In order to determine suitable storage periods for test and calibrator 
samples, a stability study was performed.   
 
Stock solutions of CBZ and internal standard were prepared as previously described in 
Section 2.2.2.  The stock solutions were then stored in the refrigerator at 4ºC and protected 
from light using aluminium foil.  Samples were injected (n=5) at 0, 1, 2, 4, 8, 12 and 24 hours 
after preparation, over a twenty-four hour assessment period.   
 
Furthermore, a sample of 50ml withdrawn at time 0.0 hours was stored protected from light 
at room temperature, in a similar manner to those stored in the refrigerator.  Aliquots were 
removed from this sample and were analyzed daily for one week.  The results of these studies 
are expressed as the peak height ratio of CBZ and internal standard and are shown in Figures 
 42
2.6 and Figure 2.7, respectively.  Stock samples stored in the fridge showed no significant 
changes in response and thus indicate the relative stability of samples when stored under 
these conditions. 
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Figure 2.6 Stability data for stock solutions stored in the fridge protected from light. 
 
Samples stored at room temperature away from light revealed significant changes in peak 
height ratios of CBZ to internal standard.  Furthermore, peak distortion and peak tailing 
became apparent after 48 hours and this was more apparent in samples of the lower 
concentration of 20µg/ml.   
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Figure 2.7 Stability peak response for samples stored at room temperature (24ºC) 
                        away from light. 
 
 
Although no extra peaks were detected, there were significant changes in peak height ratios 
and peak shape, which was indicative of a potential degradative process affecting the 
concentration of the analyte and to a lesser extent, the concentration of the internal standard 
assessed.  It is possible that these degradants could be detected at by using other wavelengths 
of analysis, higher injection volumes or appropriate manipulation of the sensitivity of the 
detector.  
 
It was concluded that stock samples should be stored at 4ºC protected from light to maximize 
their shelf life and that calibrator samples should be freshly made and not used after storage 
for more than 24 hours, after preparation.  In addition, storage of stock solutions at 4ºC and 
protected from light would extend their shelf life, thus minimizing the need to prepare fresh 
stock solutions on a daily basis.  
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2.8 CONCLUSION 
 
A modular HPLC system was used for the development and validation of an isocratic method 
for the analysis and quantitation of CBZ in pharmaceutical dosage forms. The analytical 
method was developed and validated according to scientifically established acceptability 
criteria. 
 
The method was optimized by the manipulation of mobile phase composition, pH and 
molarity in addition to the selection of an appropriate analytical column and wavelength for 
detection.  A suitable internal standard was selected and its response optimized to allow for 
the more accurate quantitation of CBZ during formulation development and dissolution 
studies. 
 
The method was found to be acceptable for use  with respect to linearity, accuracy, precision, 
specificity, selectivity and stability of the analyte, and by defining the range of the analytical 
method as well as the LOQ and LOD.  These parameters were established in accordance with 
recognized scientific guidelines, and therefore this analytical method can be applied to the 
precise and accurate measurement of CBZ during formulation development and assessment 
studies. 
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CHAPTER THREE 
DOSAGE FORM ASSESSMENT 
 
3.1 Introduction 
 
It is essential that pharmaceutical dosage forms undergo analytical testing to ensure quality 
assurance of a finished product.  Quality control tests are undertaken prior to, during and after 
production of pharmaceutical dosage forms, as part of the overall manufacturing process to 
ensure the ultimate quality of pharmaceutical products. Analytical testing of dosage forms 
was used as a tool during dosage form development, formulation optimisation and for tablet 
evaluation and assessment, in these studies. 
 
Moisture content analyses were performed using the Karl Fischer titration method, which is a 
standard well-recognised analytical procedure.  Potential solid-solid interactions between 
drug candidates and tablet excipients were investigated using differential scanning 
calorimetry (DSC), a thermal analytical technique routinely used for these purposes.   
 
Following manufacture, the physical parameters of tablets such as uniformity of weight, 
hardness, diameter, thickness and friability were assessed. All of the aforementioned 
procedures are used for quality control purposes during formulation development and large-
scale production in the pharmaceutical industry.  Furthermore, content uniformity analyses 
were performed on selected batches of CBZ sustained release tablets in addition to residual 
content determination following dissolution testing of particular formulations.   
 
In vitro dissolution rate studies were performed on every batch of tablets manufactured to 
evaluate the potential in vivo performance of tablets and served as a tool to compare batches 
to each other and to the reference product, Tegretol® CR tablets.  Dissolution testing provides 
a useful tool to evaluate the effect of formulation and manufacturing process variables on 
drug release performance.  In addition, dissolution data were used to assess the possible 
mechanism(s) of drug release and to design an ANN to predict formulation compositions and 
their respective dissolution profiles.  These techniques allow the formulator to modify and 
optimise formulation parameters so as to produce tablets with the desired physical and release 
characteristics as rapidly as possible, so as to shorten development times. 
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3.2 Moisture Content Analysis 
 
The Karl Fischer titration method is a sensitive analytical technique used for measuring the 
quantity of water present in a solvent or that is adsorbed onto the surface of particulate solids 
[55,56].  The reagents used in Karl Fischer analysis, consist of I2, pyridine and SO2 in a 
1:10:3 mole ratio dissolved in methanol or 2-methoxyethanol (CH3OCH2CH2OH) [55,56].  
When the analyte or powder to be analysed, is mixed with the reagent, the presence of water 
results in a sequence of reactions that is driven by the alcoholic solvent.  The reagent is 
initially standardised by titration with the Karl Fischer reagent, prior to dissolving the analyte 
of interest and commencing the assay [56].  During the reaction process, one molecule of 
iodine is present in the sample to depolarise the cathode, and therefore ensure that a current 
will flow [56].  The end point of the titration is reached when the iodine present in solution 
has been depleted and the current flow decreases to zero.  The moisture content is then 
calculated based on the amount of reagent used during the analytical procedure. 
 
The Karl Fischer titration method was used to determine the moisture content of CBZ and the 
tablet excipients used for the manufacture of matrix tablets, in these studies.  Furthermore, 
moisture determinations were also performed on selected production and stability batches to 
assess moisture content prior to and during, stability testing.   
 
 
3.2.1 Methods and Equipment 
 
The moisture content of the samples to be analysed was determined using a Mettler D18 Karl 
Fischer titrator (Mettler Toledo, Geneva, Switzerland) with Hydranal® Composite 5 (Riedel-
de Haen, Seelze, Germany) as the one-component reagent.  HPLC grade methanol (Romil, 
Cambridge, IL, USA) was used as the solvent for all analyses.  A stirring time of ten minutes 
for all powder blends and excipients was used to ensure that the water content of all samples 
could be accurately determined. 
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3.2.2 Results and Discussion 
 
The moisture content of the CBZ, excipients and selected batches of tablets are summarised 
in Table 3.1.  Excipients such as HPMC and microcrystalline cellulose are hygroscopic and 
are able to adsorb atmospheric moisture. Therefore care should be taken during storage of 
these materials or during the manufacture of dosage forms that contain these compounds, to 
minimise uptake of water by these excipients.  It is clear that these excipients have a higher 
moisture content than the other excipients used in these studies.  A target moisture content of 
less than 10% was set as the limit for the excipients that were used to produce tablets during 
these studies.  Despite the higher relative humidity moisture content of the HPMC and MCC, 
when combined in a blend with the API and other excipients, the resultant moisture content 
of the blend was effectively reduced allowing for the effective manufacture of the relevant 
batches of tablets.  
 
CBZ possessed a negligible amount of moisture and any filming or sticking of tablets during 
the manufacture process was attributed to the hygroscopic excipients with an equilibrium 
moisture content of greater than 5%.  The low moisture content of CBZ and other excipients 
allowed for successful adaptation of the wet-granulation formula to a direct compression 
formulation which is suitable for direct compression manufacture.   
 
                         Table 3.1 Moisture content of raw materials used for 
                                          matrix tablet manufacture. 
Raw Material Moisture Content 
CBZ 0.82% 
Methocel® K4M 6.54% 
Methocel® K100M 6.11% 
Emcompress® 0.55% 
Emcocel® 90M 8.05% 
Spray-dried lactose 5.53% 
 
The results of moisture content determination in selected batches of tablets are summarized in 
Table 3.2.  These batches were key batches for formulation decisions during development 
and also included the batch manufactured for in vivo administration.  The resultant overall 
moisture content for these batches and the other production batches was below 5%, which 
allowed for the production of suitable tablets.  Tablets with the low moisture content showed 
no filming or sticking during tablet manufacture.  It is also evident that tablets stored under 
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accelerated conditions adsorbed a large % w/w of water, whereas those tablets stored under 
long-term stability conditions did not adsorb water to any great extent.  
 
  
      Table 3.2 Moisture content of selected CBZ tablet blends. 
Batch  Moisture Content 
(%) 
Relative Humidity 
(%) 
C-061005-01 (ANN predicted batch) 2.39% 46.0 
C-061005-02 (ANN predicted batch) 2.42% 46.0 
C-160905-01 (Biostudy batch) 2.46% 74.4 
C-160905-01 (Accelerated stability) 12.33% 75.0 
C-160905-01 (Ambient stability) 2.52% 60.0 
 
 
3.2.3 Conclusion 
 
The moisture content of CBZ, excipients and selected batches were accurately determined 
using a standard Karl Fischer titration method.  The determination of moisture content of 
excipients, powder blends and provides useful information regarding the compression 
potential of excipients and powder blends prior to compaction and aids the formulator to 
predict process anomalies that may be related to a high equilibrium moisture content of 
powder blends.  Furthermore, this test was used for the determination of moisture content of 
batches of tablets that were placed on stability and the results assist in the selection of 
appropriate packaging materials for batches of tablets susceptible to moisture uptake, as these 
batches that contain large proportions of MCC and HPMC, are. 
 
 
3.3 Differential Scanning Calorimetry (DSC) 
 
DSC analysis of materials provides a means of measuring thermal events that are 
characteristic of a single material and that occur during the application of heat at a constant 
rate.  DSC is a method in which a sample and a control lot are heated by separate energy 
sources and the difference between the heat that is required to maintain both samples at the 
same temperature is recorded.  In this way, endothermic or exothermic thermal events are 
reported as deviations from a baseline measurement, with endothermic transitions producing 
deviations in a positive direction, since more energy is required during an endothermic event, 
than exothermic events.  In comparison, less energy is supplied to the reference sample, to 
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achieve the desired sample temperature when exothermic events occur with a resultant 
baseline deviation that moves in a negative direction [57]. 
 
DSC may also be used to predict potential incompatibilities between drugs and excipients 
intended for inclusion into tablets or other pharmaceutical dosage forms [58,59].  Although 
excipients are considered medicinally inert, physical and chemical interactions with APIs 
may occur and these should be identified early during preformulation studies so as to prevent 
any possible future instability or product failure [60].  CBZ was assessed for potential 
interactions with the excipients to be used for the formulation of sustained release matrix 
tablets.  It was expected that any shifts in the DSC thermograms of the API-excipient 
mixtures would occur when a potential solid-solid interaction between the drug and excipient 
in a mixture, may be possible.  It is important to note, however, that these deviations do not 
necessarily indicate an incompatibility [61] but allow the formulator to anticipate potential 
formulation difficulties that may arise at the later stages of the product development process.  
In-depth chemical and physical analyses in addition to DSC should be performed during the 
product development process to eliminate incompatibilities between the intended components 
of a formulation. 
 
 
3.3.1 Method 
 
DSC thermograms of CBZ and excipients were generated separately, in order to produce a 
reference thermogram for the comparison to samples in which CBZ and excipients were 
combined.  Combination samples were prepared for analysis by mixing one part drug to one 
part excipient (1:1) together, using a pestle and mortar.  Due to the requirements of the 
apparatus used, approximately 2 – 5mg of the powder mixture was accurately weighed and 
sealed in flat-bottomed aluminium pans prior to analysis.  Each sample was analysed under 
an atmosphere of nitrogen with an empty aluminium pan used as the reference sample.  
Heating of the sample, from 25°C to a temperature exceeding the melting point of CBZ, i.e. 
220ºC was achieved at a rate of 10°C per minute.  All pure excipient samples were analysed 
in the temperature range from between 25°C to 250°C using a Perkin-Elmer DSC 7® 
Differential Scanning Calorimeter (The Perkin-Elmer Corporation, Norwalk, CT, USA) and 
Perkin-Elmer Pyris® software for the analysis of all sample thermograms. 
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3.3.2 Results and Discussion 
 
The resultant thermograms generated for the analysis of each of the materials under 
investigation are presented Appendix 1. No significant thermal shifts were observed for CBZ, 
when it was assessed in combination with the other excipients intended for use in tablet 
production. It appears as though CBZ is compatible with all excipients tested and no major 
interactions were observed between the excipients or between CBZ and the excipients.  
Therefore, based on thermal analysis data, it was concluded that CBZ could be formulated 
with combinations of the excipients tested, as potential major incompatibilities were not 
evident.  However, more rigorous, long-term stability testing of manufactured dosage forms 
should also be conducted to rule out real-time long-term dosage form instabilities. 
 
 
3.4 X-Ray Diffraction 
 
Many substances have the ability to crystallise in more than one crystalline form and this is 
true of CBZ where four polymorphic configurations have been identified, the three most 
often reported forms of which are the alpha, beta and dihydrate form [62].  The existence of 
different crystal structures which, although chemically identical, can display different 
physicochemical properties and may influence important pharmaceutical qualities such as 
tableting characteristic, dissolution profile as well as chemical and physical stability during 
storage [62,63].  XRD studies were performed to elucidate possible polymorphic transition 
during powder blending and tablet manufacture.  CBZ is available commercially as the beta 
form and that is the relevant polymorph when anti-epileptic therapy is considered. 
 
3.4.1 Method 
 
The characteristics of the conditions, parameter settings and equipment used for X-ray 
powder diffraction (XRPD) studies are summarised in Table 3.3. A copper target and nickel 
filter was used and the radiation obtained was Copper K-α, which generated a radiation of 
1.5404-angstrom units.  XRPD studies of the coarse grade (CG) CBZ were undertaken on 
material that had been ground for approximately ten minutes with a mortar and pestle. The 
use of a mortar and pestle was thought to simulate friction and mechanical stress that may be 
encountered during manufacturing processes such as blending, granulation and compression.  
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Although not entirely accurate, this simple procedure was deemed sufficient to detect any 
possible interference by the manufacturing process on the coarse grade material.  Therefore, 
any potential polymorphic transitions of the drug that may occur during tablet manufacture 
could potentially be isolated using a XRPD method. 
  
                 Table 3.3 Parameters and variables used for XRPD analysis. 
 
 
 
 
 
 
 
 
 
 
3.4.2 Results and discussion 
 
The x-ray diffractograms that were generated during XRD analysis of the original CG CBZ 
and the ground CG CBZ are shown in Figures 3.1 and 3.2 respectively.  Visual analysis of the 
XRD patterns showed no significant peak shifts or interactions.  A slight decrease in the 
intensity of response was observed as has been previously reported [63].  Therefore, there is 
more than likely no potential for polymorphic transformations to occur during the application 
of physical stress to the CG CBZ during blending, granulation and tablet manufacture.  
 
Generator Seifert ISO Debyeflex 1001 
Seifert, copper target tube 
Nickel filter 
Tube voltage 40 kV 
Tube current 50 ma 
X-ray diffractometer type 
Detector 
Philips upright goniometer 
Xenon-filled proportional counter 
Electronics Custom-built electronic circuit 
Time Constant 1 s 
Scan Rate 1 degree per s  (files ≈ 600kb) 
2 degrees per s (files ≈ 300kb) 
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                    Figure 3.1 X-ray diffractogram of CG CBZ. 
 
 
The absence of a characteristic and intense peak at 5° 2θ in the XRD depicted in Figure 3.2 
that was generated for the ground CG CBZ, excluded the possibility of the presence of the α 
form of CBZ [64].  The same XRD pattern was obtained with the original CG CBZ and is 
depicted in Figure 3.1 and therefore it was concluded that grinding did not induce any 
polymorphic transitions of CBZ.  Therefore, any changes in the rate and extent of dissolution 
that may be observed during dissolution testing are more than likely due to the dissolution 
test conditions and dosage form performance, rather than a consequence of polymorphic 
transformations that may occur during tablet manufacture. 
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Figure 3.2 X-ray diffractogram of CG CBZ, ground for 10 minutes, 
                             with a mortar and pestle. 
 
 
 
3.5 Physical Assessment of Tablets 
 
The physical characteristics of tablets are regularly tested on random samples to identify 
potential areas of difficulty that may occur during the manufacturing process. In addition, 
such testing also forms part of the overall quality assurance of a product intended, to be 
marketed, for human or animal use.  Tablets were subjected to physical testing to provide 
relevant information that would assist to improve and optimise formulation composition and 
process variables throughout these studies, as well as to provide an indication of ultimate 
product quality.  All batches that were manufactured in these studies were assessed 
accordingly however the results for selected batches are depicted here.  Summary batch 
records, in which the results of physical testing of all batches is reported, are contained in the 
summary sheet in Appendix II. 
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3.5.1 Methods 
 
Physical testing of all tablets manufactured during formulation development was carried out 
in accordance with USP specifications where applicable, with tests performed to determine 
the uniformity of weight, thickness, diameter and hardness (n=20). In addition, friability was 
determined for each batch of tablets produced during these studies (n=10).  Twenty tablets 
from each batch were individually weighed and the thickness and diameter of each tablet 
measured using a PharmaTest® PTB 311E Automated Tablet Testing Instrument 
(Pharmatest®, Hainburg, Germany).  Friability was assessed according to the guidelines in the 
USP [9] on ten tablets from each batch, which are subjected to tumbling at a rotation speed of 
33 r.p.m for three minutes using an Erweka® friabilator (Erweka, Heusenstamm, Germany). 
 
 
3.5.2 Result and Discussion 
3.5.2.1 Tablet Diameter, Thickness and Weight 
 
Deep concave hardened steel tooling (Chamunde, Ahmedabad, India) was used for the 
manufacture of all tablets, to ensure that the size and shape of dosage forms remained 
constant.  It was considered important to minimise variations in size and shape of the matrix 
tablets, as it is well, known that such parameters can affect the rate and extent of drug release 
from monolithic matrix dosage forms as described in Section 4.2.  Different powder blends 
have varying degrees of elastic and/or plastic deformation of materials after compaction and 
subsequently behave differently following the release of stress during compaction, resulting 
in possible variations in tablet thickness, which may impact on release rates. 
 
The bulk densities of formulation blends vary with the inclusion of different excipients, more 
particularly for formulations prepared for manufacture by blending for direct compression 
into tablets. Consequently different mass:volume ratios of powder may fill the die cavity, if 
powder flow is not optimised and therefore tablets of varying weight may be produced.  
Tablets in these studies were compressed to a constant target hardness therefore any mass 
variation would be reflected not only in the mean tablet weight but also in the mean thickness 
of the dosage form.  It is evident from the data presented in Table 3.4 that there is a direct 
relationship between these two tablet features, where heavier tablets produced tablets with a 
larger mean thickness. 
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Table 3.4 Mean Tablet Weight, Thickness and Diameter values for selected tablet 
batches (n=20). 
Batch Number Tablet Weight 
Mean ± SD 
mg 
Tablet Thickness 
Mean ± SD  
mm 
Tablet 
Diameter 
Mean ± SD  
mm 
C-160905-01 (Biostudy batch) 800.82 ± 4.13 8.56 ± 0.07 11.44 ± 0.02 
C-030703-01   506.22 ± 11.60 6.07 ± 0.11 11.22 ± 0.01 
C-030703-03 496.37 ± 6.65 6.16 ± 0.08 11.24 ± 0.01 
C-030703-04   516.33 ± 11.23 6.18 ± 0.09 11.23 ± 0.01 
C-030703-05   532.21 ± 11.71 6.30 ± 0.11 11.22 ± 0.01 
C-030703-06   602.18 ± 20.86 6.87 ± 0.15 11.23 ± 0.01 
C-190603-01 570.57 ± 8.84 6.53 ± 0.04 11.22 ± 0.01 
C-190603-02 622.44 ± 9.60 7.13 ± 0.14 11.22 ± 0.01 
C-190603-03 655.75 ± 9.42 7.30 ± 0.09 11.22 ± 0.01 
C-200603-01 531.95 ± 4.40 6.34 ± 0.03 11.23 ± 0.01 
C-200603-02 527.14 ± 4.06 6.26 ± 0.07 11.22 ± 0.01 
C-200603-03 530.56 ± 6.44 6.24 ± 0.05 11.22 ± 0.01 
C-250303-00   704.05 ± 10.30 7.54 ± 0.18 11.23 ± 0.01 
C-211202-01 674.52 ± 7.32 7.54 ± 0.18 11.23 ± 0.01 
C-211202-03 683.65 ± 8.45 7.92 ± 0.26 11.25 ± 0.01 
C-091202-01 747.53 ± 6.59 8.02 ± 0.07 11.26 ± 0.01 
C-091202-02 728.43 ± 8.52 8.48 ± 0.17 11.29 ± 0.01 
C-260303-01 658.32 ± 6.75 7.95 ± 0.10 11.24 ± 0.01 
C-260303-02   663.28 ± 10.34 7.68 ± 0.11 11.23 ± 0.01 
*All results for all batches can be located in the summary sheets produced for all batches as shown in 
Appendix II. 
 
The target tablet weight between batches differed depending on the drug-loading 
requirements for the specific batches, where a heavier tablet was necessary to deliver a larger 
dose.  Twenty tablets were tested for weight uniformity despite the recommendation in the 
USP [9], which suggests that the use of ten may be sufficient, for certain dosage forms.  
Direct compression powders do not flow as efficiently as granules and variations in tablet 
weights, tend to be more significant, therefore, twenty tablets were tested during these 
studies.   
 
 
3.5.2.2 Tablet Hardness and Friability 
 
The target hardness for all batches of tablets produced in these studies was set at between 120 
and 150 N.  For most of the batches manufactured, the resultant values for hardness were 
between found to be between 40 and 90 N, as summarised in Table 3.5.  During the 
manufacture and compaction of some powder blends, the tablet press was placed under 
excessive strain, which necessitated a decrease in the compaction force that was applied to 
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the blends, to ensure that production continued and excessive mechanical damage to the 
tablet press was avoided.  Therefore, a lower actual hardness value was ultimately achieved, 
when compared with the target hardness.  A target hardness of between 120 and 150N was 
thought to be appropriate for the sustained release matrix tablets so as to maintain their 
physical integrity, should a protective coating require to be applied to the tablets, at a later 
stage.  Tablets that have a suitable tensile strength and hardness would be resilient to 
chipping, abrasion and breaking during coating and other transitory abrasive events that may 
occur during tablet manufacture. 
 
Resistance to abrasion is a significant attribute and takes precedence over tablet hardness 
since tablets may chip or break during transport of batches between manufacturing 
procedures or within the final packaging, prior to and during use by patients [65].  The 
friability results of selected batches as shown in Table 3.5 are acceptable according to USP 
guidelines [9], since not more than 1% of the tablet mass was lost for all batches tested.  This 
is an indication that the tablets are adequately resistant to any potential abrasion that may be 
encountered during handling, transport or storage of tablets following manufacture.  
                         
              
 
              Table 3.5  Hardness and friability values for selected batches. 
Batch # Hardness  
Mean ± SD 
(N) 
Friability 
(% Loss) 
C-160905-01 (biostudy batch) 132.2 ± 6.40 0 
C-030703-01 101.67 ± 16.67 0.20 
C-030703-03 33.26  ± 12.16 0.8 
C-030703-04 63.62 ± 7.86 0 
C-030703-05  72.46  ± 17.82 0 
C-030703-06 113.62 ± 12.69 0 
C-190603-01 105.77 ± 17.32 0 
C-190603-02 146.91 ± 13.42 0.16 
C-190603-03 142.93 ± 18.63 0.15 
C-200603-01 45.24 ± 7.61 0.19 
C-200603-02 80.39 ± 7.98 0.19 
C-200603-03  89.23 ± 13.59 0.19 
C-250303-00 143.43 ± 31.48 0.19 
C-211202-01 71.04 ± 7.35 0.31 
C-211202-03   57.7  ± 10.32 0 
C-091202-01  63.88 ± 5.25 30 
C-091202-02 59.51 ± 5.53 50 
C-260303-01  87.49 ± 13.46 0.4 
C-260303-02  89.85 ± 12.29 10 
               *All results for all batches can be located in the summary sheets produced for all batches as  
                 shown in Appendix II 
 56
The tablets from Batch C-160905-01that were stored under accelerated conditions, failed the 
friability test due to the fact that the tablets broke and crumbled during testing.  Friability 
testing may be used as an indication of the potential for tablets to withstand physical stress 
and friction during a coating process that may be applied after compaction and where the 
physical integrity of tablets can be destroyed.  
 
Batches C-091202-01, C-091202-02 and C-260303-02 contained < 5% DCP and this may 
account for the fact that these batches of tablets were the most friable with friability of 30%, 
50% and 10 % respectively. DCP is an excipient that is used to enhance the tensile strength of 
tablets produced by direct compression. 
 
It is clear that most of the tablets that were produced using the different formulation 
compositions were found to be suitable based on the results of friability testing, however 
were not within specification with respect to the achievement of the target hardness. 
Therefore tablet formulation compositions would require substantial modification to include 
excipients that would impart the necessary cohesion to powder blends to achieve a desired 
target hardness of 120N and allow flexibility to the formulator to introduce a coating process 
to the manufacturing procedure. The development of modified formulations will form part of 
future development studies, as it was evident from the results of accelerated stability testing, 
that a protective aesthetic film coating may be necessary to ensure product integrity is 
retained until use.  
 
3.6 Tablet Assay 
3.6.1 Content Uniformity, Assay and Residual Content Analysis  
 
Two methods have been described as being suitable for the demonstration of content 
uniformity of dosage units in the USP [9]. In certain circumstances, weight uniformity may 
be used as an indication of content uniformity, however under other conditions, a chemical 
analysis is considered more appropriate. Content uniformity analysis and bulk asssay was 
performed on all batches during the development process and was also performed on the 
batch intended for in vivo administration.  Content uniformity testing is a quality control tool 
that ensures product quality and marketing integrity of a specific product.   
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3.6.2 Method 
 
Bulk assay was performed on batches according to USP guidelines, where 20 tablets were 
weighed and crushed.  The mass equivalent containing a theoretical quantity of 100mg was 
transferred to a 50ml volumetric flask and 40 ml of methanol was added.  This was sonicated 
for fifteen minutes using a Model 8845-30 Ultrasonic Cleaner (Cole-Parmer Instrument 
Company, Chicago, IL, USA).  Methanol was added up to volume and the resultant solution 
was filtered and the first 5ml of the filtered solution was discarded.  A 5ml aliquot was 
withdrawn from the filtered solution and this was made up to volume in a 50ml volumetric 
flask with a 1:1 solution of methanol and water.  A 2ml aliquot was withdrawn from this 
solution, spiked with the internal standard and assessed using the validated HPLC method 
described in Section 2.5.3.  All reagents and water used for the assay was HPLC quality 
reagents.  The % values for bulk assay were calculated as mass recovered based on the 
theoretical value of 100mg. 
 
 
Content uniformity analysis was performed on ten tablets randomly selected from the specific 
batch to be analysed.  Each tablet was individually weighed and crushed in a mortar and 
pestle and quantitatively transferred to a 100 ml volumetric flask, with the aid of HPLC grade 
methanol (Romil, Cambridge, IL, USA).  Approximately 70ml of methanol was added to the 
volumetric flask, which was then mechanically shaken using a Junior Orbit Shaker (Labline 
Instruments Inc., Melrose Park, IL, USA) for sixty minutes.  The solution was sonicated 
using a Model 8845-30 Ultrasonic Cleaner (Cole-Parmer Instrument Company, Chicago, IL, 
USA) for fifteen minutes and then made up to volume with HPLC grade methanol.  The 
solution was allowed to stand for approximately ten minutes prior to the removal of a 1ml 
aliquot, which was further diluted to100ml with HPLC grade methanol, in an A-grade 
volumetric flask and then analysed using the validated HPLC method previously described in 
Section 2.5.3.   
 
Content uniformity was expressed as the mean percent drug recovered for the ten tablets 
assayed.  A similar procedure was used on each tablet core that remained after the twenty-two 
hour dissolution period, to determine the percent drug retained in the dosage form, for the 
purposes of mass balance analysis.  These studies were considered important to ascertain 
whether the low % CBZ released from selected batches were a result of low drug loading or 
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due to the rate retardant formulation composition. The percent content of each formulation, as 
shown in Table 3.5, was calculated by expressing the amount recovered, as a percent of the 
total theoretical content of CBZ expected in the tablets for a specific batch. 
 
 
3.6.3 Results and Discussion 
 
Bulk assay results for all batches are reported in Appendix II.  The results of selected content 
uniformity assays are presented in Table 3.6.   Content uniformity assessment of formulations 
developed during the early stages of these studies, were out of the acceptable range of the 
specifications that were set according to USP guidelines [9].  These tablets were produced by 
WG and drug loss was attributed to the granulation and transfer processes that occur during 
manufacture.  During the blending phase, drug and excipient particles become dispersed in 
the surrounding air and accounts for approximately15 to 20% drug loss.  Furthermore, during 
the screening of the wet-mass, clumping and retention of some of the wet powder mass 
occurs, on the metal mesh of the oscillating granulator as previously described in Section 
5.3.4.1.  Following the drying phase, the granule-powder mass was transferred to the blender 
for further manipulation that may have accounted for additional drug loss.  Furthermore, 
inadequate blending prior to granulation of CG CBZ as well as potential segregation of the 
larger particle size CG CBZ may also account for poor blend uniformity. 
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     Table 3.6 Content uniformity and assay results for CBZ matrix tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
                 *Batches produced by WG 
 
 
The percent CBZ recovered for the residual content analyses that were performed on batches 
where the dosage form was intact following dissolution testing are shown in Table 3.7.  This 
was accomplished by performing assay analysis on the solid remains of the tablet.  The 
tablets that were produced by WG did not completely erode during the twenty-two hour 
dissolution test period, and were still intact, whereas the batches that were produced by DC 
were completely eroded. Therefore only the batches of tablets that had been manufactured by 
WG were subjected to residual content analysis.  The results shown in Table 3.7 reveal that 
not all the CBZ that was in the tablet had been released from these batches during dissolution 
testing as shown by the mass balance analysis. Consequently the low % drug released from 
these tablets was more than likely a function of the dosage form design, solubility of the CBZ 
and/or the formulation composition, rather than poor content uniformity or low CBZ content 
in the tablets.  The final percent of CBZ released from these dosage forms was calculated as a 
function of the theoretical dose within the dosage form. 
 
Tablets produced by DC completely eroded and no intact tablet remained after the dissolution 
test period, therefore residual content analysis could not be performed on these batches. 
Batch Number Content Uniformity 
% Recovery 
Assay 
% Recovery 
C-160905-01 (biostudy batch) 112.44 ± 1.42 104.83 
C-030703-01 95.43 ± 4.03 98.35 
C-030703-03 90.49 ± 2.63 100.51 
C-030703-04 91.10 ± 3.55 103.87 
C-030703-05 90.15 ± 5.13 104.32 
C-030703-06 93.35 ± 4.15 99.35 
C-190603-01 98.53 ± 4.43 101.65 
C-190603-02 97.63 ± 3.48 100.06 
C-190603-03 96.94 ± 3.51 103.22 
C-200603-01 100.23 ± 3.35 107.56 
C-200603-02 97.58 ± 4.27 98.95 
C-200603-03 99.72 ± 5.24 99.37 
C-200704-01 104.42 ± 2.40 98.37 
C-250303-00 96.57  ± 4.41 100.15 
*C-091202-01 87.52 ± 4.75 99.89 
*C-091202-02 88.53 ± 2.61 101.86  
*C-171202-00 89.47 ± 4.23 99.09  
*C-211202-01 95.44 ± 3.99 100.23 
*C-211202-02 101.15 ± 2.30 96.89 
*C-211202-03 99.58 ± 2.35 101.59 
*C-211202-04 98.12 ± 3.26 104.32 
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Table 3.7 Residual Content Analysis after dissolution of CBZ matrix tablets produced  
                 by WG. 
Batch # Content 
(%) 
Residual Content 
(%) 
Final % Released Total % 
C-211202-01  95.44 ± 3.99 26.35 ± 3.68 63.11 ± 1.68 89.46 
C-211202-02    101.15 ± 5.30 29.37 ± 4.52 64.62 ± 4.25 93.99 
C-211202-03   99.58 ± 2.35  24.16 ± 3.22 59.20 ± 0.95 83.36 
C-211202-04   98.12 ± 3.26 35.15 ± 3.74 52.20 ± 0.64 87.35 
C-091202-01 87.52  ± 4.75 16.28 ± 2.77 57.10 ± 0.74 73.38 
C-091202-02 88.53 ± 2.61 15.85 ± 3.05 71.62 ±13.01 87.47 
C-171202-00 89.47  ± 4.23 22.80 ± 2.23  59.14 ± 1.23 81.94 
 
 
3.7 CONCLUSION 
 
The results of content uniformity analysis of selected batches of CBZ matrix tablets are 
summarised in Table 3.6. It is clearly evident that the results are variable for the tablets 
manufactured by DC, which is to be expected since blend composition is DC tablets is critical 
for the maintenance of dosage form quality. Particle size and bulk density differences 
between API and components of DC formulations may contribute to the variable distribution 
of CBZ in a batch of tablets produced in this way [66]. 
 
The recovery of CBZ was found to be high for the batch intended for in vivo testing and was 
> 110% which is out of the official USP range, of not less than 90% and not more than 110% 
for such tablets [9].  These results are more than likely due to the use of a 10% overage of 
CBZ that was included into the biostudy formulation to compensate for potential drug losses 
that could occur during the weighing, blending and transfer processes involved throughout 
manufacture.  Most of the batches were produced on a small scale and no batch was greater 
than 800g therefore, any inconsistency in weight uniformity of the tablets as a consequence 
of poor powder flow or non-uniform die filling as a consequence of the small batch sizes and 
inconsistent gravitational fill of dies, may be reflected in content uniformity assessment. 
Furthermore should non-uniform blending or unblending occur during the manufacturing 
process, content uniformity of the tablets batches might occur.  Blend uniformity tests were 
not conducted on these batches and therefore future studies should investigate blend 
uniformity and the potential challenges of maintaining content uniformity in direct 
compression manufacturing processes.  The results of the assay on the GMP batch that was 
used for in vivo study revealed that the average amount of CBZ in these tablets was 104.83% 
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and following investigation, the results of the content uniformity test were evaluated in 
conjunction with the assay results and the tablets were thus used for in vivo testing.  
 
3.8 Dissolution Testing 
 
In order for an API to exert an appropriate pharmacological effect in vivo, it must initially be 
released from a dosage form and the dissolve, to be made available for absorption.  
Dissolution testing is an in vitro method of assessing the rate and extent of drug release for all 
batches of a development, new or commercially available products. Dissolution testing is a 
valuable tool when developing a generic drug product as dissolution profiles of test 
formulations can be compared to those of the reference product. 
 
In addition to elucidating the drug release characteristics of test products, dissolution testing 
is a valuable quality control tool for assessing batch-to-batch uniformity and also provides a 
basis for dosage form improvement.  Dissolution testing can also be used to demonstrate 
dosage form stability and batch-to-batch uniformity, as well as assessing the effects of a 
change in formulation variables [67].  In vitro testing is a preliminary step in predicting the 
behaviour of the performance of a dosage form in vivo, but should not be considered as a 
substitute for in vivo testing. 
 
Dissolution testing was used to compare CBZ release rates from all test formulations to that 
of the innovator product, Tegretol® CR.  Furthermore, dissolution rate profiles were used to 
evaluate the effects of changes of formulation effects on CBZ release rates and elucidate 
possible mechanisms of drug release from these products. 
 
 
3.8.1 Variables Affecting Dissolution Rates 
 
There are numerous variables that play a significant role in dissolution testing and the choice 
of optimal dissolution test conditions will depend, to a large extent, on the properties of the 
API being tested [43].  It is desirable to select dissolution test conditions, which are relevant 
to the physiological conditions, in vivo, in order to obtain meaningful in vitro test results.  
Therefore for the most part, aqueous dissolution media are preferred and are most frequently 
used for testing drug release characteristics from solid oral dosage forms. 
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Active pharmaceutical ingredients have an intrinsic dissolution rate that is dependant on its 
solubility and particle size [43,68].  The properties of an API may influence the choice of 
dissolution medium, particularly with respect to pH as many drugs are weak acids or bases, 
which are more soluble in basic or acidic solutions, respectively [43].  The particle size and 
size distribution of the drug in a formulation is also an important consideration, as dissolution 
is a diffusion controlled process that is affected by the area of exposed solid that is available 
for dissolution to occur [68,69]. 
 
HPMC and other hydrophilic matrices have been found to undergo dissolution and therefore 
drug release rates may be affected by the dissolution rates of the polymeric materials that 
comprise the matrix. Dissolution rates may also be affected by the test apparatus selected [70] 
as the hydrodynamic conditions that prevail when using USP Apparatus 3 may increase the 
erosion rate of the polymeric matrix, and increase the contribution of erosion to the release 
rate of an API in the dosage form, when compared to those conditions that prevail when 
using USP Apparatus 1 or 2.  Furthermore, high pH, osmotic and ionic strength have been 
reported to reduce the dissolution rates of API from HPMC matrices, while low pH values are 
associated with an increase in dissolution rates in media with high osmotic and ionic strength 
[70]. 
 
Although the in vitro dissolution profile of an API is useful in postulating the potential in vivo 
behaviour of a dosage form, it does not always provide an accurate prediction of the in vivo 
performance an unless an in vitro-in vivo correlation has been established, dissolution results 
should not be assumed to represent the ultimate in vivo performance of a product [71].  
Differences in behaviour between dosage forms are more pronounced in vitro than in vivo 
[72,73], but absorption in vivo is frequently slower than release rates in vitro [72]. Therefore, 
the use of an appropriate and discriminatory dissolution test with an established in vitro-in 
vivo correlation would provide the formulation scientist with suitable data to develop a 
suitable formulation with a shortened development time. 
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3.8.2 Dissolution Apparatus 
 
The USP lists several official apparatus for the purposes of conducting dissolution testing, 
some of which have specialised and limited application [9,67].  The two most commonly 
used apparatus are USP Apparatus 1, commonly known as the Basket apparatus and USP 
Apparatus 2, commonly referred to as the paddle apparatus.  These two apparatus are similar, 
but when using Apparatus 1 the dosage form to be tested, is placed in a basket attached to a 
rotating shaft which is lowered into a dissolution vessel containing the appropriate dissolution 
medium, whereas when using Apparatus 2, the dosage form to be tested is placed at the 
bottom of a dissolution vessel and a rotating paddle provides the necessary impetus for 
medium agitation.   
 
The USP Apparatus 3, or the BioDis®, is specifically designed for the assessment of 
dissolution rates of extended-release dosage forms [9].  The apparatus consists of six rows 
and in which each row holds six or seven receptor vessels, depending on the design.  The 
dosage form to be tested is placed in an inner glass tube that has a mesh at each end and 
which is attached to a drive unit by means of a stainless steel shaft and the six or seven inner 
tubes correspond to the receptor vessels in a specific row.  The drive shaft allows the inner 
tubes to reciprocate vertically within a corresponding receptor vessel, in a row,  at a particular 
dip rate, for a set period of time.   
 
The inner tubes have two openings, which are closed by use of a mesh of specific dimensions 
that are selected according to the required specifications for analysis. The mesh permits 
dissolution fluid to enter the inner tube on the down stroke and exit as the inner tube is 
withdrawn, thus facilitating dissolution of the drug and excipients within the dissolution 
medium in the receptor vessels.  The time allowed for the dosage form to reciprocate in a row 
in addition to the dip rate may be changed to suit a specific application.   In addition, the pH 
and molarity of the dissolution media can be varied between vessels and rows, thus allowing 
for the dissolution test to mimic the physiological conditions in the GIT.  The choice of 
apparatus may influence the results of the dissolution test [74] and thus is important since 
different dissolution apparatus use varying volumes of dissolution medium and mechanisms 
of agitation, which promote varying types and degree of flow dynamics.  These factors do 
ultimately affect the in vitro performance of dosage forms and therefore the choice of the 
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correct apparatus to develop a discriminatory dissolution test is vital in the early stages of 
product development. 
  
The USP also lists several other official apparatus for dissolution testing, and of these only 
one apparatus, viz., USP Apparatus 4 may have application for the assessment of the dosage 
forms developed and manufactured in these studies, but has yet to be used in any official 
monograph for the purposes of dissolution rate testing. Therefore, the aforementioned and 
other official apparatus are not described in detail, herein.    
 
 
3.8.3 Preliminary Selection of Dissolution Testing Apparatus 
 
A dissolution test procedure should be designed in such a way such that it is discriminatory 
and the most appropriate apparatus for dissolution testing of sustained release matrix tablets 
must be determined. The USP Apparatus 2 is most frequently used for dissolution testing of 
sustained release dosage forms however, the use of USP Apparatus 3 or the BioDis® is 
becoming more accepted and is the preferred apparatus for dissolution rate studies of 
sustained release dosage forms [9,75]. 
 
The advantages of using Apparatus 3 as compared to Apparatus 2 include better simulation of 
the gastro-intestinal environment in terms of the pH range and gastric motility that a dosage 
form may be exposed to during gastric transit, in vivo.  Furthermore, undesirable effects such 
as coning that is caused by the laminar flow of dissolution media when using Apparatus 2 are 
avoided [75]. 
 
Dissolution methods used to assess the rate and extent of drug release from sustained release 
dosage forms using USP Apparatus 3 are usually designed to expose the tablets being tested 
to dissolution media of six different pH values for various times over periods of between 6 
and 24 hours. Dosage forms are therefore exposed to media of different pH and times and 
therefore exposure is similar to that the dosage form would encounter as it progresses from a 
low to high pH during GI transit, from the stomach, through the small intestine and ultimately 
the large intestine. Therefore by selection of an appropriate pH and composition for a series 
of dissolution media, the test can mimic, in some respects, the transit of dosage forms from 
an acidic environment in the stomach to a more alkaline environment such as in the small 
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intestine and colon. In contrast, as dosage forms are exposed to only one dissolution vessel 
with one dissolution medium when using Apparatus 2, it is more difficult and complex to 
change the dissolution media during testing over extended periods of time.  
 
3.8.4 Method 
 
In order to determine which dissolution method and apparatus was most appropriate for the 
purposes of assessing the in vitro release rates of CBZ from formulations, the reference 
product Tegretol® CR (Novartis, Quebec, Canada) was subjected to dissolution testing using 
either USP Apparatus 2 or 3. 
 
The dissolution test conditions for the preliminary dissolution testing of the reference 
product, using either Apparatus 2 or Apparatus 3 (BioDis®) are summarized in Table 3.7.  
Dissolution testing of the dosage forms using USP Apparatus 2 was achieved using a fully 
automated Model SR 8 PLUS dissolution apparatus (Hanson Research Corporation, 
Chartsworth, CA, USA) fitted with an Autoplus™ Multifill™ and a Maximizer Syringe 
Fraction Collector (Hanson Corporation, Chartsworth, CA, USA). The dissolution testing of 
dosage forms using USP Apparatus 3 was achieved using a Model 25-1100 Vankel BioDis® 
(Varian, Cary, NC, USA) extended release dissolution tester with a Vankel VK750D (Varian, 
Cary, NC, USA) water circulation heater. 
 
The dissolution media used was phosphate buffer, prepared as described in Section 2.2.3 and 
was the same molar concentration for both test systems.  The pH of the dissolution media 
used for the evaluation the reference product release rates using Apparatus 2 was maintained 
at pH=7.2 as it was thought that this would be the pH to which the dosage form would be 
exposed for the longest period following oral administration, whereas the pH was varied 
between 1.6 and 7.2 and the dosage form exposed to the different media for different periods 
of time, for the dissolution method using USP Apparatus 3 as described in Table 3.8. 
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Table 3.8 Dissolution test conditions for USP Apparatus 2 and 3. 
Parameter USP 2 (Paddle) USP 3 (BioDis®) 
Temperature 37.5°C 37.5°C 
n  6 6 
Test period 24 hours 22 hours 
Agitation rate *100 r.p.m *20 d.p.m. 
Dissolution 
media 
0.1M phosphate buffer pH 7.2 
(900ml) 
0.1M phosphate buffers of varying pH 
(185ml) 
Sampling 
schedule 
  Vessel pH Dissolution time 
 0.5 hours     
1 hour 8 hours 1 1.6 1 hour 
2 hours 10 hours 2 3.4 1 hour 
3 hours 12 hours 6 4.7 4 hours 
4 hours 16 hours 10 6.8 4 hours 
5 hours 20 hours 14 7.2 4 hours 
 
6 hours 24 hours 22 7.2 8 hours 
 
 
Test samples were collected automatically, at the pre-determined times throughout the twenty 
four hour period for the test conducted using Apparatus 2, and at the end of the twenty two 
hour test period from each receptor vessel for the test conducted using USP Apparatus 3.  All 
samples were analysed using the validated HPLC method previously reported in Chapter 2 
and the cumulative percent drug released was plotted as a function of time for the test period 
under consideration, to generate dissolution rate profiles for the reference product for each 
apparatus.   
 
 
3.8.5 Results and Discussion 
 
The dissolution rate profiles generated for CBZ following testing of the Tegretol® CR tablets 
using both USP Apparatus 2 and 3 are depicted in Figure 3.3.   
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Figure 3.3 Mean (n=6) dissolution rate profiles of CBZ release from Tegretol® CR 
                        tablets using either USP Apparatus 2 or Apparatus 3. 
 
 
The total percent drug recovered or fraction released, at the end of the 24-hour test period 
using Apparatus 2 was < 50% of the theoretical drug loading and label claim of 400mg.  The 
aqueous solubility of CBZ is 170mg/l and the average amount of CBZ recovered in 900ml of 
the dissolution media was found to be 147.21mg, which is in excess of the saturation 
solubility limit of CBZ.  Therefore, due to a combination of the high drug loading of 400mg 
and the poor water solubility of CBZ, the saturation solubility of CBZ is reached after 
approximately 36% of the CBZ had been released when using Apparatus 2.  In contrast, the 
use of USP Apparatus 3 simulates gastro-intestinal pH conditions more closely and the 
results of dissolution testing reveal better drug recovery than that observed when testing with 
USP Apparatus 2. These results are more than likely due to the fact that during extended 
dissolution testing using USP Apparatus 3, tablets are placed in fresh dissolution media of 
different pH at predetermined times.  Furthermore, the total volume of dissolution media used 
in Apparatus 3 was 1110ml, subdivided into six equivalent volumes of 185ml and therefore 
saturation solubility is not reached as early or to as great an extent as that observed when 
using Apparatus 2. 
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In addition, tablets tested using USP Apparatus 2 sank to the bottom of the dissolution vessel 
and therefore the nature of the paddle apparatus and associated fluid dynamics results in a 
phenomenon of coning which prevents multi-dimensional drug release from dosage forms.  
Therefore, the surface area of the dosage form exposed to the dissolution medium, was 
limited to those surfaces exposed to the flow effects that are present during dissolution testing 
when using this apparatus. In contrast, the vertical reciprocating motion of the BioDis® and 
associated turbulent dissolution medium flow, ensured that the tablets were exposed to 
dissolution medium on all surfaces, thereby permitting multi-dimensional drug release. 
 
CBZ is a neutral drug and therefore pH is unlikely to affect the rate and extent of dissolution 
as shown in Section 2.4.4, in which buffer pH did not affect the chromatographic retention 
times of CBZ. Therefore the relatively high fraction of CBZ that was observed when using 
USP Apparatus 3 cannot be attributed to pH effects but rather the continual and renewed 
exposure of the dosage form to sink conditions for the periods described in Table 3.8.  
 
 
3.8.6 Sample Treatment 
 
Following dissolution testing using Apparatus 3, 1ml samples were removed from the 
relevant receptor vessels and analysed by the validated HPLC method, described in Chapter 
2. The samples were diluted by addition of 1ml of HPLC grade water and internal standard 
added as previously described in Section 2.2.2.  Plots of the cumulative percent drug or 
fraction released as a function of dissolution time were generated for each batch of tablets 
manufactured, during these studies. The dissolution profiles of all batches of tablets assessed 
in these studies are summarized in batch summary records contained in Appendix II.  
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3.8.7 CONCLUSION 
 
The USP Apparatus 2 was found to be inappropriate for the testing of CBZ sustained-release 
dosage forms, due to the poor water solubility of CBZ and therefore the resultant low percent 
drug released. In addition, the associated fluid dynamics and effects related to the use of this 
apparatus, may have also had an impact on drug release.  It is evident that when testing high 
dose products of sparingly soluble drugs such as CBZ, saturation solubility can occur to a 
greater extent when using Apparatus 2, than when using USP Apparatus 3. 
 
The USP Apparatus 3 was found to be more applicable for the characterization of dissolution 
profiles of this matrix type sustained release dosage form. It is likely that the continual 
movement of tablets into fresh dissolution media, thereby avoiding saturation conditions 
would enable greater discrimination when testing formulations of different composition.   
Furthermore, the use of USP Apparatus 3 provides a more stringent test procedure, a higher 
degree of precision, and a more realistic dissolution environment, through simulation of the 
GIT pH range and peristalsis [76].  In addition, the exposure of dosage forms to a range of 
media of different pH was considered valuable and more meaningful for assessing dosage 
form performance than exposure to a single dissolution medium, as is the case if USP 
Apparatus 2 were used for testing these products. 
 
Therefore, dissolution testing for all formulation and development batches was undertaken 
using Apparatus 3, with the conditions as summarized in Table 3.9. 
 
 
   Table 3.9 Dissolution test conditions used for all tablet batches. 
Apparatus USP Apparatus 3 (Vankel)   
Temperature 37.5°C   
Sample size (n) 6   
Test length 22 hours   
Agitation rate 20 dips per minute   
    
Dissolution media pH (0.1M 
phosphate buffers, 185ml) 
Dissolution medium # pH Dissolution time 
 1 1.6 1 hour 
 2 3.4 1 hour 
 3 4.7 4 hours 
 4 6.8 4 hours 
 5 7.2 4 hours 
 6 7.2 8 hours 
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3.9 Statistical Comparison of Dissolution Rate Profiles 
 
Statistical and mathematical models that have been developed and applied to the assessment 
and comparison of dissolution rate profiles include the Rescigno Index, ANOVA, model-
independent similarity and difference factors and ratio tests [71,77-83].  During in vitro 
dissolution testing when developing new generic formulations, dissolution profiles of test 
products are compared to that of a selected reference product containing the same drug 
loading, thus providing valuable information to the formulation scientist during the product 
development process.  Therefore, it is important that these comparisons are made with 
scientific validity and confidence based on sound statistical models or mathematical 
relationships. 
 
The Rescigno index provides a different approach, whereby the concentrations of drug at 
various time points are used to calculate a dimensionless number that falls in the range 
between 0 and 1, and which is termed the bioequivalence index [84].  This index, when 
applied to dissolution data as a measure of the dissimilarity between curves, has been shown 
to have bias when the dissolution curve of a test product produces concentrations that are 
higher than that of the reference product [81]. 
 
Comparisons performed in this study were performed using the f1 and f2 difference and 
similarity factors [81], as these parameters are recommended by the FDA for the comparison 
of in vitro dissolution profiles.  Moore and Flanner [81] described two functions that can be 
used to evaluate the degree of difference and similarity between two release profiles. Each 
release profile is a vector 1( , , )nx x x= K  where each ix  is a non-negative real number. 
Usually, one of the profiles, 1( , , )nT T T= K say, is a test profile while the other, 
1( , , )nR R R= K  say, is a release profile which is to be compared to T .  For such a vector x , 
the 1l -norm of x  is defined by  
                                                      1
1 1
|| || | |
n n
i i
i i
x x x
= =
= =∑ ∑                                                    Eq 3.1 
since each 0ix ≥ . The 2l -norm of x  is defined by  
                                                     22
1
|| ||
n
i
i
x x
=
= ∑ .                                                            Eq 3.2 
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In the case 2n = or 3n = , the 2l -norm is the length of the vector obtained by the theorem of 
Pythagoras. Both norms are generalisations of the notion of length of a vector and for both 
norms, || ||x y− is a generalisation of the notion of distance between the vectors. The norms 
are equivalent in the sense that 2 1 2|| || || || || ||x x n x≤ ≤ . This means that if 1|| ||x y ε− < then 
2|| ||x y ε− < and if 2|| ||x y ε− < then 1|| ||x y nε− < . For release profiles ,R T the numbers 
1|| ||R T−  and 2|| ||R T− both give measures of the distances between the vectors. The 1f  
difference measure is defined by 
                                         11
1
100 || ||( , )
|| ||
R Tf R T
R
−=                                               Eq 3.3 
 
and ( , )f R T  represents the relative percentage error between R and T . ( , )f R T  must fall 
below 15 for the curves to be considered similar with statistical confidence.  
 
The 2f similarity measure between R and T is defined by 
 
 
 
 
                                                  Eq 3.4 
 
 
Since ( , ) 100f T T =  the highest measure of similarity is 100 and the measure decreases 
logarithmically as the difference, 2|| ||R T− , increases. For example if  
(0,16,28,42,56,67,78)T =  and R differs from T by 5% at each coordinate then 2 ( , )f R T  is 
obtained, using MATLAB, as described in Figure 3.4. 
 
T =[ 0    16    28    42    56    67    78] 
>> R=1.05*t 
R =[0 16.80 29.40 44.10 58.80 70.35 81.90] 
>> f2(R,T) 
ans =  79.0327 
Figure 3.4  2 ( , )f R T  if R differs from T by 5% 
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∑
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By way of further examples, if R differs from T by 10% and 15% at each coordinate then 
2 ( , )f R T is obtained as described in Figures 3.5 and 3.6, respectively. 
>> R=1.1*T 
R =0 17.60 30.80 46.20 61.60 73.70 85.80 
>> f2(R,T) 
ans =65.2310 
Figure 3.5  2 ( , )f R T  if R differs from T by 10% 
 
>> R=1.15*T 
R =0 18.40 32.20 48.30 64.40 77.05 89.70 
>> f2(R,T) 
ans =56.6746 
Figure 3.6  2 ( , )f R T  if R differs from T by 15% 
 
If 2 ( , )f R T is plotted against the percentage difference between the coordinates of R and 
T the resultant plot is as depicted in Figure 3.7. 
0 10 20 30 40 50
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40
50
60
70
80
90
100
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Figure 3.7  Plot of 2 ( , )f R T  versus percentage difference between the coordinates of  
                      R and T  
 
 
 
This is achieved with the simple MATLAB script given in Figure 3.8 
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%f2comp 
clear all; close all 
T=[0 16 28 42 56 67 78 ]'; 
for k=1:11 
     R=(1+(k-1)*5/100)*T; 
     F(k)=f2(R,T); 
end 
F=F(:); P=[0:5:50]';M=[P F]'; 
fprintf('percent diff: %5.0f \t f2: %5.2f\n',M) 
plot([0:5:50],F,'.') 
xlabel('percent difference');ylabel('f2');grid 
Figure 3.8 Script to produce 2 ( , )f R T  as a function of the percentage coordinate-wise 
                        difference between R and T  
 
The script also returns the 2f values given in Figure 3.9 
percent diff:     0   f2: 100.00 
percent diff:     5   f2: 79.03 
percent diff:    10   f2: 65.23 
percent diff:    15   f2: 56.67 
percent diff:    20   f2: 50.52 
percent diff:    25   f2: 45.71 
percent diff:    30   f2: 41.77 
percent diff:    35   f2: 38.44 
percent diff:    40   f2: 35.55 
percent diff:    45   f2: 33.00 
percent diff:    50   f2: 30.71 
Figure 3.9 2f values versus percentage coordinate-wise difference  
 
As can be seen from the plot in Figure 3.9, a 20% coordinate-wise difference between the 
profiles ,R T  results in 2 ( , ) 50.52f R T = . The lower threshold value for statistical similarity 
is considered to be 50, as defined in the FDA Guidance for Industry [71,85,86].   
 
Although, the FDA accepts this method of comparison, it recommends that the %RSD for 
dissolution data be less than 20% for early samples and less than 10% for the balance of the 
data collected during dissolution testing.  The f2 value is reported to be sensitive to 
measurements in which more than 85% of the API had been released from either the test or 
reference formulations and it is therefore recommended that only one data point be included 
for the comparison if several samples reveal that more than 85% API has been released [85].  
It has also been suggested that the f2 similarity factor has complicated statistical properties, 
which may jeopardise the validity of its use for the comparison of dissolution test results [85]. 
 
Currently, the 1f  and 2f  functions developed by Moore and Flanner [81], which appear in 
the FDA guidance to industry for Scale-Up and Post-Approval Changes (SUPAC) [71], 
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amongst others, are the most frequently cited parameters used for the comparison of 
dissolution rate profiles between test and reference products [82,83,85,87]. Furthermore, it 
has been suggested that most pair wise and model independent statistical test methods give 
meaningful results for dissolution curve comparisons [82]. 
 
Dissolution profile similarity depends on the similarity between the profiles at each time 
point and the similarity between the overall profiles [85].  The similarity between overall 
profiles is particularly important for dissolution testing of immediate release formulations 
[78,85], and has been used in these studies for the comparison of sustained release 
formulations, with some degree of success.  When comparing dissolution profiles it is 
important to ensure that the test conditions are identical [78,85] and that sample times used 
are representative of the entire dissolution rate profile being developed [78]. 
 
If it is considered more important for the profiles to match at certain coordinates then this is 
achieved with a weighting vector ),,( 1 nwww L= . The weighted similarity measure, 
2 ( , , )f R T w  is given by equation 3.11 
 
                                      Eq 3.5 
    
 
 
 
If, for example, the second dissolution point is considered very important and the remaining 
points are of diminishing importance as the index increases, then a weighting vector, 
),1,1,1,2,4,8,0(=w  could be used to adjust the weighting of the data in the determination of 
similarity. In order to keep the weighted similarity measures on the same scale, it is necessary 
to replace the weighting vector by a corresponding normalized vector. Therefore, w would be 
replaced by 
2|||| w
w . In this case, the weighting vector would be )1,1,1,2,4,8,0(
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1  and an 
example of the application of this weighting vector if the percent difference between R  and 
T  were 15% is shown in Figure 3.10.  
 
>> T=[0 16 28 42 56 67 78 ]; 
>> R=1.15*T 
2 10
2
1
100( , , ) 50 log .
( )
1
n
i i i
i
f R T w
w R T
n
=
⎛ ⎞⎜ ⎟⎜ ⎟⎜ ⎟= ⎜ ⎟⎜ ⎟−⎜ ⎟+⎜ ⎟⎝ ⎠
∑
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R = 0 18.40 32.20 48.30 64.40 77.05 89.70 
>> w=[0,8,4,2,1,1,1]; 
>> w=w/norm(w) 
w = 0 0.8577 0.4288 0.2144 0.1072 0.1072 0.1072 
>> f2(R,T,w) 
ans = 76.4791 
 
Figure 3.10  2 ( , , )f R T w  if R  differs from T by 15% using a normalized weighting 
vector. 
 
 
The objective of these studies was to produce a test formulation to match especially the first 
hour of in vitro drug release to that of Tegretol® CR. In Chapter 7 an artificial neural network 
is constructed and then used to simulate on a range of input vectors which represent 
formulations with gradually changing percentages of two forms of the active ingredient. The 
corresponding activations represent release profiles which are to be compared with the 
release profile of Tegretol® CR. This can be seen in Figure 7.5. Thus the highest weighting 
was assigned to the data predicted after the first hour with less emphasis and therefore 
weighting on subsequent sampling times.   
 
 
3.10 CONCLUSION 
 
The f1 and f2 statistical factors provide a useful and convenient method to establish similarity 
between two sets of release rate profiles.  This allows the formulator to objectively assess 
release rate profiles and compare them to reference products so that formulation adjustments 
can be made during dosage form development.  The difference and similarity factors adopted 
for assessment during these studies provided a tool to compare the release profiles of 
formulations produced in this study to Tegretol® CR.  Furthermore, the f2 factor was adopted 
and incorporated into the neural network application as described in Chapter 7 so that drug 
release prediction was further tailored with this additional parameter. 
 
 
The f1 and f2 difference and similarity factors is also endorsed by the FDA as a guideline in 
industry for the comparison of drug release profiles and therefore, concluded the use of this 
statistical tool. 
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3.11 Stability Assessment of the Biostudy Test Batch 
3.11.1 Introduction 
 
The ultimate stability of a pharmaceutical dosage form may be affected by various factors 
including the stability of the API, potential physical and chemical interactions between an API 
and excipients, packaging and storage conditions, length of time between manufacture and use of 
the product as well as the environmental conditions that the product is exposed to during 
transport, storage and handling [194,195].  The predominant processes by which drugs degrade, 
include hydrolysis, oxidation, thermolabile reactions and photo-catalysed reactions in the 
presence of light or photolysis.  Extreme environmental conditions, that include these elements 
that contribute to product instability, can accelerate degradation processes [194-196].  These 
factors must be considered and assessed appropriately as this affects both the chemical and 
physical stability of a drug, the integrity of a dosage form and ultimately, dosage form 
performance that may be adversely affected. 
 
According to the ICH Guidelines [197,199], stability testing should be conducted on a number of 
batches of a final product, packaged in the containers and/or devices that will be used during the 
normal storage, use and distribution of a product.  The recommended test conditions include an 
isothermal and humidity constraint.  The recommendations for storage conditions differ between 
countries, which have been divided into different climatic zones.  South Africa falls into climatic 
Zones I and II and therefore stability testing should be conducted under the conditions described 
in Table 3.10 [194-199]. 
 
Table 3.10 Recommended storage conditions for stability testing in Zones I and II. 
 Temperature Relative Humidity Test Length References 
Long term 
 
Intermediate 
 
Accelerated 
25 ± 2°C  
 
30 ± 2°C 
 
40 ± 2°C 
60 ± 5% RH 
 
60 ± 5% RH 
 
75 ± 5% RH 
1-5 years 
 
6 months 
 
6 months 
77-79, 82 
 
77-79 
 
77-79, 82 
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Stability testing is important to elucidate information regarding the recommended storage 
conditions and shelf life or expiry date of a particular product [194-200].  Stability testing is a 
standard requirement and an essential adjunct to the assurance of quality of all pharmaceutical 
products.  For controlled release formulations, stability testing allows for the identification of 
any quantitative changes or decline in the content of an active ingredient within a product or a 
change in release characteristics that may ultimately lead to failure of the dosage form in vivo.  In 
addition, stability testing allows for the identification of physico-chemical changes to an active 
ingredient that may occur and that may induce toxic or adverse effects on administration to 
patients following long-term storage of these types of products. 
 
 
3.11.2 Stability Studies 
 
Preliminary stability studies were performed on Batch C-160905-01 to gain insight into the 
stability profile of the matrix tablets that were to be tested in a bioequivalence study to compare 
Tegretol® CR to the test formulation.  The use of accelerated storage conditions may provide 
insight into the feasibility of using uncoated matrix tablets as a twice daily sustained release 
dosage form.  The use of a protective coating would add complexity to the manufacturing 
procedure and possibly introduce more variability in product performance and would necessitate 
the need for additional manufacturing equipment. 
 
The stability study was conducted using humidity chambers prepared in dessicators with 
saturated salt solutions, to achieve a desired relative humidity condition [139].  The chambers 
were prepared using sodium chloride which is reported to produce an approximate relative 
humidity of 75% at 40°C, to simulate the conditions required for accelerated stability testing.  
Testing was conducted for one month (thirty days) using storage conditions of 25°C/60% RH 
and 40°C/75% RH. 
 
Two lots of approximately 200 tablets from Batch C-160905-01 were collected and one lot 
exposed in a dessicator chamber containing a saturated sodium chloride solution.  The dessicator 
chamber was placed in an oven that was maintained at 40°C for one month and the resultant 
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relative humidity was maintained at 75%.  The second lot were stored at room temperature by 
storing the dessicator chamber in a dark cupboard in the laboratory where the ambient 
temperature was maintained at ±25°C and the humidity of 60%.  The tablets were placed in open 
glass jars and stored for thirty days.  Although dosage forms should be tested in their final 
packaging, the use of exposed tablets in these conditions would give a rapid indication of the 
ability of the dosage form to resist extreme changes in humidity and temperature.  
Thermohygropens (Cole Palmer Instrument Company, Vernon Hill, IL, USA) were used to 
monitor the temperature and humidity in each chamber on a weekly basis. 
 
At the end of the one month stability test period, the two lots of tablets were assessed in terms of 
changes in visual appearance, content and weight uniformity, hardness, moisture and friability.  
Furthermore, dissolution testing of the tablets stored at ambient conditions was conducted.  The 
visual assessment of colour and overall impression of the dosage form provides an early 
indication of any potential drug or tablet degradation and is therefore a valuable QC tool.    
 
 
3.12 Results of Stability Testing 
3.12.1 Visual Appearance 
 
The tablets exposed to conditions of 40°C/75%RH showed signs of discolouration, tablet 
swelling and cracking within twenty four hours of exposure.  After one week, the discolouration, 
and cracking was highly pronounced but did not progress beyond this extent for the remainder of 
the test period.  Tablets that were tested at ambient conditions did not display any discolouration, 
swelling or cracking behaviour for the duration of the study.  These tablets retained their elegant, 
smooth aesthetic appearance and can therefore be considered for further long term testing. 
 
 
3.12.2 Tablet Hardness 
 
Tablet hardness was determined using a PharmaTest® PTB 311E Automated Tablet Testing 
Instrument (Pharmatest, Hainburg, Germany).  The results of hardness testing for the lots 
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subjected to different storage conditions as well as the hardness data for the batch determined 
prior to storage are listed in Table 3.11. 
 
 
Table 3.11 Result of hardness testing 
Batch Type  
(Biostudy Batch # C-160905-01) 
Average Hardness ± SD 
n =10 
% RSD 
After Manufacture 132.2 ± 6.41 N 4.85 
25°C/60% RH  
Period of study = 1 month 
118.56 ± 17.96 N 15.15 
40°C/75% RH  
Period of study = 1 month 
12.13 ± 6.49 N 53.54 
 
 
The tablets stored at 40°C/75% RH showed a significant decrease in hardness as can be seen 
from the data in Table 6.2.  The tablets were extremely soft and crumbled upon testing and 
careless handling.  The moisture content increased markedly to approximately 12% under the test 
conditions with subsequent tablet swelling which caused the tablets to be softer.  Tablets stored 
at ambient conditions showed some loss of hardness and greater variation in hardness between 
tablets was observed when compared to the control lot.   The changes caused by high humidity 
and temperatures were considered to be unacceptable as these tablets could not be effectively 
used by a patient and the changes would certainly affect dosage form function. 
 
 
3.12.3 Tablet Weight 
 
The results of the uniformity of tablet weight determination are listed in Table 3.12.  The weight 
of the tablets stored under accelerated conditions increased markedly, where a mass increase of 
approximately 37% was observed and the % RSD of 2.92 was higher in this test lot than for the 
other lots tested.  The most significant contributing factor to the weight gain was the moisture 
content which increased significantly and that is consistent with the swelling behaviour observed 
with this lot of tablets.  The tablets stored under ambient conditions showed an increased weight 
 81
variation when compared to the control lot due to its exposure to higher humidity conditions but 
had far less variation in weight than was observed for the lot stored under accelerated conditions. 
 
Table 3.12 Tablet Weight Uniformity 
Batch C-160905-01 Average Weight ± SD 
n=10 
mg 
% RSD 
After Manufacture 
 
800.82 ± 4.13 0.52 
25°C/60% RH 
Period of study = 1 month 
  807.0 ± 0.01 0.001 
40°C/75% RH  
Period of study = 1 month  
1099.0 ± 0.03 0.002 
 
  
3.12.4 Tablet Friability 
 
The determination of friability was undertaken using an Erweka Friabilator (Erweka-Aparatebau-
GMBH, Heusenstamm, Germany) set to achieve 33 drops per minute over a 3 minute test period 
and the results of these determinations are shown in Table 3.13.  Tablets stored under accelerated 
conditions failed the friability test as the tablets crumbled and broke during the test.  This 
corresponds to a complete loss of tensile strength of this test lot.  Tablets that were stored under 
ambient conditions showed a net loss of less than 1% which was within the acceptable limits for 
friability according to USP guidelines [9].  This is an indication that these tablets would probably 
maintain their physical integrity during transport and handling of the dosage form if exposed to 
conditions of 25°C/60% RH for an extended period of time.  However, longer test periods must 
be used to establish real time stability of these dosage forms.  
 
         
Table 3.13 Tablet friability. 
Batch Type C-160905-01 Friability (% mass loss) 
n=10 
T=0 - 
25 °C/60% RH T=1 month 0.61  
40°C/75% RH T=1 month - 
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3.12.5 Moisture Content 
 
The uptake of moisture by tablets during storage was determined using the Karl Fischer 
procedure as described in Section 3.2.1.  The tablets tested prior to storage had an average 
moisture content of 2.46%.  A moisture content limit of 5% was selected as an appropriate limit 
for these tablets for these studies.   
 
The moisture content of the tablets stored under accelerated conditions increased significantly 
from 2.6 to 12.33% and these results are consistent with the observed tablet swelling, increased 
tablet weight and subsequent loss of tensile strength of the tablets that was observed after storage 
for one month under these conditions.   
 
The tablet batch stored under ambient conditions showed a minor increase in moisture content 
where an ultimate moisture content of 2.52% was observed for this batch and this increase was 
considered negligible for these tablets.   
 
Significant moisture increase in formulations, affect the physico-chemical stability of the 
excipients and drug within the tablets.  Thus, dosage form performance becomes affected, which 
could result in poor or toxic pharmacotherapy due to failure of dosage form function.  
Furthermore, physical anomalies in these tablets due to the moisture uptake make the tablets 
unacceptable for patient use as well as impractical where tablets swell to proportions which are 
too large for patients to swallow with ease.   
 
3.12.6 Assay 
 
The determination of CBZ in these tablets was performed in accordance with USP guidelines for 
CBZ extended release tablets that has been previously described in Section 3.7.1.  The results 
obtained for the assay performed for the three test lots of CBZ tablets from batch # C-160905-01 
are summarised in Table 3.14.  For the purpose of the assay, the theoretical recovery from these 
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tablets was considered 100mg according to USP method of analysis.  The lot stored under 
accelerated conditions showed an assay determination of approximately 92 mg recovery but this 
result is within acceptable limits.  However, the recovery of 92mg after one month may not be 
indicative of appropriate stability characteristics and should be further investigated.  The lot 
stored under ambient conditions showed a recovery after of approximately 107mg after one 
month and that implies the formulation may be stable under these conditions. 
 
Tablet 3.14 Assay results. 
Batch C-160905-01 Average Recovery ± SD 
(n=20) 
mg 
% RSD 
T=0 112.44  ± 1.42 1.26 
25°C/60% RH T=1 month 106.84  ± 0 0.0 
40°C/75% RH T=1 month 92.53  ± 1.42 1.53 
 
 
3.12.7 Dissolution Testing 
 
The tablets stored under ambient storage conditions were subjected to dissolution testing to 
assess their in vitro performance and the dissolution rate profiles of this lot following storage and 
that of the control lot are shown in Figure 3.11.  The curves appear similar and an assessment for 
similarity revealed f1 and f2 values of 4.0 and 83.0, respectively which indicates that there is no 
difference between these curves following the period of storage. 
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Figure 3.11 Dissolution profiles of the test Batch C-160905-01, at t=0 and after storage  
                        under ambient conditions for one month.  
 
In terms of in vitro dosage form performance after storage for a month, the tablets tested for 
stability under ambient conditions show that drug delivery rates are exactly the same when 
compared to the control lot.  Due to the obvious physical unacceptability of the lot stored under 
accelerated conditions, it was not considered necessary to perform dissolution studies on these 
tablets.   
 
A key factor in assessing the stability of controlled or sustained release dosage forms is to 
ascertain whether the dissolution rates of CBZ are altered on storage.  In this case, it is apparent 
that the release of CBZ following a period of storage of one month at 25°C/60% RH is unaltered 
and therefore the stability of these products must be further evaluated. 
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3.13 CONCLUSION 
 
The results obtained for the tests conducted on the lots subjected to storage under selected 
conditions, reveal a definite increase in moisture content was observed.   This was evidenced by 
a corresponding increase in tablet weight and friability and a decrease in tablet hardness.  Tablets 
stored under accelerated conditions showed the greatest increase in moisture content whereas the 
batch stored at ambient conditions showed a moisture content increase that was well within the 
acceptable pre-set limits.  Temperature and humidity have a considerable effect on the physical 
properties of a dosage form and environmental limitations should be defined and optimal 
conditions must be specified for both factors when defining storage conditions for these tablets.  
The results also indicate that packaging for the tablets would be a critical consideration during 
further formulation development.  Furthermore, the use of a protective non-functional aesthetic 
coating would be appropriate to maintain the physical stability and acceptability of these tablets 
for an extended period of time, in particular in high humidity climate. 
 
The tablets stored under ambient conditions displayed reasonably good stability and in vitro 
behaviour despite the lack of a protective coating and the effects of the environmental conditions 
on this lot were identical to that of the control lot.  This indicates the physical robustness of the 
dosage form where the appropriate packaging and storage instructions given to patients may be 
adequate to maintain the shelf life as well in vivo performance of these dosage forms. 
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CHAPTER FOUR 
PHARMACEUCTICAL APPLICATIONS OF HYDROPHILIC POLYMERIC MATRIX 
SUSTAINED RELEASE TECHNOLOGY 
 
4.1 Introduction 
 
The oral route of drug delivery is a common and convenient means of drug administration [88].  
This is due to the inherent simplicity of using this route of administration and the inherent 
simplicity of oral delivery system formulation [89].  Formulation designs, which aim to tailor 
drug delivery, have received increasing attention as formulators attempt to deliver drugs more 
‘intelligently’ to enhance drug therapy, where the rate of release of a drug is dependent on the 
delivery device rather than physiological conditions [89-91].  The safety and efficacy profile of 
drug therapy can be improved significantly, in addition to patient compliance, as a consequence 
of a reduced dosing frequency with a subsequent improved overall therapeutic benefit for the 
patient [89,92,93].  Many pharmaceutical companies are now focusing on the development of 
novel and better methods of drug delivery such that existing and new drug molecules can gain an 
increased market share or an extended patent life [92]. 
 
Sustained-release dosage forms have been referred to as controlled-, delayed-, extended- or 
modified-release dosage forms [93-105].  These terms describe a dosage form that controls the 
drug absorption rate to achieve a desired plasma profile defined by steady-state pharmacology, 
for a particular compound after pre-determined lag times or intervals [89,106].  However, not all 
drug candidates are suitable for inclusion in sustained drug delivery dosage forms due to their 
physicochemical properties, in addition to the physiological constraints associated with their use.  
Therefore consideration of all interacting factors must be assessed during dosage form 
development to optimise drug delivery [88].   In general, the development and application of 
sustained-release delivery systems is suitable for active pharmaceutical ingredients (API) with a 
high degree of solubility in GIT fluids, rapid and near complete absorption, relatively fast 
elimination rates and rapid distribution of the drug into body tissues [95]. 
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Conventional dosage forms present challenges relating to optimum drug delivery such as 
frequency of dosing intervals and extreme plasma drug concentration fluctuations as well as 
challenges in the achievement of desired clinical effects or a reduction in adverse effects.  
Modified-release formulations offer solutions to the difficulties associated with conventional 
drug delivery system development and use [92].  It has been shown that a more stable 
plasma/serum concentration of CBZ can be achieved through the use of controlled release 
delivery systems [102].   
 
Some of the advantages of an ideal controlled-release dosage form include the reduction in the 
high degree of fluctuation of circulating drug levels, the avoidance of night-time dosing, a more 
uniform therapeutic effect and the reduction of gastro-intestinal irritation and other dose-related 
side-effects [88,93,101,107-109].  However, controlled-release formulations are often more 
expensive to manufacture than conventional formulations and cannot be justified unless they 
offer distinct, measurable, clinical and practical advantages over conventional delivery systems 
[109]. 
 
Several potential disadvantages of controlled release dosage forms include cost, unpredictable 
and often poor in vitro-in vivo correlations and potential dose dumping [109].  Furthermore, there 
is a decreased potential for dosage adjustment where tablets are required to be administered 
intact [109].  In general, there is an increased potential for first pass clearance and therefore poor 
systemic availability of API from these systems [101,102,109].  In addition the effective drug 
release period for oral dosage forms is influenced and limited by gastro-intestinal transit time 
which is generally between 8 – 21 hours [101,109]. 
 
Therefore the suitability of the drug candidate for inclusion in drug delivery systems in addition 
to any potential therapeutic benefits must be completely assessed to justify the value of such 
formulations in drug therapy prior to embarking on expensive formulation development. 
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4.2 Sustained-Release Delivery Systems  
 
Monolithic polymeric devices are a well-known, well-established and widely used method of 
sustaining drug delivery [94,110].  Their widespread use is primarily due to their simplicity, 
relative ease of manufacture and low cost [88,89,111].  Almost all oral solid controlled release 
products currently marketed are based on matrix, membrane-controlled or osmotic systems [89]. 
Swelling-controlled release systems are also referred to as hydrogel or polymeric matrices that 
exhibit moving boundaries or are swellable matrix tablets [89,120]. Monolithic matrix systems 
generally consist of the API dissolved or dispersed within a skeleton-like structure, which is the 
matrix, and that is the rate-controlling polymer, with or without the addition of other excipients 
[95,108]. 
 
Both hydrophilic and hydrophobic polymeric matrix systems are widely used to control delivery 
of drug substances because of their versatility and effectiveness in prolonging drug release 
during conventional gastric transit times [89,107].  These systems are also suitable for “in-
house” development since they are easily manufactured using conventional equipment and 
processing methods [89,102,105].   
 
A variety of both hydrophilic and hydrophobic polymers are available for matrix device 
application, of which the most commonly used is hydropropylmethylcellulose (HPMC) 
[101,106,112,113].  HPMC is highly swellable on contact with aqueous media and the degree of 
swelling has a considerable effect on the resultant release kinetics of a drug contained in delivery 
devices that are primarily comprised of HPMC [64,89,103-105,114-116].   
 
There are two major mechanisms by which drug release from these dosage forms is controlled, 
viz., diffusion or dissolution-control [89,97,102,103].  Controlled drug release from HPMC 
matrix tablets may be affected by several formulation variables such as polymer content and 
molecular weight, drug content and solubility, type of excipient(s) as well as tablet shape and 
size or geometry [116].  Changes or modifications in polymer type, excipients and 
manufacturing processes can be modified to achieve specific release rates [103,113].  The 
 89
HPMC concentration and viscosity grade within a formulation have been most often manipulated 
to regulate drug release both kinetically and mechanistically from these systems [103].   
 
On exposure to aqueous fluids as water diffuses into the tablet, the matrix swells and a viscous 
gel layer forms around the exterior of the tablet [116] followed by drug diffusion through the gel 
layer and into the surrounding medium [88].  Therefore, as the matrix comes into contact with 
the dissolution medium, the polymer undergoes relaxation and two fronts are established around 
the core tablet, viz., the penetration and dissolution fronts [103].  At the same time, other soluble 
excipients or drug substances that comprise the delivery device will also dissolve and diffuse out 
of the matrix while insoluble excipients or APIs will be retained until the surrounding 
polymer/excipient/drug complex erodes, dissolves or disintegrates [118].  
 
The penetration front is defined as the interface between the unhydrated or non-relaxed polymer 
and the gel layer [103], whereas the dissolution front is defined as the interface between the gel 
layer and the dissolution medium [103].  Hydration, swelling and coalescence of polymer 
particles occurs at the penetration front whereas polymer chain disentanglement and dissolution 
of the hydrated matrix occur at the dissolution front [103,115,116].  The diffusional path length 
available to a drug within a matrix device is represented by the gel layer thickness and 
corresponds to the distance between the penetration and dissolution fronts [103].  Drug release 
from swellable and erodible hydrophilic matrices can be attributed to polymer dissolution or a 
matrix erosion mechanism, drug diffusion through the gel layer, or a combination of both 
processes [103,104,116].  Diffusion is the principle mechanism governing drug release in the 
case of water soluble APIs whereas the release of water-insoluble drugs is predominantly 
dissolution controlled [103,116], and  where surface erosion of the matrix polymer may 
contribute more significantly to overall drug release rates than drug dissolution [116]. 
 
The process of formulation development to produce a generic product that matches an innovator 
or reference product in vivo, initially involves matching the dissolution rate profiles based on 
statistical analysis by use of the difference and similarity, 1f  and 2f  factors.  However, during 
the process these parameters may be of value to assess the impact of modifying formulation 
parameters and dissolution rate profiles [67] 
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4.2.1 Mechanisms of Drug Release 
 
Controlled-release systems consist of a drug or solute that is distributed in a polymeric phase that 
can be referred to as the glassy state [119,120]. Sustained drug release occurs as a result of the 
use of rate-controlling hydrophilic, swellable polymers such as HPMC, which is a carrier 
material that is commonly used for oral-controlled drug delivery [123].  Pharmaceutical devices 
with an initial drug concentration greater than the solubility of the drug in the surrounding fluids 
are referred to as monolithic dispersions [122].  Dissolution of a polymer within the dissolution 
medium involves two transport processes, viz., solvent diffusion into the dosage form and 
subsequent polymer chain disentanglement and relaxation [119,122].   
 
In a thermodynamically compatible solvent the polymer requires an induction time prior to 
dissolution, after which the polymer swells and dissolves [119,120]. Transitions from a glassy to 
a rubbery state are accompanied by the simultaneous volume expansion of the device. Swelling 
of a device and subsequent polymer disentanglement results in the formation of a gel-like 
pathway, which is adjacent to the solvent-polymer interface due to plasticization of the polymer 
by the solvent, which is also capable of preventing matrix disintegration and further rapid water 
penetration [119-121].  Water penetration, polymer swelling, drug dissolution and diffusion and 
matrix erosion are the phenomena that ultimately determines the gel layer thickness and thus 
drug release rates [90,118,120]. 
 
Diffusion occurs as a result of the relaxation of macromolecular chains taking the polymer from 
a glassy to rubbery phase and this dynamic, swelling behaviour of the glassy polymer is 
generally the controlling mechanism for release of an API from polymeric matrices 
[90,119,120].  A linear relationship exists between the release rates and the reciprocal of the 
weight of HPMC used in the matrices.  Therefore, higher molecular weight HPMC polymers 
would produce lower drug release rates [121]. Furthermore, upon contact with the receptor 
medium and by virtue of the excipients used in the formulation, water-filled channels or cavities 
may be created within the device followed by drug transport from the tablet via diffusion through 
these domains resulting in a change in the drug release kinetics from these systems [122].  
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Three moving fronts have been identified to describe drug movement in swellable matrix 
systems [98].  These fronts are: 
 
A. a swelling front that describes the boundary between the existing glassy polymer and its 
rubbery phase; 
B. a diffusion front which describes the boundary between the solid as yet undissolved drug 
and the dissolved drug in the gel layer; and 
C. an erosion front that describes the boundary between the matrix and the dissolution 
medium [98,120]. 
                                                                                                                                                               
A schematic representation of the processes involved in drug release from polymeric matrix 
devices is depicted in Figure 4.1 
 
 
 
 
 
Figure 4.1 Diagrammatic representation of the swelling and erosion processes 
                        associated with matrix tablets. 
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Front synchronisation occurs when the velocity of glass-rubbery interface is in equilibrium with 
the rubbery-solvent interface.  In devices where dissolution-control is predominant, front 
synchronisation leads to zero-order drug release [119,124].  A schematic representation of the 
dynamic changes that occur during drug release from polymeric matrix type delivery systems is 
shown in Figure 4.2.   
 
 
 
 
 
Figure 4.2 Swelling dimensions for a monolithic matrix tablet [111]. 
 
 
There are numerous mathematical models and theories have been developed in an attempt to 
describe drug release kinetics from controlled-release dispersed systems such as polymeric 
monolithic matrix tablets [120,123,125,126]. 
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4.3 Mathematical Modelling of Drug Release from Polymeric Matrix Tablets 
4.3.1 The ‘power law’ 
 
Modelling of drug release from swellable polymeric systems belongs to a category of diffusion 
problems known as moving-boundary or Stefan-Neumann problems [127].  Throughout drug 
release from HPMC matrices, synchronization of front movement is difficult to reach, therefore, 
the kinetics of drug release depends on the relative movement of the erosion and 
swelling/diffusion fronts [120].   
 
Diffusion is one of the most important mechanisms controlling drug release from pharmaceutical 
formulations and the “power law” as defined by Peppas et al [123] describes more specifically 
the type of release that occurs in matrix systems with expanding boundaries such as those 
previously described in Section 4.2.  The differential between diffusion and erosion fronts is 
decisive for describing the release kinetics where drug release rate depends on the diffusion front 
velocity [120].  A mathematical representation of the “power law” is shown in Equation 4.1  
 
ntM kt
M∞
=                                                   Eq. 4.1                                 
where, 
t  = the elapsed time; 
tM = the mass of drug released at time t ; 
lim ttM M∞ →∞= , the limiting amount of drug released (the amount released in ‘infinite time’); 
 k  = a proportionality constant that incorporates structural and geometric characteristics of a 
        dosage form; 
n  = the release exponent.  
   
The specific value of n is indicative of the mechanism of drug release from matrix systems.  
Siepmann and Peppas [123,125] derived different values for specific geometric delivery systems.  
In the case of a sphere, an n  value ≤ 0.45 is indicative of drug release by Fickian diffusion 
[123,125], with water transport controlled by a concentration gradient [98].  Within a sphere, 
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values of n  between 0.45 and 0.85 are indicative of anomalous transport whereas n  ≥ 0.85 
reveals that Case-II type transport is occurring [123,125].  Case-II or time-independent transport 
represents swelling-controlled drug release with polymer relaxation determining the rate-limiting 
step [89-91,120] and anomalous transport can be observed in systems where the water uptake 
mechanism results in drug transport behaviour that displays both Fickian and Case-II type 
transport [98,123,125].  In Case-II type transport, solvent mobility is much higher than the 
segmental relaxation rate of the polymer [90,91,117,120,127].   
 
A value of  n = 1  is indicative of zero-order release from a planar surface but for spheres, such 
as matrix tablets and cylinders a value of n≈1 may not correspond directly to zero-order release 
due to the effect of geometric factors on the mathematical analysis of the data [115].  Thus, a 
value of 1 merely emphasizes that the release of drugs from these systems is not Fickian 
diffusion-controlled and may indicate contributions to drug release mechanisms by erosion of the 
polymeric matrix [115].  In a swellable matrix tablet, the erosion front movement determines the 
kinetics of the diffusion front  and therefore the rate of drug release [90,120]. 
 
However, a mathematical description of the entire the drug release process is complex and 
difficult due to the number of physical characteristics or constraints that must be taken into 
consideration, including diffusion of water into the HPMC matrix, swelling of the matrix, drug 
diffusion out of the device, polymer dissolution, axial and radial transport in a three dimensional 
system and concentration dependant diffusivities of the API or compound(s) of interest [128].  In 
addition, factors such as the initial drug loading within the device, tortuosity of the water-filled 
pores following hydration, the partition coefficient of the drug between water and polymer and 
the particle size distribution of the drug can significantly influence drug release kinetics from 
these dosage forms [90,120,128].  It has also been shown that a major factor controlling drug 
release from HPMC matrices is the drug:HPMC ratio [121]. 
 
Due to the complexity of the drug release process, certain assumptions, such as the restriction of 
drug transport to one-dimension or ignoring the effects of polymer swelling and/or polymer 
dissolution, are made [128].  Consequently, the use of a mathematical model becomes restricted 
to certain drug-polymer systems which are geometrically specific.  Since drug release kinetics 
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become dependent on the size and shape of a dosage form, a desired release profile can be 
obtained through the adjustment and manipulation of the geometry and dimensions of a system 
or by means of adjusting the formulation content and/or the method of manufacture 
[105,108,116,121]. 
 
 
4.3.3 Matrix Tablets 
 
The type of matrix systems produced in this study, were monolithic polymeric systems. The 
systems consisted of CBZ dispersed in a hydrophilic polymeric material [122,129].  On exposure 
to biological or other aqueous fluids, the tablet thickness and volume increases which permits the 
dissolution of CBZ from the formulation into the surrounding liquid medium at a controlled rate.  
The retardation of drug release is erosion- controlled in cases where drug diffusion in the gel 
layer is slow, relative to the rate at which the polymer dissolves [129]. For drugs with low water 
solubility, such as CBZ, the most important process that determines the rate of drug release is 
erosion of the polymer used to fabricate the matrix system.  
 
Dissolution-controlled release is achieved when the rate of dissolution of the polymer is slow 
when compared to the rate of dissolution of the drug.  Diffusion-controlled drug release is 
prevalent when polymer dissolution is slower than drug diffusion [129].  A low viscosity grade 
HPMC may be more appropriate for use in matrix systems which carry low solubility drugs and 
a high viscosity grade HPMC may be required in systems in which a water soluble drug is to be 
formulated.   
 
The aforementioned selection of polymer grade may be considered a guide in the selection of 
polymeric materials for matrix delivery system development.  However, it is likely that a 
combination of one or more viscosity grade materials may be more appropriate than the use of a 
single grade of material in order to achieve the necessary control over drug release. 
 
The aim of these studies was to produce a matrix tablet that would sustain CBZ release over a 
22-hour period and to elucidate the probable mechanism that controls the release of CBZ from 
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these systems.  In addition, the system should match the in vitro dissolution profile of Tegretol® 
CR. 
 
 
4.3.4 Fick’s Second Law 
 
Fick’s second law defines mass transport such that a change in concentration occurs at a specific 
time at a definite location, rather than the mass diffusing across a unit area of a barrier in a unit 
of time [130].  Fick’s second law is depicted in Equation 4.2. 
 
2
2
C CD
t x
∂ ∂=∂ ∂                                                Eq. 4.2                                    
where, 
t  = the elapsed time; 
D  = the diffusion coefficient of the drug; 
C  = the drug concentration in the reservoir;  
x  = the perpendicular distance travelled by the drug. 
 
Drug transport from the inner core of a matrix type dosage form to the external dissolution 
medium is facilitated by fluid penetration into the core creating areas of high diffusivity and the 
API can escape form the release device by diffusion from these high diffusivity ‘channels’ [91].  
The process of diffusion is the principal mechanism that controls drug release from these systems 
and is more applicable for describing release of water soluble drugs where drug diffusion of the 
drug from the device occurs before dissolution of the polymer that makes up the device [91].   
 
Deviations from Fick’s law have been associated with the rate at which the polymer structure 
rearranges to accommodate solvent molecules [90].  Case-I type transport corresponds to 
diffusion-controlled systems where solvent mobility is much slower than the segmental 
relaxation rate of the relevant polymer system [90].  Diffusion of the drug occurs because of the 
relaxation of macromolecular chains taking the polymer from a glassy to rubbery phase.  Case-I 
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type transport corresponds to n values ≤ 0.5 derived from the ‘power law’ as described in Section 
4.3.1. 
 
The resultant drug release profiles are inherently first-order in nature and show square root of 
time dependence with continuously diminishing release rates that are a consequence of an 
increasing diffusion distance and decreasing surface area at the penetrating diffusion front [111]. 
 
 
4.3.4 The Higuchi Model 
 
One of the most common methods of determining whether diffusion is the dominant process 
controlling drug release is to use the square root of time relationship established by Higuchi for 
the characterisation of diffusional drug release from non-swelling, non-erodible polymeric slabs 
[116].  In addition, Higuchi derived a relationship which describes the release of a poorly water 
soluble drug from the single face of a tablet [115].  The amount of drug released from matrix 
systems in which the dissolution medium is essentially a perfect sink as defined by Higuchi 
[126] is shown in Equation 4.3. 
 
(2 )s sQ D A C C t= −                                       Eq. 4.3                                    
where, 
t  = the elapsed time; 
Q  = the amount of drug released after time t per unit exposed area; 
D  = the diffusivity of the drug in a homogeneous matrix media; 
A  = the total amount of drug present in the matrix per unit volume (the initial 
        drug concentration); 
sC  = the solubility of the drug in the matrix material.                                              
 
This relationship can be modified to take into account the tortuosity and porosity of a system. 
For matrix systems in which drug leaches through pores and channels, by diffusion, the 
previously defined equation is modified to include the effective volume in which diffusion can 
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occur as well as the effective diffusional path length [126] and the modified equation is depicted 
as Equation 4.4. 
 
 
( )2 s sDQ A C C tε ετ= −                                      Eq. 4.4                                        
where, 
t  = the elapsed time; 
Q  = the amount of drug released after time t per unit exposed area; 
D  = the diffusivity of the drug in the permeating fluid; 
τ  = a factor representing tortuosity of the capillary system; 
sC  = the solubility of the drug in the permeating fluid; 
ε  = the porosity of the matrix system.     
 
Most matrix-type tablets release drug according to the square root of time kinetic model as 
described by Higuchi and as shown in Equation 4.4 [105].  For the regions that are a linear 
function of the square root of time, it has been established that diffusion dominates the overall 
release mechanism of drug release from such polymeric matrices [105,116,126,130]. 
 
 
4.3.5 An Alternative ‘first-order decay’ model 
 
Several first-order or exponential models have been developed and used for the analysis of 
dissolution-release data [91,132-136].  These models have attempted to describe the release 
kinetics of drugs from theoretical laws.  
 
For each formulation, the amount of the drug released at times, 22] 14, 10, 6, 2, [0,1,T =  were 
measured, resulting in the data set { }TttYY ∈= :)( . 
 
A MATLAB script was written which invoked the MATLAB function nlinfit to fit the 
function nkty =  with parameters k  and n  to the data sets { }TttYt ∈:)(,(  
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The relevant lines of code in the script are shown in Figure 4.3 
 
 
 
s=[1,.6];                    %initial estimate of parameters 
[S,R,J]=nlinfit(X,Y,@f,s);   %optimal parameters  
k=S(1); 
n=S(2); 
Figure 4.3 The MATLAB code for the ‘power law’. 
 
The function f referred to is nkttf =)( . The function nlinfit uses a gradient descent method 
to minimise the sum of squares of the errors between the regression curve and the data points. It 
returns optimal values of the parameters k  and n . 
 
The coefficient of determination 2R  statistic was also determined and it was found that 
99.097.02 −≈R in each case, indicating a good fit of the regression curve to the experimental 
data sets.  
 
Since ∞=∞→
n
t
ktlim the model provides a good approximation for only the initial portion of the 
release. Rinaki et al are careful to point out that the value of the “power law” is confined to the 
first 60% of the release curve [117,132-136,192].  Therefore, an attempt was made to derive a 
model that is able to describe the entire release profile. 
 
An alternative model was developed and applied to the analysis of CBZ dissolution rate data. 
This model is not new and can be found in [195] but the details are presented for completeness.   
To this end, t  and M∞  are as before and ty M= is the amount of drug released after time t . If 
dy is the amount of drug released in the time interval from t  to t dt+ then it is proposed that  
amount released per unit time is constant
amount remaining
                     Eq 4.5 
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In other words, for some constant r : 
                                                           
dy
M y rdt
∞ − =                                                 Eq 4.6 
 
This is equivalent to 
                                                   ( )dy r M y
dt ∞
= −                                                            Eq 4.7 
The solution of this first order ordinary differential equation with the initial condition (0) 0y =  is 
given in Equation 4.8 
                                                           (1 ) ( )rty M e g t−∞= − =                                            Eq 4.8   
 
This model was called the ‘first-order decay’ model for the purposes of these studies. In the case 
of sustained-release dosage forms, the release data follow apparent first-order kinetics.   
                                                                                                 
A similar MATLAB script as shown in Figure 4.3 was written which fits this new regression 
curve )(tg  to the experimental data points, for the test formulations and stores the parameters 
rM ,∞ , in addition to the 
2R statistic.  
 
It was found in all cases that the 2R values were in the range ≈ 0.97 - 0.99. The advantage of this 
natural model over the ‘power law’ is that the parameter r  gives the fraction of the amount of 
the drug remaining to be released per unit time and it models the entire release profile as opposed 
to 60% described by the ‘Power Law’[88, 131-136].  Furthermore, the limit of the function g(t) 
as defined in Equation 4.9 is M∞ and is one of the parameters obtained from the regression 
analysis.  
 
 
∞∞→ = Mtgt )(lim                                                   Eq. 4.9                                   
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A plot of the linear fit in which r is correlated to n derived from the ‘power law’is depicted in 
Figure 4.4, where it is clear from the correlation matrix depicted in Figure 4.5, that there is a 
strong correlation between the parameters n  and r .  The parameter r, offers an alternative 
method to describe release, to the n value derived from the ‘power law’ and due to the 
correlation can be used to describe the mechanism of drug release throughout the entire drug 
release profile. 
 
 
             Figure 4.4 Fit depicting the linear relationship between n and r as derived from 
                               the MATLAB computational environment. 
 
The correlation matrix between the parameters n and r  is shown in Figure 4.5.  It is clear from 
these data that n and r are strongly correlated. 
 
 
⎥⎦
⎤⎢⎣
⎡
−
−=
0000.19554.0
9554.00000.1
cm  
         Figure 4.5 Correlation matrix 
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The coefficients of the regression line in Figure 4.4 are ]7693.0,9926.1[−=c and therefore the 
relationship between n and r can be described by Equation 4.10. 
 
7693.02 +−≈ rn                                                       Eq. 4.10 
 
Using Equation 4.10, a value for r corresponding to n = 0.5 can be obtained. Solving Equation 
4.10 for n = 0.5 yields an r value of approximately 0.35 or 13.5% remaining to be released per 
unit time. 
 
Rinaki et al [91,131-136,192] demonstrated that the ‘power law’, in particular the n  value, can 
describe the mechanism of drug release for a particular drug-release profile. From the above 
discussion it follows that the alternative first-order model, in particular the r  value, can also 
describe drug-release profiles adequately 
 
An n value of 0.5 represents perfect diffusion of a drug from a matrix and was used as a 
reference value to determine an equivalent value for the parameter, r.  The inverse correlation 
between n and r as shown in Figure 4.3 means that increments in n represents a decrease in r.  
The converse is true for decreasing values of n from the ‘power law in relation to the r value 
from the proposed ‘first-order decay’ model.  These parameters can be used as numerical 
indicators of the probable mechanism of drug release from these systems. 
 
From the correlation established between n and r, an r value of 0.35 or 13.5% is indicative of a 
diffusion-controlled mechanism of drug release analagous to that described by the n = 0.5 
exponent from the ‘power law’. 
 
The relationship between n  and r  was further investigated by regression analysis of a quadratic 
relationship and the resultant plot of this fit is depicted in Figure 4.6.   
 
. 
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Furthermore, the relationship can be mathematically described using Equation 4.11.  
 
9.023.53.12 2 +−≈ rrn                                            Eq. 4.11 
 
If we plot n against r for the whole data set of 41=N profiles we obtain: 
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Figure 4.6 Fit depicting the quadratic relationship between n and r as derived from 
                        the MATLAB computational environment. 
 
 
To discover an approximation to the relationship between n and r we can try a regression 
polynomial )(rpn = . The higher the degree the better the fit. But the higher the degree, the 
greater the number of inflection points and the worse the ability of the polynomial to interpolate. 
We assume that the errors, iii nrpe −= )( are normally distributed about zero. The variance is 
then ∑
=
N
i
ieN 1
21 . If the degree of the regression polynomial is k then an unbiased estimate of the 
variance is ∑
=−=
N
i
iekN
v
1
21 .One way of deciding on the degree of the regression polynomial is 
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to increase k until the v starts to increase. The other way is to simply use common sense and 
expert knowledge and scientific intuition about the data. The following figures show the 
regression curves and their 2R values. 
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Figure 4.7 Fit depicting the cubic relationship between n and r as derived from 
                     the MATLAB computational environment. 
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Figure 4.8 Fit depicting the quartic relationship between n and r as derived from 
                      the MATLAB computational environment. 
 
The 2R values and the corresponding estimates of the variance are listed: 
 
degree 1 estimate: 0.00164113    R^2: 0.86096727 
degree 2 estimate: 0.00014643    R^2: 0.98926734 
degree 3 estimate: 0.00008870    R^2: 0.99369303 
degree 4 estimate: 0.00009068    R^2: 0.99372244 
 
The regression curves are: 
83.043.2 +−= nr  
183.562.14 2 +−= nnr  
06.199.772.3558.59 23 +−+−= nnnr  
4 3 290.24 16.72 28.80 7.55 1.05r n n n n= − − + − +  
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The unbiased estimates first decrease and then starts to increase after degree 3. The 2R value 
steadily improves. From degree 1 to degree 2 there is a significant improvement. From degree 2 
to degree 3 there is a slight improvement at the expense of simplicity. There therefore is a case 
for choosing the quadratic over the cubic: in regression, simpler is better. 
 
Using the quadratic regression curve, the rn, values are listed: 
r              n  
0.0500    0.7440 
0.0600    0.7018 
0.0700    0.6625 
0.0800    0.6262 
0.0900    0.5928 
0.1000    0.5623 
0.1100    0.5347 
0.1200    0.5101 
0.1300    0.4884 
0.1400    0.4696 
0.1500    0.4537 
0.1600    0.4408 
0.1700    0.4308 
0.1800    0.4237 
0.1900    0.4196 
0.2000    0.4183 
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With r as the dependent variable: 
n            r  
0.4500    0.1527 
0.4600    0.1458 
0.4700    0.1398 
0.4800    0.1343 
0.4900    0.1292 
0.5000    0.1245 
0.5100    0.1200 
0.5200    0.1158 
0.5300    0.1118 
0.5400    0.1080 
0.5500    0.1043 
0.5600    0.1008 
0.5700    0.0974 
0.5800    0.0941 
0.5900    0.0909 
0.6000    0.0878 
0.6100    0.0847 
0.6200    0.0818 
0.6300    0.0789 
0.6400    0.0761 
0.6500    0.0734 
0.6600    0.0707 
0.6700    0.0680 
0.6800    0.0655 
0.6900    0.0629 
0.7000    0.0604 
0.7100    0.0580 
0.7200    0.0556 
0.7300    0.0532 
0.7400    0.0509 
0.7500    0.0486 
0.7600    0.0464 
0.7700    0.0442 
0.7800    0.0420 
0.7900    0.0398 
0.8000    0.0377 
 
 
We see that 5.0=n corresponds to %45.121245.0 ==r and so on. 
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4.3.6 Application of the ‘first-order decay’ Model. 
 
The dissolution rate profiles of twelve experimental formulations and the innovator product 
Tegretol® CR were generated and fitted to the ‘power law’ and the ‘first-order decay’ model.  A 
summary of the model parameters generated from these data in addition to the f1 and f2 difference 
and similarity factors are shown in Table 4.1. 
 
     Table 4.1 Statistical and mathematical parameters for the experimental 
                      formulations tested. 
Formulation k  n  1f  2f  ∞M  r  
 Tegretol® CR 18.87 0.47 - - 77.90 0.1486 
 C-280503-01 25.97 0.42 20.8 48.3 87.86 0.1875 
 C-190603-02 14.97 0.52 10.7 63 78.43 0.1130 
 C-190603-03 15.66 0.49 12.5 59.9 72.88 0.1279 
 C-200603-01 14.95 0.51 13.9 57.5 71.87 0.1277 
 C-200603-02 19.25 0.43 8 62.6 67.47 0.1835 
 C-200603-03 21.74 0.41 5.7 72.2 71.59 0.1981 
 C-030703-01 13.81 0.63 14.7 52.8 114.98 0.0777 
 C-030703-03 8.78 0.71 17.1 51.0 102.74 0.0614 
 C-030703-04 13.09 0.62 9.3 62.4 101.04 0.0848 
 C-030703-05 19.2 0.48 6.2 71.9 85.52 0.1344 
 C-260303-01 7.26 0.62 45 32.1 59.22 0.0764 
 C-260303-02 12.00 0.47 35.6 36.6 50.41 0.1504 
                    *Shaded values indicate dissolution profile similarity 
 
From the data summarized in Table 4.1, it is clear, by way of example that Batch C-190603-02 
and C-190603-03 exhibit pure diffusion controlled release whereas Tegretol® CR with an n value 
0.47 and corresponding r value of 14.9% exhibits near pure diffusion controlled release. 
 
The 1f  and 2f values shown in Table 4.1 were calculated using Tegretol
® CR dissolution rate data 
as the reference set.  It is clear that the release profiles of several formulations show similarity, 
using the 1f   and 2f  difference and similarity factors, to the reference product Tegretol
® CR.   
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The derived values for n  and r were used to determine the mechanism of drug release, as 
defined by Peppas et al [122,123,128], and formulations showing similarity when comparing the 
f1 and f2 difference and similarity values are highlighted in Table 4.2.  Batch C-260303-02 has 
the same n  value of 0.47 as Tegretol® CR( r =14.9%), and although the amount of drug released 
may show no similarity to the reference product, the mechanism of release may be simulating 
similar behavior that of Tegretol® CR based on the assumptions and conclusions using these 
mathematical parameters. 
 
In this manner, it is possible to identify formulations that show in vitro mechanistic similarities 
through the application of statistical and mathematical modelling, to that of the reference 
formulation.  Therefore, it is hoped that these formulations will mimic more closely the in vivo 
behaviour of Tegretol® CR which is in clinical use for the prevention of epileptic seizure 
behaviour.  These mathematical models allow for a ‘honing-in’ on the formulation closest to the 
innovator product. 
 
 
4.3.7 Comparison of the ‘Power Law’ and the ‘first-order decay’ Model 
 
 
The dissolution data of Tegretol® CR fitted to the “power law” where the k and n values are 
elucidated is shown in Figure 4.9  The dissolution profile of Tegretol® CR fitted to the ‘first-
order decay’ model where the r parameter and the total drug release parameter, M∞, are 
elucidated is shown in Figure 4.10.  This is an alternative method to describe drug release over 
the entire drug release profile whereas the ‘power law’ only describes the first 60% of the drug 
release profile [117]. 
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 Figure 4.9 Dissolution profile of Tegretol® CR fitted to the ‘power law’. 
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Figure 4.10 Dissolution profile of Tegretol® CR fitted to the ‘first order 
            decay’ model. 
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Drug release from Batch C-030703-05 was similar to Tegretol® CR using the f1 and f2 difference 
and similarity factors.  In addition the n value was similar to that of Tegretol® CR relative to the 
other formulations produced in these studies.  The dissolution profile of batch C-030703-05 was 
fitted to both models and these data graphically depicted in Figures 4.11 and 4.12. 
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        Figure 4.11 Batch C-030703-05 fitted to the ‘power law’. 
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       Figure 4.12 Batch C-030703-05 fitted to the ‘first-order decay’ model. 
 
 
4.3.8 Elucidation of Mechanism of CBZ Release from HPMC Matrix Tablets 
 
The results obtained from fitting experimental dissolution data to the ‘power law’ and to the 
‘first-order decay’ model are listed in Table 4.2.  In addition, the difference and similarity factors 
f1 and f2 were calculated for these data sets using Tegretol® CR as the reference formulation and 
these data are also summarised in Table 4.2.  Formulation profiles that showed similarity to 
Tegretol® CR when comparing f1 and f2 difference and similarity factors, did not necessarily 
show similarity when their respective n  exponents and r  values were compared to those  of 
Tegretol® CR. 
 
The values of n and r  obtained for Batches C-190603-02, C-190603-03, C-200603-01 and  
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C-030703-05 indicated that the most probable mechanism controlling CBZ release from these 
products is Fickian diffusion with square root of time dependant, drug release.  
 
Square root of time plots are depicted in Figure 4.13 and R2 values obtained from linear 
regression analysis of these plots are shown in Table 4.2.  Linearity was established using the 
square root of time relationship and suggests that the predominant mechanism controlling drug 
release from these specific formulations was diffusion. For highly water-insoluble compounds 
such as CBZ, erosion of the polymer plays a more significant role controlling drug release from 
these delivery systems [103].   
 
 
 
 
  
-10
0
10
20
30
40
50
60
70
80
90
100
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
square root of time (Hours)
Fr
ac
tio
n 
R
el
ea
se
d
C-190603-02 C-190603-03 C-200603-01 C-030703-05
 
   Figure 4.13 Higuchi plots for dissolution profiles of selected formulations over a 22 hour                          
                        period. 
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                                    Table 4.2 R2 values for square root of time plots. 
Formulation R2 
C-190603-02 0.9954 
C-190603-03 0.9948 
C-200603-01 0.9921 
C-030703-05 0.9945 
 
 
Diffusion control may be time-specific and square root of time plots, were generated to assess 
linearity over the first six hours of the dissolution process.  Linear regression plots for dissolution 
data Batches C-190603-02, C-190603-03, C-200603-01 and C-03070305 where the fraction 
released for the first six hours was assessed according to the Higuchi relationship [126] are 
depicted in Figure 4.9. 
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Figure 4.14 Higuchi plots for dissolution profiles of selected formulations over a 6 hour 
                        period. 
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The R2 statistic for the Higuchi plots shown in Figure 4.14 are depicted in Table 4.3 and from the 
apparent improved linearity, it may be possible that diffusion is pre-dominant during the early 
stages of the drug release process from these hydrogel matrix tablets, an as time proceeds, so the 
control of the release form these dosage forms is affected by the erosion and dissolution of the 
HPMC in the matrix. 
 
  Table 4.3 R2 values for square root of time plots for the first 6 hours. 
Formulation R2 
     C-190603-02 1 
C-190603-03 0.998 
C-200603-01 0.995 
C-030703-05 0.994 
 
The dissolution profiles of CBZ Batches C-200603-02 and C-200603-03 also showed statistical 
similarity to Tegretol® CR but yielded n values < 0.5 which is indicative of pure Fickian 
diffusion-controlled release.  Batches C-030703-01 and C-030703-04 yielded n values > 0.5, 
which is a mathematical indicator describing anomalous, Case-II type transport which is 
complex and confounded by polymer erosion.   
 
According to the mathematical parameters derived for the various formulations tested revealed 
that, a range of values were obtained where some formulations perform by diffusion control 
whereas other formulations release the API by anomalous, Case-II type transport where erosion 
and dissolution rate of the polymer determines the release kinetics of CBZ. 
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4.4 CONCLUSION 
 
There is no single, overall mathematical model that can be used to describe all the mass transport 
mechanisms and chemical processes that occur in these disparate systems [90] and thus the 
availability of a range of mathematical modelling tools provide greater insight into drug release 
mechanisms from swellable hydrogel matrices.  
 
 It is evident that both models, viz., the ‘power law’ and ‘first-order decay’ models fit the data 
reasonably well and it is not the intention of the author to suggest superiority of one model over 
another but to highlight that the ‘first-order decay’ model provides mechanistic information 
effectively over the entire release profile whereas the ‘power law’ predicts and explains drug 
release mechanisms for only the first 60% of the drug release profile.  
 
The mechanisms by which drug was release from the formulations produced during these studies 
varied between diffusion control and anomalous transport. Matrix dissolution or matrix erosion, 
which is an important characteristic of swellable and erodible systems, is not considered in the 
Higuchi, square root of time model. Therefore mechanistic information obtained by this method 
should be viewed and assessed with caution [103].  Some of the formulations developed in these 
studies showed evidence of diffusion controlled release where square root of time plots for the 
first six hours and the entire dissolution time of twenty two hours showed good linearity. 
 
Changes in the swelling kinetics of the HPMC matrices can lead to changes in drug release 
through two distinct mechanisms.  For a drug that has not completely dissolved in the hydrated 
matrix, faster matrix dissolution would result in an increased drug release rate by the process of 
matrix erosion.  Secondly, changes in the swelling can lead to changes in the diffusional path 
length and/or diffusional resistance of the gel layer which becomes pertinent in the case of a drug 
that completely dissolves at the medium penetration front and released by a diffusional 
mechanism where changes in the gel layer thickness can affect drug release kinetics [103]. 
 
In the cases of the formulations where the n  values are suggestive of diffusion-controlled 
release, it may be possible that polymer erosion is slower than the drug release rate and therefore 
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diffusion of the API is far more significant at that stage of the release process.  These effects 
become formulation specific since different formulations produced different mathematical 
parameters following assessment of their dissolution profiles using modelling techniques.   
 
Diffusion is especially significant during the initial stages of tablet behaviour in a dissolution 
medium as shown in Table 4.4, since as the swelling process proceeds, the gel layer gradually 
becomes thicker and therefore the drug concentration gradient along the diffusional pathlength is 
decreased which results in progressively decreased drug release rates [103].  Furthermore, for 
diffusion-controlled systems, the surface area: volume ratio is a key variable in controlling drug 
release form HPMC matrices [116].  This becomes especially pertinent with respect to these 
dosage forms where polymer swelling and erosion affect the surface area: volume ratio.  Surface 
area:volume ratios can be used to duplicate drug release profiles for tablets having different 
sizes, shapes and dose levels [116], where different physical configurations can be adapted to 
have the same surface area:volume ratios.  Therefore, surface area:volume ratio dependent drug 
release can be identical for two differently shaped tablets with this parameter the same. 
 
Therefore polymer erosion and dissolution may become more significant in effecting drug 
release where the concentration and viscosity grade of the polymer become relevant in 
determining gel layer thickness and degree of erosion during extended dissolution testing. 
 
It is generally believed in the field of oral controlled drug delivery, that zero-order drug release 
from a delivery system reflects optimised drug delivery [102].  Synchronisation of the swelling 
and erosion fronts during the release process is associated with zero-order drug release and this is 
true for drug release from surface erodible systems in the flat sheet geometry [112].  No dosage 
form produced during these studies showed zero-order drug release ( n  = 1) [105] and this is to 
be expected given the geometry of the dosage form where due to the shape of the tablets, 
biconvex or disc-shaped, it is theoretically impossible for these delivery devices to release the 
API at a zero-order release rate [105].  This is because the system erodes which is the case with 
most polymers, and the surface area exposed to the dissolution fluid continually decreases, i.e., 
the diffusion path for water-soluble drugs increases in length [105].  Although values obtained 
for some formulations assessed during these studies implicated diffusion as a release mechanism, 
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CBZ is a highly water-insoluble drug therefore, diffusion may a predominant mechanism for 
specific formulations.  Generally, water soluble drugs follow a diffusion-controlled mechanism 
of drug release from polymeric matrices.  A value n  = 1 indicates zero-order drug release from a 
planar surface and not for spheres or cylinders [115].  Thus values of n  = 1 for the matrix 
devices assessed during these studies merely emphasize that release from these dosage forms is 
not Fickian controlled and implies large contributions to drug release kinetics by erosion of the 
polymer[115]. 
 
For the maintenance of zero-order controlled-release, tablet matrices should be as near spherical 
as possible to produce minimum drug release rates. A linear relationship between release rate 
and surface area exists where drug release kinetics from hydrogel matrices is controlled by the 
releasing area increase produced by the swelling phenomenon [104,121].  
 
Mathematical modelling of controlled drug delivery systems can yield information about the 
mechanisms involved in the release of therapeutic agents from sustained release systems [90].  
Furthermore, modelling can provide insight into the effects of varying several dosage form 
parameters such as geometry or composition, on drug release kinetics.  In addition, modelling 
can be used as a tool for the optimisation of existing drug delivery systems and for the 
development of more appropriate novel therapeutic drug delivery systems in the future [90].  
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CHAPTER FIVE 
FORMULATION DEVELOPMENT OF SUSTAINED RELEASE CBZ MATRIX 
TABLETS 
 
5.1 Rationale for the Sustained Delivery of CBZ 
 
The advantages of a controlled release dosage form over immediate release products includes 
improved patient compliance due to a reduced dosing frequency, a decreased incidence and/or 
intensity of side effects, a greater selectivity of pharmacological activity with a prolonged and 
constant therapeutic effect, in addition to improved cost-effectiveness [101].   
 
CBZ is one of the most important drugs used for the treatment of psychomotor epilepsy and 
trigeminal neuralgia [102,107].  Physiologically, it displays slow and irregular gastro-intestinal 
absorption, due to its low water solubility and has a short biological half-life when used for 
chronic therapy as a consequence of the auto-inductive effects of CBZ on liver enzymes 
[64,93,97,102,107].  An initial half-life of approximately twenty four to forty hours is reduced to 
twelve hours with chronic monotherapy and eight hours in patients taking other enzyme-inducing 
drugs [102,107].  
 
Consequently, CBZ is dosed frequently as three or four doses per day, which reduces patient 
compliance as well as promoting plasma level fluctuations and therefore, concentration-related 
side-effects may occur [93,107].  In addition CBZ has a narrow therapeutic window and large 
diurnal variations in the plasma concentration of CBZ may lead to several side-effects such as 
headache, sedation, diplopia, blurred vision amongst others [93].  
 
A more stable serum/plasma concentration of CBZ can be achieved through the use of slow-
release preparations such as polymeric matrix tablets [102] where the ideal use of such dosage 
forms would decrease plasma concentration fluctuations through the constant and controlled 
release of CBZ, thereby reducing dose-related side-effects and improving patient compliance 
[93].   
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5.2 Formulation Development 
5.2.1 Tablet Manufacture 
 
Tablets are solid oral dosage forms that are a most popular and convenient means of drug 
delivery.  The technology and processes involved in the tabletting industry have evolved and 
advanced to optimise large-scale production in addition to drug delivery techniques.  Two 
methods of tablet manufacture were used during these studies, viz., wet-granulation (WG) and 
direct compression (DC) methods of manufacture. 
 
5.2.2 Wet Granulation 
 
WG is a well-known and widely used manufacturing technique used for the preparation of 
powders for the purposes of tablet production.  Most powders do not flow readily and for the 
purposes of tableting, powders are converted into agglomerates or granules that are free-flowing 
and can be compressed into tablets.  The relevant powders, drug and excipients, are weighed and 
screened through an appropriately sized mesh.  The sieved powder bulk is then blended and 
granulated with the aid of a suitable granulating fluid.  The choice of granulating fluid will 
depend on the properties of the drug candidate to be tabletted in addition to the desired release 
properties of the API from the tablet.  The wet mass is then screened through an appropriate 
mesh and the resultant granules are dried under specific conditions.  Dried granules may be re-
screened and then further manipulated by the addition of additional drug, excipients and a 
lubricant which are again blended to promote uniformity of distribution of the API.  The blend is 
then compressed into tablets.  A schematic diagram of the WG process used for tablet 
manufacture, illustrating the processes and variables used in these studies is depicted in Figure 
5.1. 
 
Some of the factors and process variables that affect tablet manufacture in addition to dosage 
form performance include the amount and method of binder added during granulation, the 
method of granulation, e.g., high or low shear, granulate size distribution and compression force 
[137]. 
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Changes or modifications in polymer type and excipients and manufacturing processes can 
modify and obtain specific drug release rates [113].  The presence of low percent w/w quantities 
of HPMC and the high water mobility during WG allows for greater chain mobility, swelling and 
spreading which results in slower tablet erosion and thereby increasing the lag-time of drug 
release from time-delayed HPMC dosage forms [106].  This may contribute to low drug release 
rates from controlled release dosage forms and becomes important when using a highly water-
insoluble drug such as CBZ in such systems. 
 
 
5.3 Experimental 
5.3.1 Overview 
 
A wet granulation formulation was adopted as a prototype formulation and further modified to 
investigate the effects of selected formulation variables on CBZ release from these products 
[138]. 
 
The performance of the manufactured matrix formulations and in relation to formulation 
modifications was assessed by means of in vitro dissolution testing and by assessment of the 
physical properties of the tablets produced.  Dissolution studies were conducted as described in 
Section 3.8.4 and the CBZ release profiles and data generated were assessed statistically as 
described in Section 3.9 to elucidate the performance of the batches relative to each other and 
relative to the innovator product Tegretol® CR (Novartis, Quebec, Cananda).   
 
Furthermore, two particle size grades of CBZ were assessed for their effect on dosage form 
performance, either alone or in varying proportions and combinations.  Other formulation 
variables were assessed for their impact on dosage form performance as discussed in Chapter 6 
where formulations were assessed and effectively optimised to produce tablets with specific drug 
release and physical characteristics. 
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5.3.2 Materials 
5.3.2.1 CBZ 
 
Two particle size grades of CBZ were donated by Noveon Pharma (Raubling, Germany).  The 
fine grade particle size FG (approximately 7 µm tested diameter) and course grade particle size 
CG (approximately 13 µm tested diameter) were used without further modification. 
 
Properties of the drug substance that influence the dissolution rate and its subsequent 
bioavailaibility include its solubility, particle size distribution as well as crystalline state such as 
polymorphism, state of hydration or complexation [118].  These factors were considered and 
some were investigated for their impact on drug release rates. 
 
5.3.2.2 Excipients 
 
All materials used in this study are Generally Regarded as Safe (GRAS) listed, and appear in the 
Food and Drug Administration Inactive Ingredients Guide for inclusion in oral formulations 
[139]. 
 
5.3.2.3 Hydroxypropylmethylcellulose (HPMC) 
 
Cellulose derivatives are widely used in the formulation of hydrogel matrices for controlled drug 
delivery [104].  HPMC is a non-ionic, water-soluble, semi-synthetic ether derivative of cellulose 
made by The Dow Chemical Company (Midland, MI, USA) and marketed as Methocel® by 
Colorcon (Orpington, Kent, UK) [101,112].  It is soluble in water and forms a viscous colloidal 
solution on hydration [34].  HPMC is frequently used due to its low toxicity, ease of use and 
availability, minimal influence of processing variables on drug release, its ease of compression 
and its capability to accommodate high levels of drug [103-105,112].  Some additional 
advantages, especially pertinent to this study, is their innate flexibility and ability to achieve 
specific drug release profiles, their application in matrix tablets which is fairly extensive, in 
addition to their cost-effectiveness and broad FDA acceptance [118].   
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The concentration and viscosity grade of HPMC are the most often variables that are changed to 
regulate drug release from dosage forms and these variables may affect the kinetics and 
mechanisms of drug release [103-104].  Hydrogel polymers such as HPMC form the basis for 
implantable, transdermal and oral-controlled release systems [115], where it could be used either 
as a binder, a film-coating agent or as a sustained release matrix-forming excipient [139].   
 
It is available in a variety of different grades, depending on the degree of substitution on the 
polymer chain backbone and the average molecular weight of the polymer [139].  One of the 
most important characteristics of HPMC is its high swellability on contact with aqueous media, 
which has a considerable effect on the release kinetics of drugs in HPMC matrices [114].    
 
The manufacturing process has a significant impact in determining the dissolution characteristics 
of HPMC matrix tablets [137].  HPMC displays good compression characteristics and has 
adequate swelling properties and can accommodate a high level of drug loading [140].  In 
addition, HPMC is unaltered by shear forces that are applied in the granulation step where the 
presence of water mobility during wet granulation at low concentrations of HPMC allows greater 
chain mobility/swelling and spreading [106].   
 
High viscosity grades may be used to retard the release of drugs from matrices at levels of 10% 
w/w to 80% w/w in tablets and capsules [139].  It appears likely that different combinations of 
polymers will be applicable to different drugs in order to match the rate of the advancement of 
swelling into the glassy core and the rate of attrition of the polymer [105].  The drug candidate 
used in this study was highly water insoluble and both high and low viscosity grades of HPMC 
were assessed for their effects on drug release rates.  For hydrophilic matrix tablets that contain 
water-soluble, swellable polymers such as HPMC, the release kinetics are described by a 
combination of drug diffusion and polymer dissolution or surface erosion as discussed in Section 
4.2 [116].  
 
Some approaches to overcoming the dissolution limitation of poorly water-soluble drugs is the 
formulation of the drug in an amorphose form [141].  HPMC is known to promote the stability of 
this form through the inhibition of the transformation of CBZ to CBZ dihydrate in the gel layer 
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and participates in the crystallisation process to induce amorphism, which may aid the rate and 
extent of drug dissolution [142,143].   
 
For a highly water-insoluble drug such as CBZ, the lower viscosity grades of HPMC become 
more suitable for controlling drug release since surface erosion of the polymer may be the 
predominant factor, controlling drug release from these systems [116].  Polymer grade, 
proportion and polymer grade combinations were assessed and optimised to effectively deliver 
CBZ from a matrix formulation produced by either wet granulation or direct compression.  
Methocel® K4M and K100M were donated by Colorcon Limited (Orpington, Kent, UK) and 
used in varying proportions in  an attempt to sustain drug release. 
 
In addition, the addition of a partial amount of HPMC intergranularly in the dry blend step of the 
wet granulation process has been shown to desensitize drug release profiles to the effects of the 
manufacturing process [137].  This was the case for these formulations where additional HPMC 
(grade specific) was added during the blending step of dried granules with additional excipients.  
 
5.3.2.4 Dibasic Calcium Phosphate (DCP) 
 
DCP is available in an anhydrous or dihydrate form and both forms are used as an excipient and 
a source of calcium in nutritional supplements [139].  Two particle-size grades of both 
anhydrous and dihydrate DCP are used in the pharmaceutical industry, i.e., a milled version and 
unmilled or coarse grade material which is typically used in direct-compression formulations 
[34].  DCP imparts tensile strength to tablets due to its abrasive properties and a lubricant is 
usually required for tabletting, e.g., 1% magnesium stearate or 1% sodium stearyl fumarate 
[139].  In these studies, Emcompress® (Edward Mendell Co. Inc, NY, USA) was used as the 
DCP source.  DCP has been shown to yield lower drug release, and to a lesser extent, the soluble 
excipients within a formulation due to it water insolubility [118]. 
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5.3.2.5 Microcrystalline Cellulose (MCC) 
 
MCC is widely and commonly used in pharmaceutical manufacturing [144], primarily as a 
binder/diluent in oral tablet formulations where it is used in both wet-granulation and direct 
compression formulations [139,144].  In addition MCC has some lubricant and disintegrant 
properties that make it useful in tableting [139].  It is available in different particle size and 
moisture grades [144], where larger particle size grades afford better flow properties to 
formulations and low moisture grades are used with moisture-sensitive materials [139].  
Emcocel® 90M (Edward Mendell Co. Inc, NY, USA) was used for the formulations in these 
studies.  This grade of MCC has a mean particle size of 91 µm, and moisture content of less than 
5.0%.  MCC is a hygroscopic material and should be stored appropriately [139]. 
 
5.3.2.6 Lactose 
 
Lactose is widely used as a filler or diluent in tablets with various grades that have different 
physical properties such as particle size distribution and flow characteristics being available 
commercially [139].  The grade of lactose chosen for inclusion in formulations is dependant on 
the type of dosage form to be produced, where direct-compression grades of lactose are more 
fluid and compressible than crystalline or powdered lactose.  DC grades of lactose are generally 
comprised of spray-dried lactose that contains specially prepared pure α-lactose monohydrate 
along with a small amount of amorphous lactose [139].  Lactose is water soluble [139] and also 
adds to the wetting capabilities of matrix tablets which become especially useful for application 
to insoluble drug candidates such as CBZ.  Spray dried lactose monohydrate (The Lactose 
Company, Wellington, New Zealand) was used in these studies.  The combination of HPMC and 
lactose may be used to control drug delivery from extended release formulations [106]. 
 
5.3.2.7 Sodium Lauryl Sulphate (SLS) 
 
Surfactants are commonly used in pharmaceutical dosage forms as wetting agents [146].  SLS is 
an anionic and water-soluble surface active lubricant [139,145].  It can be used effectively as a 
wetting agent in both alkaline and acidic conditions [139].  SLS is stable under normal storage 
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conditions but undergoes hydrolysis to lauryl alcohol and sodium bisulphate at pH values of ≤ 
2.5 [139].  SLS has been used in quantities of 1% w/w for its surface tension lowering capability 
and to improve dissolution of CBZ [145].  When used in formulations in which magnesium 
stearate is included, in the solid state at a ratio of 1:5, SLS can suppress any retardation of in 
vitro dissolution caused by prolonged mixing of magnesium stearate [145].  SLS has been shown 
to improve the water solubility of CBZ even at a concentration of 0.1% w/w [146], which is 
considerably below the cricitcal micelle concentration (CMC) of SLS [146].  Surfactants can also 
modify the rate of crystal form transformation and the rate of growth of the stable crystal form as 
well as the crystal habit and therefore affect stability and bioavailability of CBZ [146].  SLS was 
purchased from Sigma Aldrich (Johannesburg, Gauteng, South Africa). 
 
5.3.2.8 Magnesium Stearate (Mg stearate) 
 
Mg stearate is widely used as a lubricant in tablet manufacture for pharmaceutical formulations 
[139].  Mg stearate is hydrophobic and when used in quantities > 5% w/w may retard drug 
release from solid dosage forms [139].  Blending times with Mg stearate have to be monitored 
and controlled when using Mg stearate as this material when over-blended results in a decrease 
in tablet dissolution rates and crushing strength of tablets, as well as increased tablet friability 
[139].  During these studies, Mg stearate was used at concentrations of ≤ 1% w/w.  Mg stearate 
was donated by Aspen-Pharmacare (Port Elizabeth, Eastern Cape Province, South Africa).  
 
5.3.2.9 Polyvinyl Alcohol (PVA) 
 
PVA is a water-soluble synthetic polymer used in sustained-release formulations for oral 
administration [139].  It is useful for application as a granulating fluid, for both hydrophilic and 
hydrophobic drugs despite their high water content [147].  Solutions of 2% w/v were used to 
granulate powder blends in these studies, where it was intended that the wetting potential of 
PVA, due to its solubility, would enhance fluid penetration into the dosage form and thus 
enhance drug release from the tablet.  PVA was purchased from Sigma Aldrich (Johannesburg, 
Gauteng, South Africa).  
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5.3.3 Manufacturing Methods 
 
Matrix tablets were manufactured using the formula listed in Table 5.1 and the WG method 
outlined in section 3.6.3.2.  Tablets were manufactured using the principles of Good 
Manufacturing Practice (GMP) with the maintenance of appropriate documentation of any 
observations and irregular events that were encountered during the manufacturing process, viz., 
granulation, blending and compaction.  The relevant documentation for selected batches of 
tablets, manufactured both by WG and by DC are shown in Appendix II.  A summary of the 
pertinent characteristics of all batches produced for these studies is shown in Appendix II. 
 
 
Table 5.1 Wet Granulation Tablet Formulations 
1.Granules  C-211202-01 
% w/w 
C-211202-02 
% w/w 
C-211202-03 
% w/w 
C-211202-04 
% w/w 
 Active 50 50 50 50 
 Methocel® 
K4M 
10 10 10 10 
 Emcocel® 90M 20 20 20 20 
 Emcompress® 12 12 12 12 
 Lactose 8 8 8 8 
  100 100 100 100 
2. Polyvinyl alcohol     
(2% w/v) 
≈ 100 mL per 
1000g (10%) 
    
      
3. Final Formulation      
 Active 16 16 32 32 
 Granules 67 67 35 35 
 Methocel® 
K100M 
- 9 - 15 
 Methocel® 
K4M 
9 - 15 - 
 Emcocel® 90M 4 4 8 8 
 Emcompress® 4 4 10 10 
 SLS 1 1 1 1 
4. Mg stearate  1 1 1 1 
 TOTAL 102 102 102 102 
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5.3.3.1 Manufacturing Procedure 
 
A schematic diagram of the manufacturing procedure used to manufacture tablets, is depicted in 
Fig 5.1.  All powders in section 1 (Table 5.1), were separately weighed, screened through a size 
20 mesh and granulated with water or PVA solution (2, Table 5.1) using approximately 100mL 
fluid per 1000g of powder.  A Kenwood® planetary mixer (Kenwood Limited, Havant, UK) was 
used for blending and the granulating fluid was introduced using a  Masterflex Easyload 
peristaltic pump (Cole-Palmer Instrument Company, Vernon Hill, IL, USA) at a constant rate of 
1mL/minute.  The wetted powder mass was then screened through a size 10 sieve using an 
oscillating granulator (Erweka, Heusenstamm,Germany) set at 50 r.p.m.   
 
The resultant granules were dried in an oven at 60°C (Gallenkamp, Loughborough, UK) for 
twelve hours.  The dry granule mass was re-screened through a size 10 mesh and the granule 
mass was recorded.  The final formulation composition, granules and excipients (3, Table 5.1) 
were then individually weighed, screened through a size 20 mesh and blended in a 1 kg capacity 
cube blender (Erweka, Heusenstamm, Germany) set at a horizontal angle, and rotated for twenty 
minutes at 100 r.p.m.   
 
The magnesium stearate (4, Table 5.1) was then weighed, sieved through a size 44 mesh and 
added to the blend and blending was continued for a further three minutes.  The blend was 
compressed into tablets on a Manesty B3B Rotary Press (Manesty, Liverpool, UK), tooled with 
two sets of biconcave punches to a target weight of between 700 and 850mg and a target 
hardness of between 120 and 150 Newtons (12 – 15 Kp).  Tablets were dedusted using a vacuum 
through a sieve, and stored away from light until analysed.   
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Figure 5.1 Flow diagram of the WG manufacturing process. 
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5.3.3.2 Effect of polymer grade on CBZ Dissolution Rate. 
 
To assess the effect of the polymer grade, viz., Methocel® K4M and K100M, on drug release rate 
from these tablets, four formulations were developed for tablet production.  The core granulate of 
the formulation (1, Table 5.1) remained the same and adjustments were made to the outer matrix 
compensation (3, Table 5.1) to produce four different products where the HPMC and granule 
composition was varied for these studies.   
 
Two formulations containing 15.7% w/w and 18.5% w/w Methocel® K4M and two formulations 
containing 9% w/w and 15% w/w Methocel® K100M were produced.  Formulations with 
Methocel® K100M also contained and additional 6.7% w/w and 3.5% w/w Methocel® K4M from 
the due to the K4M present in the granules (1, Table 5.1) within the formulation.  Therefore, 
formulations with the same polymer were compared to each other to determine the effects of 
HPMC content and further compared to the other formulations with a different grade of polymer 
to assess the effects of both quantity and type of polymer on drug release rates.  
 
The composition of the test formulations are listed in Table 5.2 and the resultant dissolution 
profiles were compared using the f1 and f2 difference and similarity factors [81]. 
 
Table 5.2 Formulation composition for four batches containing CBZ. 
 Batch  
C-211202-01 
Batch  
C-211202-02 
Batch  
C-211202-03 
Batch  
C-211202-04 
 % (w/w) % (w/w) % (w/w) % (w/w) 
CBZ (coarse grade) 16 16 32 32 
core granules 67 67 35 35 
Methocel® K4M 9 - 15  
Methocel® K100M - 9 - 15 
Emcocel® 90M 4 4 8 8 
Emcompress® 4 4 10 10 
SLS 1 1 1 1 
Mg stearate 1 1 1 1 
     
     
% K4M 15.7 6.7 18.5 3.5 
% K100M - 9 - 15 
Total HPMC % 15.7 15.7 18.5 18.5 
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These four formulations formed the empirical basis for the selection of components for all 
subsequent formulations where all further formulations developed were adapted predominantly 
from the compositions of Batch # C-211202-02. 
 
5.4 Results and Discussion 
5.4.1 Comparison of Dissolution Rates of the Four Formulations 
 
Batches C-211202-01 and C-211202-02 were manufactured using the procedure described in 
Section 3.6.3.2 and were the same composition except that in batch C-211202-02, Methocel® 
K100M (9% w/w) was substituted for Methocel® K4M.  Similarly, batches C-211202-03 and C-
211202-02 differed in that batch C-211202-04 contained 15% w/w Methocel® K100M whereas 
batch C-211202-03 contained 18.5% w/w Methocel® K4M only. 
 
Following dissolution testing using the method described in Section 3.8.4, the difference and 
similarity factors [81] were calculated and the resultant f1 and f2 values are listed in Table 5.3 and 
the dissolution profiles are depicted in Figure 5.2.  Batches C-211202-01 and C-211202-04 were 
found to be different and this may be attributed to the fact that batch C-211202-04 contained 
15% w/w HPMC K100M whereas C-211202-01 contained K4M which is the lower grade 
HPMC. It is evident that batches C-211202-01 and C-211202-02 are similar as are batches C-
211202-01 and C-211202-03 as well as batches C-211202-02 and C-211202-03. 
    
   Table 5.3 Statistical comparisons of the four formulations 
Formulation f1 f2 
   
C-211202-01 vs C-211202-02 4.5 81.3 
C-211202-01 vs C-211202-03 10.6 67.7 
C-211202-01 vs C-211202-04 27.4 47.4 
C-211202-03 vs C-211202-04 18.8 57.7 
C-211202-02 vs C-211202-03 7.5 74.0 
C-211202-02 vs C-211202-04 24.9 50.0 
Tegretol® CR vs C-211202-01 18.8 50.3 
                *Shaded areas represent out-of-specification results 
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The release rate profiles of the four test formulations.  The slowest release was recorded from the 
formulation with the highest proportion of HPMC and also containing Methocel® K100M.  This 
result for Batch C-211202-04, is expected, since Methocel® K100M is the higher viscosity grade 
and in combination with a higher quantity of HPMC, forms a thicker gel layer after hydration, 
which is more effective in prolonging drug release from these products.  
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Figure 5.2 Dissolution profiles of CBZ from batches C-211202-01 (15.7% w/w Methocel® K4M), C                 
                   211202-02 (6.7 Methocel® K4M; 9% w/w Methocel®K100M), C-211202-03 (18.5% w/w 
                   Methocel® K4M) and C-211202-04 (3.5 % w/w Methocel® K4M; 15% w/w Methocel®    
                              K100M)). 
 
 
All formulations contained Methocel® K4M within the granule component (1, Table 5.1) of the 
final formulation, therefore drug release behaviour from batches C-211202-02 and C-211202-04 
may be attributed  to the combined effects of both grades of HPMC.  Batches C-211202-02 and 
C-211202-04 contain Methocel® K100M and K4M.  It becomes apparent that the formulation 
with a combination of the two different grades, viz., Batches C-211202-01 and C-211202-02 
displayed a higher drug release than the formulations Batches C-211202-03 and C-211202-04.  
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This suggests within certain limits that the concentration of the polymer content plays a more 
significant role in drug release rather than the actual viscosity grade of HPMC that is used.   
 
HPMC polymers are usually used as extended release-matrix forming agents at concentrations of 
between 15 and 35% w/w [139].  The formulations with greater percent of drug release had a 
total polymer concentration of 15.7% w/w whereas the batches showing lower drug release 
contained 18.5% w/w of the polymer.  This is true when using HPMC polymers since a higher 
polymer concentration or the use of a higher viscosity grade polymer would be more effective to 
delay drug release from matrix formulations. 
 
 It has been reported that the use of an anionic surfactant, such as SLS, may increase the 
viscosity of HPMC and hence decrease the release rate of a drug from HPMC matrix delivery 
systems [139].  Therefore, the additive effects of surfactant and higher HPMC concentration may 
contribute to effective retardation of drug release whereas the lower concentrations, irrespective 
of the viscosity grade, show more rapid and complete drug release.  These data sets were used to 
assist in selection of suitable composition for future formulations. 
 
The total apparent drug released from these test formulations was in the region of approximately 
60%.  In order to determine whether this amount released was a function of drug loading, a mass 
balance analysis was performed.  The result of the mass balance analysis are shown in Table 5.4 
and reveal that the apparent amount of drug released was low as a result of dosage form 
performance and not due to a low content of CBZ within the tablets.  
 
                      Table 5.4 Mass balance analysis (n=6) 
Batch # 
 
% Recovered 
(Mean ± SD) 
n=6 
% RSD 
C-211202-01 89.46 ± 5.68 6.35 
C-211202-02 93.99 ± 4.08  4.34 
C-211202-03 83.36 ± 6.04 7.25 
C-211202-04 87.35 ± 6.17 7.06 
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The particle size grade of CBZ used in these studies was the coarse grade and in the direct 
compression adaptation of the wet granulation formulation, a fine grade particle size was 
obtained for tableting purposes as particle size was viewed as a causative factor, since CBZ is a 
highly water insoluble drug and this formed part of subsequent experiments to produce a dosage 
form that matched the dissolution rate of Tegretol® CR (Novartis, Quebec, Canada).  A smaller 
particle size of CBZ would improve the surface area available for CBZ diffusion out of the 
tablets and thus improve the rate of solution of CBZ during in vitro analysis. 
 
Subsequently, a direct compression method of manufacture was chosen and Batch C-211202-02 
served as a reference formulation that was adapted for future formulation development. 
 
5.5 CONCLUSION 
 
The formulations produced in this section of the study did not match the release profile of 
Tegretol® CR.  The CG was used in these formulations and CBZ is highly water insoluble, 
therefore particle size may be a factor contributing to lower drug release.  In addition these 
tablets were produced by the WG process where PVA was used as the granulating fluid and this 
aids binding during granulation which aids prolonged drug release.   
 
Furthermore, these tablets were still intact at the end of dissolution testing and residual content 
assay as shown in Section 3.7.1 confirmed that there was undissolved drug present within the 
remaining matrix skeleton at the end of the dissolution period.   
 
In addition, HPMC effectively functions to retard drug release.  The combination of all these 
factors may serve to explain the low drug release rate from the four formulations tested.  The DC 
method of manufacture was considered for further formulation development to avoid the effects 
of the WG method of manufacture as well as granulating binding fluid effects.  The FG was used 
for subsequent formulations to aid drug release and dissolution rate of CBZ. 
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CHAPTER SIX 
THE DEVELOPMENT AND ASSESSMENT OF DIRECT COMPRESSION MATRIX 
SUSTAINED RELEASE CARBAMAZEPINE TABLET FORMULATIONS 
 
6.1 Introduction 
6.1.1 Direct Compression (DC) Tableting 
 
Wet granulation (WG) is a convenient means of creating flowable blends from non-flowing 
powders and excipients.  The WG process is time-consuming and many process variables 
affect dosage form production and may subsequently affect dosage form performance in vitro 
and in vivo.  Furthermore, variability may be enhanced during WG when compared to DC 
due to the increased number of unit processes in WG procedures and associated variables.  
However, DC has several limitations which must be overcome during manufacture to ensure 
uniform dosage form production.   
 
It has been suggested in Section 3.5.2 that the WG process may contribute further to lag times 
and sustained-drug release from tablets than other manufacturing methods.  The formulations 
produced by WG yielded a low fraction of CBZ released and therefore it was decided to 
investigate the DC method of manufacture to determine whether the manufacturing process 
contributes significantly to the low rate and extent of CBZ release observed from tablets 
produced by WG  
 
Advances in pharmaceutical excipient technology, have led to the development of powders 
that compress and flow better than those traditionally used for WG and excipients such as 
spray-dried lactose and microcrystalline cellulose have been adapted for use in direct 
compression manufacture.  The method of DC tablet manufacture is a less time and energy 
consuming process with a reduced number of unit processes, thus minimising processing 
errors that can occur during tablet manufacture.  In addition, modern tablet presses may use 
forced or induced powder feeders that ensure adequate and constant filling of die cavities 
with powders, that do not exhibit optimum gravitational flow characteristics, to facilitate the 
tableting process [84,148]. 
 
For drug loads in tablets of lower than 25% w/w, suitable diluents may be used in a 
formulation to provide adequate flow and compaction properties to the powder blend, 
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whereas for formulations containing higher drug loads, the drug itself should be sufficiently 
compressible and have a minimal effect on the flow properties of a powder blend [148]. 
 
Although the DC process contributes to the efficiency of a manufacturing process, this 
method produces tablets that show a high degree of variability in terms of tablet weight, 
hardness and thickness, which is more than likely due to the sub-optimum flow and 
compression properties of powder blends, when compared to wet granulation blends.  
Sticking of tablets to die walls and punch face surfaces is also commonly observed with DC 
formulations and the use of anti-frictional agents is usually required to enhance the flow 
properties of a blend and to minimise or prevent sticking, picking or other difficulties during 
the compression or ejection phases of tablet manufacture. 
 
6.2 Experimental 
6.2.1 Overview 
 
The objective of these studies was to use the composition of a reference wet granulation 
formulation and adapt it to develop a DC formulation with an in vitro release comparable to 
that of the previously developed wet granulation product.  Comparisons between DC and WG 
dosage forms were also made with respect to the physical characteristics of the resultant 
tablets such as uniformity of weight, thickness, diameter, hardness and friability. 
 
Furthermore, the DC formulations were optimised in an attempt to produce in vitro release 
profiles comparable to a commercially available reference product, viz., Tegretol® CR 
(Novartis, Quebec, Canada).  Dissolution profiles were compared statistically for similarity 
using the f1 and f2 difference and similarity factors [81]. 
 
To further understand the behaviour of these dosage forms in vitro, the role of selected 
excipients were investigated for their effects on matrix tablet performance.  The viscosity 
grade of HPMC was varied and assessed for its impact on in vitro drug release rates.  As CBZ 
is poorly water soluble, the use of a surfactant (SAA) such as SLS in the formulation may 
improve the rate and extent of drug release from these tablets.  Therefore, the impact of SLS 
use in the formulation composition, in addition to the type of anti-frictional agent included, 
was also investigated during early formulation studies. 
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Drug particle size distribution may also affect drug release rates from sustained release 
dosage forms and two particle size grades of CBZ were used and assessed to determine their 
effect on CBZ release rates.  Furthermore various proportions of the two particle size grades, 
used in combination, were assessed to determine their effect on CBZ in vitro release rates.   
The advantage of combination formulations is that release rates may be modified by either 
enhancing or limiting drug release by the selective use of a specific particle size grade of 
CBZ.  
 
Finally, a database of in vitro release profiles of 36 selected formulations was established and 
used to develop an artificial neural network (ANN).  The in vitro release data was matched to 
the respective formulation composition and these formed the basis of the data sets/pairs for 
the training of the ANN.  The ANN was then used to predict a formulation composition that 
would provide an in vitro release profile that matched the innovator reference product, 
Tegretol® CR (Novartis, Quebec, Canada). 
 
6.2.2 Direct Compression Excipients 
 
All the excipients except for talc and colloidal silica included in the direct compression 
formulae had been used in the wet granulation method of tablet manufacture. A summary of 
the relevant properties of these excipients are described in Section 5.3.2.  Talc and colloidal 
silica were assessed only in DC formulations.  All of the materials are included in the FDA 
Inactive Ingredient Guide and all except purified talc are GRAS listed.  
 
6.2.2.1 Purified Talc 
 
Purified talc is a native, anhydrous magnesium silicate [139,143], mainly used as a dusting 
powder in topical preparations and in solid oral dosage forms, as a lubricant at loads of 
between 1 and 10% w/w or as a diluent at loads of between 5 and 30% w/w.  Talc is not 
absorbed following oral ingestion and is therefore regarded as non-toxic and is included in 
the FDA Inactive Ingredient Guide [139], however in South Africa, the Medicines Control 
Council (MCC) requires that talc used for oral preparations be shown to be asbestos free 
[149]. 
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6.2.2.2 Colloidal Silicon Dioxide 
 
Colloidal silicon dioxide is submicroscopic fumed silica, which has a small particle size and 
an associated large specific surface area, resulting in excellent flow properties.  It can 
therefore be included into tablet formulations as a glidant [139].  Other uses for colloidal 
silicon dioxide are in aerosols that are not intended for inhalation and in semi-solid 
preparations, where it used as a stabilising or suspending agent [139].  Different grades of 
colloidal silica with different particle sizes are available and the grade used in this study, 
Cab-O-Sil® M5 (Cabot Corp, Madras, India) has a specific surface area of approximately 150 
m2/g and a mean particle diameter of approximately 15 nm [139].  All grades of colloidal 
silica are hygroscopic, however large quantities of water may be absorbed without the 
powder liquefying or the flow properties being affected [139].  Consequently, colloidal silica 
can also be employed as a dessicant in tablet formulations in which this function may be 
required.  Colloidal silica was used an anti-frictional agent in these studies. 
 
6.2.3 Methods 
6.2.3.1 Direct Compression Tablet Composition 
 
A prototype DC formulation, viz., Batch C-250303-01, was adapted from the WG 
formulation that was used to manufacture Batch C-211202-02 and the compositions are listed 
in Table 6.1 and the percentage w/w of each excipient incorporated in the wet granulation 
formula has been listed for comparative purposes.  CG CBZ was used for the production of 
the DC and WG formulation. 
 
 
Table 6.1 DC Formula with corresponding WG composition 
 
Composition 
Batch 
C-250303-01 
% w/w 
Batch 
C-211202-02 
% w/w 
CBZ (CG) 49.5  49.5  
Methocel® K100M 9 9 
Methocel® K4M 6.7 6.7 
Emcocel® 90M 17.4 17.4 
Emcompress® 12.04 12.04 
Spray-dried lactose 5.36 5.36 
SLS 0.4 1 
Mg stearate 0.2 1 
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6.2.3.2 Direct Compression Manufacturing Process 
6.2.3.2.1 Original Process (A) 
 
A schematic diagram depicting the DC manufacturing process is shown in Figure 6.1.  All 
powders, except for the magnesium stearate were individually weighed, screened through a 
size 20 mesh and blended in a cube blender, set at a horizontal angle, at 100 r.p.m for twenty 
minutes.  The magnesium stearate was weighed, screened through a size 44 mesh and added 
to the powder mix and blending was continued for a further three minutes.  The powder blend 
was subsequently compressed on a Manesty® B3B (Manesty, Liverpool, UK) rotary press set 
at between 40 and 60 r.p.m and that was tooled with one or two sets of deep biconcave 
punches.  The target weight was set at between 700 to 750mg and target hardness was set at 
between 120 and 150 Newtons (12 – 16 Kp).  Tablets were dedusted by vacuum through a 
screen and stored away from light in airtight bags prior to further testing.  
 
6.2.3.2.2 Modified Process (B) 
 
During the latter part of these studies, the DC method of manufacture was further modified 
where the powder for compression was compacted using deep biconcave punches.  The target 
hardness of pre-compressed tablets was set at between 100 and 120N.  Thereafter, the tablets 
were crushed and granulated by passing the pre-compressed tablets through a Model TG 
2000 dry granulator (Erweka, Heusenstamm, Germany) set at between 170 and 180 r.p.m.  
This process was repeated twice to ensure that the ‘slugs’ had been completely granulated.   
The resultant granules were compressed again to the pre-set requirements using a M 
anesty®B3B rotary press that was tooled with the same deep biconcave punches.  The 
resultant tablets were stored away from light in airtight containers prior to further testing. 
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Figure 6.1 Schematic diagram showing the original (A) and modified (B) direct 
                  compression process. 
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6.3 Investigation of Ruggedness of the Formulation 
6.3.1 Adaptation of WG to DC method of Manufacture 
 
The WG formula used for Batch C-211202-01 was adapted for the manufacture of a DC 
Batch C-250303-01 and the two compositions are shown in Table 6.1.  The proportions of the 
formulation components of the WG batch were retained and tablets were manufactured as 
described in Section 6.2.3.2.  The particle size grade of CBZ used for both formulations 
remained the same.  The profiles were compared for similarity using the f1 and f2 difference 
and similarity factors [81].  
 
6.3.2 Effect of CBZ Particle Size 
 
Anhydrous CBZ is practically insoluble in water as described in Section 1.2.3 and the particle 
size distribution of CBZ can influence the dissolution rate [118,142].  CBZ was generously 
donated by Noveon Pharma (Raubling, Germany) and was made available in two particle size 
grades, viz., a coarse grade (CG) particle size and a fine grade (FG) particle size.  The initial 
WG formulations, viz., Batches C-211202-01, -02, -03, -04 were manufactured using the CG 
CBZ.  The total percent drug released for these tablets was between 50% and 60%, and 
therefore it was decided to investigate the use of FG CBZ in the test formulations.  Two 
formulations with the same amount of a specific grade of CBZ were manufactured and 
assessed to investigate the effect of particle size on CBZ release from DC matrix tablets.  The 
two formulation compositions for the batches in which particle size effects were assessed, are 
listed in Table 6.2.  Batches C-030703-04 and C-030703-01 contained the CG and FG CBZ 
respectively and the tablets were manufactured using the procedure outlined in Section 
6.2.3.2. 
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Table 6.2 Formulation composition for the formulations used to assess the effect of CBZ  
      particle size on in vitro dissolution rates of CBZ 
 
Composition 
Batch C-030703-04 
 
% w/w 
Batch C-030703-01 
 
% w/w 
   
CBZ (FG) - 40 
CBZ (CG) 40 - 
Methocel® K100M 9 9 
Methocel® K4M 13 13 
Emcocel® 90M 17 17 
Emcompress® 15 15 
Spray-dried lactose 5 5 
SLS 0.67 0.67 
Mg Stearate 0.33 0.33 
 
In addition, various combinations of the two particle size grades were investigated in an 
attempt to modify drug release rates to achieve dissolution profiles that were equivalent to 
that of the innovator product Tegretol® CR (Novartis, Quebec, Canada).  The compositions of 
the formulations in which different combinations of FG and CG were used are summarised in 
Table 6.3. 
 
Table 6.3 Composition of formulations used to assess the effect of FG and CG CBZ on 
                 in vitro dissolution rates of CBZ.  
 
Composition 
Batch  
C-030703-06 
% w/w 
Batch  
C-190603-02 
% w/w 
Batch  
C-190603-03 
% w/w 
    
CBZ (FG) 39.6 30 24.75 
CBZ (CG) 9.9 19.5 24.75 
Methocel® K100M 9 9 9 
Methocel® K4M 6.7 6.7 6.7 
Emcocel® 90M 17.4 17.4 17.4 
Emcompress® 12.04 12.04 12.04 
Spray-dried lactose 5.36 5.36 5.36 
SLS 0.4 0.4 0.4 
Mg stearate 0.2 0.2 0.2 
 
 
6.3.3 Effect of HPMC Grade on Dissolution Rate 
 
The rate retarding effects of two viscosity grades of HPMC, viz., Methocel® K100M and 
K4M were investigated to determine the effects and degree of control over CBZ release rates 
that can be achieved by use of HPMC in these formulations.  The composition of the four 
formulations adopted for the purposes of these studies are summarised in Table 4.4.   
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Table 6.4 Formulation composition for the assessment of polymer viscosity grade on 
                 CBZ dissolution rates. 
 
Composition 
Batch 
C-140705-02 
% w/w 
Batch  
C-180705-01 
% w/w 
Batch 
C-190705-01 
% w/w 
Batch 
C-200705-01 
% w/w 
CBZ (FG) 59 59 59 59 
Methocel® K100M 26 32 - - 
Methocel® K4M - - 26 32 
Emcompress® 4 4 4 4 
Spray-dried lactose 10 4 10 4 
Mg stearate 1 1 1 1 
 
 
Two of the formulations contained Methocel® K100M at levels of 26% and 32% w/w 
whereas two different formulations were manufactured with Methocel® K4M at 26% and 
32% w/w.  These formulations were adapted from the initial test batches, viz., the C-211202- 
series and thus the compositions were selected based on the compositions of those 
formulations.   
 
Since these were preliminary studies intended to elucidate the potential effects of HPMC 
content on drug release, only a six percent increase in HPMC content was used.  Any larger 
increase would necessitate major adjustments to the formulation composition in order to 
manufacture suitable tablets.  Furthermore, to maintain the target tablet weight, the 6% w/w 
increase of HPMC content was compensated for by decreasing the content of spray-dried 
lactose by an equivalent amount. 
 
 
6.3.4 Effect of Sodium Lauryl Sulphate (SLS) on Dissolution Rate 
 
In order to determine whether the inclusion of a SAA would enhance the rate and extent of 
CBZ release from these matrix tablets, SLS was either included or excluded from the 
formulation.  The formulation composition was kept constant and was similar to that used for 
the previous batches studied, except that SLS only was included or excluded to determine the 
effect of its use on dissolution rates. SLS was included at 0.67% w/w in the formulation since 
it is effective even at concentrations < 1%.  Furthermore, large quantities were avoided so 
that the delivery device could still maintain its sustained-delivery mechanism.  The 
formulation compositions for these studies are listed in Table 6.5.  
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Table 6.5 Formulation composition used to evaluate SLS effects on the in vitro  
                 dissolution rate of CBZ. 
 
Composition 
Batch  
C-030703-03 
% w/w 
Batch  
 C-030703-04 
% w/w 
CBZ (CG) 40 40 
Methocel® K100M 9 9 
Methocel® K4M 13 13 
Emcocel® 90M 17 17 
Emcompress® 15 15 
Spray-dried lactose 5 5 
SLS - 0.67 
Mg stearate 1 0.33 
 
 
 
6.3.5 Effect of Anti-Frictional Agents on Dissolution Rate 
 
The lubricant of choice for these studies was the anti-frictional agent, magnesium stearate.  
Two additional anti-frictional agents were also assessed for their impact on drug release as 
well as the physical characteristics of the resultant tablets.  Purified talc (Aspen-Pharmacare, 
Port Elizabeth, South Africa) and fumed silica (Cab-O-Sil® M5, Cabot Corp, Madras, India) 
were assessed as glidants.  A summary of the formulation compositions for the batches tested 
to determine the effect of anti-frictional agent used, on CBZ dissolution rates, are shown in 
Table 6.6.  
 
 
Table 6.6 Formulations used to evaluate the effect of anti-frictional agents on the in vitro 
                dissolution rate of CBZ. 
 
Composition 
Batch  
C-200603-01 
% w/w 
Batch  
C-200603-02 
% w/w 
Batch   
C-200603-03 
% w/w 
    
CBZ (CG) 49.5 49.5 49.5 
Methocel® K100M 9 9 9 
Methocel® K4M 6.7 6.7 6.7 
Emcocel® 90M 17.4 17.4 17.4 
Emcompress® 12.04 12.04 12.04 
Spray-dried lactose 5.36 5.36 5.36 
SLS 0.67 0.67 0.67 
Mg stearate 0.33 - - 
Talc - 0.33 - 
Cab-O-Sil® - - 0.33 
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6.4 Results and Discussion  
6.4.1 Conversion of the WG Formula to a DC Formula 
 
The resultant dissolution rate profile for the DC formulation Batch C-250303-01 adapted 
from the WG Batch C-211202-02 prototype was almost super-imposable as can be seen in the 
graphical representation of the release profiles in Figure 6.2.  The dissolution rate profiles 
were assessed for similarity using the difference and similarity factors, and the resultant f1 and 
f2 factors were 1.6 and 92.5, respectively, indicating that the profiles are indeed similar. 
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Figure 6.2  Mean dissolution rate profiles (n=6) of CBZ release from a WG formulation 
                   (Batch C-211202-02) and a DC formulation (Batch C-280503-01) of similar 
                   composition.    
 
The performance of HPMC is unaltered by shear forces that are present during granulation 
and therefore this can be eliminated as a contributing factor that may affect drug release rates 
from these dosage forms [106].  The similarity of the two profiles confirms that the 
manufacturing process has little or no impact on drug release rates, in addition to the 
significance of the contribution of HPMC with respect to controlled release.  As the resultant 
DC dissolution profile was similar to that of the WG profile, the DC method of manufacture 
was adopted for the remainder of these studies, as it is simple and more cost-effective when 
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compared to WG.  In addition, the potential effects of WG on drug release rate are therefore 
eliminated.  
6.4.2 Effects of Particle Size Grade of CBZ on in vitro Release Rates 
 
The dissolution rate profiles of two formulations with identical compositions but that differ in 
the particle size grade of CBZ only are depicted in Figure 6.3.  The challenge when 
formulating a poorly water-soluble drug is to control the rate of dissolution so as to minimise 
variations in the in vitro release rate profiles, which may minimise plasma level variations in 
vivo.  Furthermore, the maintenance of a well-dispersed system is vital to ensure optimal 
absorption of the drug, so as to ensure constant therapeutic levels are achieved in vivo [141].   
 
Formulations developed with CG CBZ generally showed incomplete drug release, with a 
total fraction of CBZ released ranging between 60 and 65%.  Therefore, the concept of 
decreasing the particle size and thus increasing the available surface area of CBZ, for 
dissolution was considered as a potential solution to increase the amount of CBZ released 
from these tablets. Therefore the use of FG CBZ was evaluated for its potential to enhance 
the rate and extent of CBZ release from these formulations during in vitro release testing. 
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 Figure 6.3 Mean dissolution rate profiles (n=6) of CBZ release from formulations 
                   containing 40% w/wCG (Batch C-030703-04) or FG (Batch C-030703-01) 
                   CBZ. 
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It is evident from the f1 and f2 values of 7.7 and 65.4, obtained for the comparison of CBZ 
release from formulations manufactured using either fine or coarse grade raw material that 
the two profiles are similar.  However, the effect may be process or formulation specific and 
warrants further investigation. 
 
The release rate profiles shown in Figure 6.3 represent those of two formulations that were 
manufactured by DC with exactly the same formulation excipient composition but differ with 
regard to the particle size of CBZ.  However, the drug release is still comparable between 
these two formulations as well as showing an average drug release higher than that displayed 
by earlier formulations that were manufactured by wet granulation.  Thus the specific 
manufacturing method such as wet granulation method may also affect drug release and 
account for any lag time or incomplete drug release observed from these matrix tablets.  The 
FG CBZ formulation however, revealed a greater extent of CBZ release from the matrix 
structure.  In addition, visual inspection of the two profiles depicted in Figure 6.3 reveal that 
drug release is more complete for the formulation in which fine grade CBZ was used.   
 
The effect of different combinations of the two particle size grades of CBZ on in vitro release 
rates were assessed at proportions of 50% FG: 50% CG; 60% FG: 40% CG as well as 80% 
FG: 20% CG for their impact on the rate and extent of drug release.  The dissolution rate 
profiles of these ‘combination’ formulations are shown in Figure 6.4.  The resultant f1 and f2 
fit factors calculated for the comparison of all formulations to Tegretol® CR and each other 
are listed in Table 6.7. 
 
It is clear that only the 50% FG and 80% FG formulations are different as both the f1 and f2 
values for this comparison did not meet the required specification. 
 
 
                Table 6.7 Similarity and difference factors for the comparison of  
                                 formulations with varying proportions of CG and FG CBZ.  
Comparison f1 f2 
FG 80% vs FG 50% 16.3 51.4 
FG 80% vs FG 60% 14.6 54.5 
FG 50% vs FG 60% 2.3 87.4 
Tegretol® CR vs FG 80% 6 69.8 
Tegretol® CR vs FG 60% 10.6 63.3 
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Tegretol® CR vs FG 50% 12.4 60 
                 *Shaded areas indicate out-of-specification results 
 
Therefore, it is clear that drug release rates can be modified and optimised by manipulation of 
the proportion of FG:CG ratio in a formulation. 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15 20 25
Time (Hours)
Fr
ac
tio
n 
R
el
ea
se
d
FG 50% FG 60% FG 80% Tegretol CR
 
Figure 6.4 Mean dissolution rate profiles (n=6) of formulations with 50% FG: 50% CG 
                  (Batch C-190603-03); 60% FG: 40% CG (Batch C-190603-02) and  
                  80% FG: 20% CG(Batch C-030703-05) and Tegretol® CR. 
                   
 
Formulations with a 10% difference in the FG:CG ratio showed better similarity when their 
dissolution profiles were compared, whereas at higher concentrations of the FG CBZ, marked 
drug release rate differences are observed.  This is probably due to the higher FG content 
contributing to higher drug release rates due to a greater surface area, which becomes 
available for drug dissolution. 
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6.4.3 Effect of Viscosity Grade of HPMC on Drug Release Rates 
 
The dissolution rate profiles of the formulations manufactured to assess the effects of 
different viscosity grades of HPMC on drug release are shown in Figure 6.5.  Visual 
inspection of these profiles reveals a distinct difference in CBZ release rates for the two 
viscosity grade polymers and furthermore, there is a difference in release rate, depending on 
the amount of the respective polymer used in a specific formulation.  It also seems likely that 
different combinations of polymers would be appropriate to alter the release rate, mechanism 
and kinetics of release of different APIs from HPMC hydrogel matrices [105].   
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Figure 6.5 Mean dissolution rate profiles (n=6) of Batches C-140705-02 (26% w/w 
                  K100M) C- 180705-01 (32% w/w K100M), C-190705-01 (26% w/w K4M)  
                  and C-200705-01 (32% w/w K4M) 
                   
 
Batches C-190705-01 and C-200705-01 were manufactured with the lower viscosity grade 
polymer, i.e., Methocel® K4M and as shown in Figure 6.5, drug release from these 
formulations was faster and more complete than from those batches that were manufactured 
using Methocel® K100M, viz., Batches C-140705-01 and C-180705-01.  In addition, two 
batches were manufactured with Methocel® K4M and a further two batches with Methocel® 
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K100M in which the level of HPMC content differed by 6% w/w of the respective polymer 
grade.   
 
The f1 and f2 difference and similarity factors calculated to determine differences or similarity 
in the release rates of CBZ from formulations manufactured to assess the impact of HPMC 
are summarised in Table 6.8. 
 
 
              
                 Table 6.8 Difference and similarity factors used to assess polymer grade 
                                  effects on CBZ release. 
Comparison f1 f2 
K100M (26% w/w) vs K100M (32% w/w) 12.9 72.2 
K100M (26% w/w) vs K4M (26% w/w) 39.9 47.6 
K100M (32% w/w) vs K4M (26% w/w) 60.6 41.9 
K100M (26% w/w) vs K4M (32% w/w) 25.4 56.6 
K100M (32% w/w) vs K4M (32% w/w) 44 48.6 
K4M (26% w/w) vs K4M (32% w/w) 10.4 69.7 
      *Shaded areas denote out-of-specification values 
 
The difference and similarity factors used to compare the dissolution rate profiles of 
formulations manufactured with the same polymer but a different % w/w composition, 
confirmed similarity in drug release from these formulations for both the polymer grades 
tested.   
 
When comparing the formulations with different grades of polymers, drug release was shown 
to be different and this effect was shown to be more relevant when comparing formulations 
that had a high proportion of each polymer, i.e., the formulations with 32% w/w of each 
grade of HPMC.   
 
It is possible to deduce from these results, that the grade of HPMC used in the formulation 
may impacts on the rate and extent of drug release.  The extent of CBZ release from the 
formulation in which Methocel® K4M was included at 26% w/w level was higher than that 
from the formulation in which Methocel® K4M had been included at a 32% w/w level.  The f1 
and f2 values of 10.4 and 69.7 respectively, confirm that release was similar between the 
formulations with Methocel® K4M with a concentration difference of 6%.  As would be 
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expected, the higher viscosity grade of HPMC sustained drug release more effectively and 
this becomes more significant at the 32% concentration level of Methocel® K100M which 
yielded the lowest CBZ release rates.  Statistical comparisons between formulations with the 
same concentration w/w but different grades of HPMC confirm dissimilar release rates and 
these are depicted in Table 6.8. 
 
It is apparent that the higher viscosity grade HPMC controls drug release more effectively 
than the lower viscosity grade as can be seen by the lower rate and extent of drug release 
from formulations in which it was included, and this was confirmed by the difference and 
similarity factors listed in Table 6.10.  The opposite, however is true, where dissolution 
profiles of formulations with equivalent amounts of different grades of HPMC showed higher 
rates and extent of CBZ release to those formulations with the lower viscosity grade HPMC.   
 
 
6.4.4 Effect of SLS on CBZ Release Rates 
 
Surfactants are commonly used in pharmaceutical dosage forms as wetting agents and SLS 
can improve the water solubility of CBZ even at concentrations of 0.1% w/w which is 
considerably below the critical micelle concentration (CMC) of SLS [146].  SLS has 
lubricant properties and was incorporated at a concentration of 0.67% w/w in the tablets 
assessed in these studies.  This was the same concentration as that of the lubricant 
incorporated in the development formulations used to manufacture WG dosage forms where 
SLS was included in the formulation during the blending of granules with additional 
excipients. 
 
The resultant dissolution rate profiles generated following testing of formulations in which 
the impact of SLS inclusion on either CG or FG CBZ release from matrix, tablets are 
depicted in Figure 6.6.  The formulation in which CG CBZ was used in conjunction with SLS 
as compared to that without SLS showed poor similarity to each other as seen from the f1 and 
f2 values listed Table 6.9, and where drug release was considerably higher from the 
formulations containing SLS. 
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Figure 6.6 Mean dissolution rate profiles (n=6) of CBZ release from formulations  
                  Containing FG with SLS (Batch C-280503-01), CG with SLS  
                  (Batch C- 030703-04), CG without SLS ( Batch C-030703-03). 
                   
 
 
Table 6.9 Difference and similarity factors used to compare the effect of SLS on CBZ   
      release rates. 
Comparison f1 f2 
Coarse grade with SLS vs coarse grade without SLS 16.4 54.7 
Coarse grade with SLS vs fine grade with SLS 8.4 65.4 
Fine grade with SLS vs coarse grade without SLS 22.8 44.7 
           *Shaded areas represent out-of-specification results 
 
 
The increased rate and extent of CBZ release from formulations in which SLS was included, 
may be due to molecules of the solubilisate, CBZ, aligning between surfactant molecules, 
therefore decreasing the repulsive forces between the molecules and inducing a lowering of 
the CMC [146].  The limited association between the solubilisate and SLS, even at this low 
concentration may be responsible for the apparent increased solubility, as is evidenced by the 
dissolution rate profiles [146].  
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Any rate-retarding or rate-accelerating effect of surfactant inclusion may be linked to the 
solubilizing capacity of SLS [146] which becomes significant for a drug such as CBZ which 
has inherently poor aqueous solubility.  SLS may also inhibit the transformation of CBZ to 
the stable CBZ dihydrate which is a more crystalline less soluble form of CBZ [146].  This 
may also contribute to any rate-enhancing effects observed with the use of SLS in these 
products. 
 
6.4.5 Effects of Anti-frictional Agents on CBZ Release Rates 
 
The dissolution rate profiles of CBZ fromformulations in which the effects of anti-frictional 
agent used, are depicted in Figure 6.7.  Statistical evaluation of these dissolution profiles 
revealed that in most cases no significant differences existed between the formulations tested 
and it was thus concluded that the anti-frictional agent used in the formulations did not 
significantly affect the in vitro release rates of CBZ from these tablets.  The resultant f1 and f2 
values for all comparisons are listed in Table 6.10. 
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Figure 6.7 Mean dissolution rate profiles (n=6) of CBZ release from formulations 
                  containing talc (C-200603-02), Cab-o-Sil® (Batch C-200603-03) and Mg 
                  stearate (Batch C-200603-01) 
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Table 6.10 Difference and similarity factors used to compare dissolution profiles 
                  of formulations with different anti-frictional agents. 
Comparison f1 f2 
Mg stearate vs purified talc 8.8 69.1 
Mg stearate vs Cab-O-Sil® 16 56.6 
Cab-O-Sil® vs purified talc 8.6 69.2 
                  *Shaded values represent out-of-specification results 
 
 
The f1 value of 16 calculated when comparing the formulations manufactured with Cab-O-
Sil®, Batch C-200603-03 and Mg stearate, Batch C-200603-01, indicate the potential for 
some alteration in drug release rates, due to the type of anti-frictional agent incorporated in 
the formulation.  The f2 value of 56.6 indicates some similarity but for the purposes of these 
studies, agreement between both f1 and f2 values were required to confirm similarity.  
Therefore, these batches were considered different and the effect of anti-frictional agents on 
CBZ release warrants further investigation 
 
 
6.4.5.1 Physical testing of tablets 
 
A summary of the results of physical testing of formulations manufactured to assess the 
impact of anti-frictional agents on tablet performance are listed in Table 6.11.  Tablets of the 
lowest hardness and thus tensile strength were produced when Mg stearate was used as the 
anti-frictional agent.  All three formulations produced tablets with hardness values that did 
not meet our pre-determined specifications. The hardness of these formulations may be a 
consequence of the other excipients within the formulation and not significantly affected by 
the anti-frictional agent used, since the hardness values were similar to values obtained for all 
batches manufactured previously.  However, as can be deduced from the results of this 
specific series of formulations, Mg stearate produced softer tablets and it has been reported to 
reduce radial tensile strength of tablets [150].  This is explained by the formation of weaker 
bonds between lubricant/lubricant particles rather than strong excipient/excipient bonds 
[150].  Mg stearate was adopted for these formulation studies due to its availability and 
widespread application and its value in improving tablet manufacturability, despite the well-
known disadvantages associated with the use of this compound. 
 
 
 155
Table 6.11 Physical characteristics of tablets with different anti-frictional agents. 
 Thickness:Diameter
(Mean ± SD) 
n = 10 
mm 
Hardness 
(Mean ± SD) 
n = 10 
N 
Weight 
(Mean ± SD) 
n = 10 
mg 
Friability 
% 
n = 10 
Mg stearate 
C-200603-01 
0.57 ± 0 45.24  ± 7.61 531.95  ± 4.4 0.19 
Talc 
C-200603-02 
0.57 ± 0 80.39  ± 7.98 527.14  ± 4.06 0.19 
Cab-O-Sil® 
C-200603-03 
0.56 ± 0  89.23 ± 13.59 530.56  ± 6.44 0.19 
 
TARGET 
 
 
- 
 
120 – 150 N 
 
500 – 550mg 
 
< 1% 
 
 
In terms of tablet weight, there was minimal variation between the tablets and friability was 
found to be 0.19% for all batches, which was well below the acceptance limit of 1% for this 
test.  The thickness to diameter ratios were consistent between these batches, thus the anti-
frictional agent does not contribute significantly to fill volume as confirmed by the 
uniformity of weight determinations and the obvious similarity in tablet weights. 
 
To thoroughly elucidate anti-frictional agent effects, further in depth studies would have to be 
performed.  These studies would involve testing new formulations with varying 
concentrations of the anti-frictional agents, alone and in combination in addition to evaluating 
process effects.  The studies reported here were conducted to determine if there was any 
potential for different anti-frictional agents to affect tablet performance and function.  
 
It is evident that the choice of anti-frictional agent has little or no effect on CBZ release rates 
and this can be attributed, in part, to the poor solubility characteristics of the API, such that 
CBZ release is more than likely independent of any potential effects that small amounts of 
the anti-frictional agent used can influence.  It was concluded that the low hardness values 
were a consequence of the specific excipient combinations rather than solely due to the 
choice of anti-frictional agent and Mg stearate was used for further formulation development, 
due to its availability and a knowledge of its effects on drug release rates and dosage form 
characteristics.  Furthermore, Mg stearate shows the ability to reduce the residual and 
ejection forces that are prevalent during tableting [150]. 
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6.4.6 Comparison of HPMC DC Matrix Tablets to Tegretol® CR Tablets 
 
The ultimate purpose of formulation development in this project was to produce sustained-
release matrix tablets for which the in vitro dissolution profile matched that of a 
commercially available dosage form, viz., Tegretol® CR (400mg) (Novartis, Quebec, Canada) 
that was used as the reference product for all in vitro and in vivo studies.  All formulation 
profiles produced during these studies were compared to those of Tegretol® CR and these 
profiles were generated using the same dissolution and analytical conditions as described 
previously in Sections 3.8.4 and 2.5.3 in Chapters 2 and 3, respectively. 
 
A number of formulations were produced during the initial development stages of the study 
where batches differed primarily with respect to polymer content and ratio as well as drug 
content, CBZ particle size grade and ratios that were included in the formulation.  An 
example of two dissolution profiles compared to that of Tegretol® CR (400 mg) is shown in 
Figure 6.8.  Batch C-200603-02 showed similarity to Tegretol® CR whereas Batch C-211202-
03 showed poor similarity when using the difference and similarity factors that are 
summarised in Table 6.12.  
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Figure 6.8 Mean dissolution profiles (n=6) of CBZ release from Batches C-200603-02 
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and C-211202-03 manufactured by DC and WG, respectively for Tegretol®       
CR. 
Batch C-200603-02 was a DC formulation that contained talc whereas Batch C-211202-03 
was a wet granulation batch in which PVA was used as the granulating fluid.  As previously 
mentioned in Section 3.5.2, the wet granulation process may contribute to any lag time 
observed in the dissolution profiles, which can be seen in Figure 6.8.                 
 
 
Table 6.12 Difference and similarity factors used to compare the dissolution 
                               profiles of batches C-20603-02 and C-211202-03 to Tegretol® CR. 
 f1 f2 
Tegretol® CR vs C-200603-02 7.9 62.4 
Tegretol® CR vs C-211202-03 27.4 42.8 
                     *Shaded areas represent out-of-specification results. 
 
 
The dissolution profiles of two further formulations produced during the initial stages of 
development are depicted in Figure 6.9.  These formulations formed part of initial 
development studies and served as reference formulations upon which further development 
was based.  Tablets were manufactured using the composition of the initial formulations 
listed in Tables 6.1 and 6.6.  Dosage forms were manufactured in order to optimise CBZ 
release so as to produce release rate profiles similar to hat of Tegretol® CR. 
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Figure 6.9 Mean dissolution rate profiles (n=6) of Tegretol® CR compared to Batches  
                  C-260303-02 and C-140705-01 manufactured by DC. 
 
 
The similarity and difference factors for the dissolution profiles of the formulations depicted 
in Figure 6.9 are shown in Table 6.13, and it is clearly evident that the profiles are not 
similar. 
 
 
Table 6.13 Difference and similarity factors used to compare the dissolution profiles of 
                   batches C-260303-02 and C-140705-01 to Tegretol® CR. 
Comparison f1 f2 
Tegretol® CR vs C-260303-02 35.5 36.5 
Tegretol® CR vs C-140705-01 43.3 33.3 
C-140705-01 vs C-260303-02 22.3 58.9 
                         *Shaded values represent out-of-specification results 
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Batch C-260303-02 contained CG CBZ at 60% w/w drug loading, whereas Batch C-140705-
01 contained FG CBZ at 49% w/w drug loading.  Furthermore, Batch C-140705-01 contained 
a total of 29.7% w/w HPMC (K4M 13.7% w/w and K100M 16% w/w) whereas Batch C-
260303-02 contained only Methocel® K4M at 18% w/w loading.  The f1 and f2 values used to 
compare these two batches indicated that the formulations were different in terms of their 
release profiles to Tegretol® CR and to each other.   
 
It is probable that within formulations, compensations to facilitate drug release are 
accommodated in terms of drug content and HPMC loading where the drug release from the 
Batch C-260303-02 which has a higher CG drug loading is compensated for by the presence 
of the lower viscosity grade HPMC at a lower loading.  Batch C-140705-01 contained the FG 
CBZ which facilitates drug release rates but release is further controlled by the presence of 
high concentrations of both the high and low viscosity grades of HPMC, as well as a lower 
drug loading when compared to Batch C-260303-02. 
 
CBZ release rate profiles of several other batches of tablets manufactured during initial 
formulation development studies are shown in Figure 6.10.  It is clear that the extent of drug 
release from some formulations were better and exceeded that of Tegretol® CR, and were thus 
not similar to Tegretol® CR according to the f1 and f2 statistical factors listed in Table 6.13. 
 
Many formulations that were developed and manufactured showed similarity to the in vitro 
dissolution profile of Tegretol® CR using the f1 and f2 factors and two such formulations are 
shown in Figure 6.10. 
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Figure 6.10 Mean dissolution rate profiles (n=6) of CBZ release from DC formulations 
                    compared to that of Tegretol® CR. 
 
 
Batches C-190603-02 and C-030703-01 showed similar dissolution profiles to Tegretol® CR 
which was confirmed by the f1 and f2 difference and similarity factors shown in Table 6.16.  
Batch C-190603-02 contained both CG and FG CBZ at a loading of 49.5% w/w whereas 
Batch C-030703-01 contained only the FG CBZ at a lower loading of 40% w/w.  Batch C-
190603-02 showed better similarity to Tegretol® CR from the f1 and f2 values listed in Table 
6.14 and contained 6.3% w/w less HPMC than C-030703-01.  Therefore, the combination of 
a lower drug loading and high HPMC concentration may be factors that account for the 
difference in the drug release rates observed.   
 
Batch C-030703-03 showed differences based on f1 and f2 values to Tegretol® CR release 
rates and this formulation was similar to that of Batch C-030703-01 except that the 
formulation did not contain any SLS.  In addition, this formulation contained CG CBZ at a 
drug loading of 40% w/w with a high HPMC concentration when compared to Batch C-
190603-02 and the combination of these variables contributes to lower drug release rates such 
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that the dissolution profiles are not comparable to that of the innovator product, Tegretol® 
CR.  Summaries of all dissolution profiles can be seen in the Appendices. 
  
             Table 6.14 Similarity factors used to compare the dissolution profiles of  
                                batches C-030703-01, C-030703-03, C-190603-01 to Tegretol®CR. 
 f1 f2 
Tegretol® CR vs C-030703-01 14.2 53.6 
Tegretol® CR vs C-030703-03  17.1 51.4 
Tegretol® CR vs C-190603-02 910.6 63.3 
                    *Shaded values represent out-of-specification results 
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6.5 CONCLUSION 
 
Various components of potential formulations were assessed for their impact on CBZ release 
rate and adjustments were made to the formulations based on the resultant dissolution 
profiles, where drug release was either enhanced or prolonged through manipulation of the 
components used.  The effects of selected factors served as a quick reference to determine 
whether these variables significantly affected CBZ release rates.  Studies to further elucidate 
the contribution of individual components to drug release from these matrix formulations 
should be considered in future research projects. 
 
For the purposes of these studies, the information obtained during early experiments was 
sufficient to make formulation decisions during the development and optimisation process.  It 
was also clearly evident that the DC method of manufacture produced results comparable to 
the same formulation produced by WG manufacture.  Therefore, the DC method of 
manufacture was adopted for the production of all subsequent formulations, as this method of 
manufacture simplifies the tablet production process.  
 
The release rate profiles of CBZ from these formulations were compared to that of the 
innovator product Tegretol® CR, which was chosen as the target release profile and reference 
formulation for these studies.  It is apparent that the variables in a formulation function as a 
complete system where individual components contribute to the overall observed release rate 
and effects and in which drug release rate profiles are affected by the concentration and type 
of excipients used.  In particular  
 
Several formulations showed similar drug release profiles to Tegretol® CR and the 
formulations served, in particular to identify the parameters such as SLS, HPMC content and 
CBZ grade effects as key components of the formulation that were found to be causative and 
therefore used for ANN training and subsequently, the production of a large-scale batch of 
matrix tablets for in vitro, in vivo and stability testing.   
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CHAPTER SEVEN 
ARTIFICIAL NEURAL NETWORKS (ANN) IN FORMULATION DEVELOPMENT 
 
7.1 Introduction 
 
A biological neural network possesses the ability to recognize features of information presented 
to it and classify this information based on previous learning or cognitive experiences.  Artificial 
neural networks (ANNs) represent an area of computational mathematical modelling that aims to 
mimic or simulate the information processing ability of the human brain [151-156] by using the 
basic learning processes of the human brain to learn and solve pattern recognition types of 
problems [154].  Another manner of describing ANNs is that the networks are machine-based 
computational tools, which attempt to simulate some of the neurological processing ability of the 
human brain [151-155,157-160]. 
 
The simplest processing element of the human brain is the neuron which consists of a cell body 
and axon along which a nerve impulse, that is generated, travels.  Synaptic connections allow for 
the interconnection of adjacent neurons.  A similar concept is adopted for ANNs where the 
artificial neuron may be referred to as a ‘node’ and is used to denote the basic processing 
elements (PE) of this computing network [151-155,158,161].   
 
Neural networks are trained to solve problems involving patterns, pattern-mapping, pattern 
classification and pattern completion [160].  ANNs simulate the learning behaviour of the brain 
through data modelling and pattern recognition for complicated, multi-dimensional problems 
[162].  ANNs can identify and learn correlative patterns between input and output data pairs and, 
once trained on a well-established set of data records, may be used to predict, forecast or 
estimate outputs from new sets of input conditions [153].   
 
The potential predictive ability of neural networks is of value in the pharmaceutical formulation 
development process, where they may be used to optimise formulation variables and processes 
involved in the design and engineering of successful formulations [153].  The use of in silica 
methods such as ANNs, substantially reduce the need for empirical data production and allows 
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for a more rational formulation development process.  Resources required for formulation 
research may be significantly reduced, thereby reducing costs and overall development time(s). 
Furthermore, ANNs have gained increasing interest in pharmaceutical applications due to their 
model-independence, non-linearity, flexibility and superior data fitting and prediction ability 
[163]. This study provides an example of this in that a relatively small, but well-chosen, data set 
is used to train a neural network which was then used to find an optimal formulation. 
 
7.2 Design and Construction of a Neural Network 
 
The multi-layer perceptron (MLP) configuration is the most common architecture employed in 
the application of neural networks [151]. The network consists of a series of highly 
interconnected layers of neurons, which are a mathematical analogue of biological neurons 
[153,164].   
 
The neurons in an ANN are arranged into layers.  The basic arrangement of these layers is that of 
an input layer which itself does not process information but serves merely as a distribution point 
of information to the subsequent layer, which is the first ‘hidden’ layer.  There may be more than 
a single ‘hidden’ layer and the outputs from the last single layer are conveyed to the output layer, 
which is the final layer of information processing and data output.  Thus, the network has one 
input layer, one or more ‘hidden’ layer/s and a single output layer and each layer has some units 
corresponding to neurons [159,165]. 
 
The number of neurons in the input layer is determined by the number of variables within the 
data record set and the neurons in neighbouring layers are fully inter-connected with links 
corresponding to biological synapses [159].  The most popular network design employed and 
reported in the literature is the Delta Back-Propagation Network (DBPN) [159,166,167] 
architectural design where input layers provide input and output layers produce an output where 
the ‘hidden’ layers provide the inter-connections between input and output layers [159].  The 
delta rule is based on reducing the error between the actual output of a node and its desired target 
through the modification of the connection weights and biases [167].  The term ‘back-
propagation’ is derived from the process of propagating the error information backward from the 
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output nodes to the hidden nodes [168] to allow modifications of the network weights and biases 
[166].     
 
The arrangements of neurons in a network is referred to as the network topology or architecture.  
The most frequently used ANNs possess more than one hidden layer, but one layer is usually 
sufficient for most classification problems [154,159].   
 
7.2.1 The Structure of a Neural Network. 
 
Let p  be an 1×r  input pattern vector, 1b  the 1 1s ×  vector of biases in the first layer and 1f  the 
transfer function in each neuron of the first layer. The weights are on the interconnections 
between the r  input nodes and the s  neurons in the first hidden layer. Let the weight, 1ijW be the 
strength of the connection between jp  and neuron i . The weight matrix, 
1W , has size 1s r×  and 
so the vector 111 bpWn +=  is the input into the first layer. The activation output from the first 
layer is the vector )( 111 nfa = . Therefore )( 1111 bpWfa += is the activation output from the 
first layer of the network. 
 
If ia is the activation output from layer i , ib  is the bias vector in layer i , if is the transfer 
function in each neuron of layer i  and iW is the weight matrix for the connections between layer 
1−i  and layer i  then  )( 1 iiiii baWfa += − .  
 
If there are m  layers then an input pattern, p , is fed through the network we have: 
)(,),(),( 1212221111 mmmmm baWfabaWfabpWfa +=+=+= −K  
 
The final activation, maa = , is then compared with the corresponding target vector t .  
 
A network that receives an r − vector and sends it through m  layers of neurons with transfer 
functions if in layer i  is given a diagrammatic representation as shown in Figure 7.1. 
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This is propagated forward through the third layer and beyond until the 
 thm layer is reached: 
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Figure 7.1 Diagrammatic representation of the layers of a neural network. 
 
The network is described as a ( )1, , , mr s s⋅ ⋅ ⋅ -feed-forward network.  For example if the inputs are 3-
vectors and the network has 2 neurons in layer 1, 2 neurons in layer 2 and 1 neuron in layer 3 
then it is described as a 3-layer network and more specifically as a (3, 2, 2, 1) -feed-forward 
network. In the literature there is some confusion about this notation. The first number in the list 
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is the dimension of the input pattern space. Since this is determined by the dimension of the input 
space and the nodes which receive these vectors do no computation, some authors omit them 
from the description, listing only the sizes of the hidden layers and the output layers. In 
particular, the MATLAB Neural Network toolbox function, newff, uses only ),,( 1 mss K to 
specify the layer sizes. 
 
The sum of squares error ( SSE  or simply E ), which is the square of the Euclidean norm of the 
error vector, tae −= , is then a function of the weights and biases in the network. It is given by 
 
                                    ∑ −=−=
i
ii tataE
22 )(||||                                                Eq 7.1 
 
If the weights and biases of the network are written as a vector ),,( 1 nxxx K=  then )(xEE = . 
Therefore E is a function of many variables and its global minimum, if it exists, can be sought by 
means of the steepest descent algorithm. This is an iterative procedure which produces a 
sequence, ),,( 21 Kxx , of weights and biases such that )( kxE  decreases as k increases. This 
requires that the transfer functions are continuously differentiable since the gradient vector, E∇ , 
is used at each iteration to determine the direction of the next step.  
 
The log-sigmoid function, logsig, the tan-sigmoid (hyperbolic tangent) function, tansig, 
and of course, the pure linear function, purelin, all have this property and are common 
choices for transfer functions. In neural network research, the investigation of this optimisation 
procedure led to the discovery of the back-propagation algorithm [165,170]. This algorithm 
allows the weights and biases to be adjusted in a pro rata fashion starting at the last layer and 
working back through the network. The weights are initially assigned randomly and then 
adjusted after each epoch using back-propagation. This process of adjusting the weights and 
biases in such a way that E decreases is called training of the network.     
 
The usual procedure for the training of a neural network is to partition the data set into three 
subsets: a training set, a test set and a validation set. The input patterns in the training set are 
presented to the network and each pass of the input patterns in the training set is called an epoch. 
 168
By virtue of the gradient-descent algorithm, the sum of squares error on the training set, 
trainE ,diminishes with each epoch. 
 
A crucial question to be answered prior to the training of the network is the number epochs to 
present. If too few are presented, the net will be inadequately trained and, conversely, if too 
many are presented the net may become overtrained. Overtraining occurs when the weights and 
biases have been adjusted to minimise the sum of squares error, trainE , bringing the activations 
ever closer to the targets at the expense of the ability of the net to interpolate. To prevent 
overtraining, the sum of squares error, valE , on the validation set, is monitored while the net is 
being trained. valE will generally decrease during the early stages of training but will start to 
increase when overtraining begins to occur. At this stage training must be stopped and the 
performance of the net can then be assessed on the test set. It is the sum of squares error, testE , 
on the test set that determines the ability of the network to interpolate. If testE  is low then there is 
a good chance that the network will be able to produce sensible activations (simulations) on 
input patterns that are similar to the ones on which it was trained. However, neural networks are 
not able to produce sensible activations on input patterns which are dissimilar to those of the 
training set. In other words, an artificial neural network can be used for interpolation but usually 
not for generalisation on input patterns which are outside of its experience.   
 
The number of neurons in each layer also affects the ability of the net to interpolate. If a hidden 
layer has too many neurons, patterns will be memorised which handicaps the network’s ability 
and speed to discern relationships [154,168]. This ‘over-fitting’ or ‘memorisation’ will result in 
poor generalisation ability of the network [154,167].  Complete memorisation tends to occur 
when the number of facts used to train the network is equivalent to the number of hidden nodes 
[154] or if it is trained over too many epochs. However, too few nodes may mean that the 
network might not have enough power to classify patterns in the data [154] and thus display poor 
mapping [167]. 
 
 169
The neural networks in this study were constructed and deployed in the MATLAB computational 
environment. In particular the MATLAB Neural Network Toolbox was used. In this environment 
there are many training algorithms available and they are summarised in Table 7.1. 
       
 
Table 7.1 Summary and description of the training algorithms in the MATLAB Neural 
                Network Toolbox. 
Training Algorithm Description 
trainb   Batch training with weight and bias learning rules 
trainbfg BFGS quasi-Newton backpropagation 
trainbr   Bayesian regularization 
trainc  Cyclical order incremental update 
traincg  Powell-Beale conjugate gradient backpropagation 
traincgf Fletcher-Powell conjugate gradient backpropagation 
traincgp Polak-Ribiere conjugate gradient backpropagation 
traingd Gradient descent backpropagation 
traingda Gradient descent with adaptive lr backpropagation 
traingdm Gradient descent with momentum backpropagation 
traingdx  Gradient descent with momentum and adaptive lr backprop 
trainlm Levenberg-Marquardt backpropagation 
trainoss One step secant backpropagation 
trainr Random order incremental update 
trainrp Resilient backpropagation (Rprop) 
trains Sequential order incremental update. 
trainscg Scaled conjugate gradient backpropagation. 
 
Of the algorithms available for use, the scaled conjugate gradient training algorithm 
(trainscg) has been found to be useful and was used in this study. In [169] it is reported that 
among the MATLAB training algorithms the Levenberg-Marquardt (trainlm) algorithm 
seems to produce a network with the best overall predictive capability. This algorithm requires 
sufficient memory to deal with large Jacobian matrices and their inverses. However, there is a 
memory reduction feature for large training sets. Furthermore, it converges to a solution in far 
fewer epochs than trainscg does. The trainlm algorithm was used as an alternative 
training method but no improvement was noticed. Once a neural network is successfully trained, 
it does not matter how the training was achieved. 
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7.3 Applications of ANN for Formulation Development 
 
The development of controlled-release drug delivery devices with the desired in vitro dissolution 
and in vivo bioavailability characteristics is often challenging and complex since non-linear 
relationships usually exist between independent formulation variables and the resultant, 
dependent drug release characteristics [162].  The ANN that was developed and used in this 
study was designed for the purpose of predicting formulation properties, characteristics and 
compositions that were required to match CBZ release from a commercially available CBZ-
containing dosage form, viz., Tegretol® CR (Novartis, Quebec, Canada).  A data set consisting of 
36 formulations matched according to their respective in vitro dissolution profiles generated 
using USP Apparatus 3 and the method described in Section 3.8.4 and was used as the training 
set for the network.    The trained network attempts to predict the percent drug released from a 
dosage form at specific time intervals.  A list of the formulation components used in these 
studies is summarized in Table 7.2.   The individual formulation components were assigned as 
input vectors and formulation composition or drug and excipient properties were matched to the 
relevant dissolution profile generated over a 22-hour period, for the purposes of training the 
network.  The quantitative effects of the excipients and formulation composition on in vitro 
performance of the matrix tablets were then evaluated. The output data was the percent dissolved 
drug at pre-determined time intervals i.e. at 0, 1, 2, 6, 10, 14 and 22 hours, respectively.  
Following the completion of the training phase, the ANN was used to predict the percent drug 
release from a dosage form of different composition at the specified pre-determined time 
intervals. 
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Table 7.2 Input variables introduced to the ANN. 
Component Component Description 
1i
p  carbamazepine, course Grade 
2i
p  carbamazepine, fine Grade 
3i
p  microcrystalline cellulose (grade specific) 
4i
p  dibasic calcium phosphate 
5i
p  hydroxypropylmethylcellulose (grade specific) 
6i
p  hydroxypropylmethylcellulose (grade specific) 
7i
p  hydroxypropylmethylcellulose (grade specific) 
8i
p  lactose (hydrous) 
9i
p  sodium lauryl sulphate 
10i
p  magnesium stearate 
 
 
7.3.1 Construction, Training and Deployment of the ANN 
 
Thirty six tablet formulations were manufactured and their dissolution profiles generated and 
recorded.  For each }36,,1{ K∈i  the vectors 361 ,, pp K  constituted input patterns for the neural 
network. Each input vector represented a formulation. For each }36,,1{ K∈i , the percentage 
CBZ released at times: 1,2,6,10,14 and 22 hours was measured and the associated target vector, 
it , was obtained. Each target vector represented a release profile. The target vector components 
are described in Table 7.3 
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  Table 7.3 Target Vector Components 
Component Component Description 
1i
t  percentage CBZ released at time 1 hour by formulation i 
2i
t  percentage CBZ released at time 2 hours by formulation i 
3i
t  percentage CBZ released at time 6 hours by formulation i 
4i
t  percentage CBZ released at time 10 hours by formulation i
5i
t  percentage CBZ released at time 14 hours by formulation i
6i
t  percentage CBZ released at time 22 hours by formulation i
 
 
Since the percentage CBZ released at time 0 is always 0 this was not included as a component of 
the target vectors. The 10 x 36 matrix, p and the 6 x 36 matrix, t, were collected together in the 
data matrix, ⎥⎦
⎤⎢⎣
⎡=
361
361
,,
,,
tt
pp
D L
L
 ,the first five columns of which are depicted in Table 7.4. 
 
           Table 7.4 First Five Columns of the Data Matrix D 
60.00 60.00 0.00 19.50 24.75
0.00 0.00 49.50 30.00 24.75
0.00 0.00 17.40 17.40 17.40
4.00 4.00 12.04 12.04 12.04
18.00 0.00 6.70 6.70 6.70 
0.00 18.00 9.00 9.00 9.00 
0.00 0.00 0.00 0.00 0.00 
18.00 18.00 5.36 5.36 5.36 
0.00 0.00 0.40 0.40 0.50 
0.33 0.33 0.20 0.20 0.25 
10.22 7.65 24.88 15.27 15.27
15.80 11.30 33.63 21.61 21.83
27.36 20.86 53.72 36.35 36.46
37.78 30.28 69.27 49.12 48.52
45.79 38.74 82.30 62.80 61.46
48.74 48.85 90.29 73.57 70.26
 
 
 
For example, the first column contains the input vector 
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⎥⎥
⎥
⎦
⎤
⎢⎢
⎢
⎣
⎡
=
33.0
60
1 Mp  
 
and an associated target vector 
 
⎥⎥
⎥
⎦
⎤
⎢⎢
⎢
⎣
⎡
=
74.48
22.10
1 Mt . 
 
This data set was too small to have a validation set and therefore it was decided to adopt the 
‘leave one out’ training strategy. This involves selecting just one input and corresponding target 
vector as a test set. The number of epochs over which to train the network was decided by 
monitoring the training window, in which the performance, SSE (or MSE: mean square error) is 
displayed as a function of the number of epochs. An example is shown in Figure 7.2.  
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Figure7.2 Graph of MSE versus number of epochs. 
 
When the graph of MSE versus number of epochs flattens and the norm of the gradient becomes 
low it is likely that further training will produce marginal improvement at the expense of the 
ability of the net to interpolate.  
 
The MSE and the gradient is also displayed in the command window as training proceeds and an 
example is shown in Figure 7.3. 
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TRAINSCG, Epoch 900/1200, MSE 0.00932127/0, Gradient 0.000519778/1e-006 
TRAINSCG, Epoch 950/1200, MSE 0.00931476/0, Gradient 0.000477872/1e-006 
TRAINSCG, Epoch 1000/1200, MSE 0.00930597/0, Gradient 0.000705202/1e-006 
TRAINSCG, Epoch 1050/1200, MSE 0.00929421/0, Gradient 0.000473016/1e-006 
TRAINSCG, Epoch 1100/1200, MSE 0.0092854/0, Gradient 0.000482811/1e-006 
TRAINSCG, Epoch 1150/1200, MSE 0.00927919/0, Gradient 0.000334451/1e-006 
TRAINSCG, Epoch 1200/1200, MSE 0.00927361/0, Gradient 0.000403976/1e-006 
              Figure 7.3 Command Window Display of MSE and Gradient During Training. 
 
From the information depicted in Figure 7.3  it can be seen that changes in the MSE  are minimal 
for epochs beyond 900 and this indicates that 900 epochs may be sufficient for training the ANN. 
Therefore, it was decided to use 900 epochs to train the ANN.  
 
The formulation vector and corresponding release profile for a tablet with 19.5% CBZ CG and 
30% CBZ FG, column 4 in Table 7.4, was hidden from the network which was trained on the 
remaining data set.  
 
The network structure was of the form [ ] [ ]6,10,16,, 321 =sss , where is , denotes the number of 
neurons in layer i .  The input layer had 10 nodes to receive the 10-dimensional input vectors, 
ip , the two hidden layers had 16 and 10 neurons, respectively and the output layer had to have 6 
neurons in order to produce a 6-dimensional activation vector, ia , the same size as the target 
vector it . The numbers 2s and 3s  were obtained by experimentation and there is some flexibility 
here. There is no deterministic method of obtaining the layer sizes. A neural network with 
9,17 21 == ss , for example, produces very similar results. The layer sizes, 21 , ss  were decided 
by adjusting these numbers and then observing testE  and trainE  as well as visually inspecting the 
activation vectors compared to the target vectors.      
 
Since the input vectors were 10-dimensional it would be necessary to have 1024210 = input 
vectors if each component were to have just two different values. Since there were only 36 input 
(and 36 corresponding target vectors) and a neural network cannot generalise outside its 
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experience, it was essential that the data set was such that the network could find the required 
formulation by interpolation. Formulation expertise and human experience were necessary to 
provide suitable training experience, in the form of input patterns and targets, for the neural 
network.   
 
The transfer functions in the layers were tansig,logsig and purelin respectively. Again, 
there is some flexibility in the choice of transfer functions and no deterministic method of 
deciding on them. The purelin transfer functions in the last layer allow the output vector 
components to attain arbitrary size. The scaled conjugate gradient method, trainscg, was used 
to train in the network over 900 epochs. 
 
Prior to training the network, the data was normalized in such a way that each component of the 
input vectors was between -1 and 1.  This is achieved by a simple transformation given in 
Equation 7.2.  
 
                                       1
)min(max
)min(2 −−
−=
pp
pppn                                      Eq 7.2 
 
MATLAB has the function premnmx which accepts the matrix, p , of all input vectors and the 
matrix, t , of all corresponding output vectors as input and returns np and nt , the normalized 
matrices, as well as vectors ttpp max,min,max,min whose components are the minima and 
maxima of each row of p  and t . After training the activations need to be rescaled using the 
inverse of the transformation, postmnmx. For simulation, the function, tramnmx is used to 
perform the appropriate scaling of inputs.  
 
The activation on the test set, which consisted of a single vector, was then compared with the 
corresponding target. The graphical output is shown in Figure 7.4, in which the components of 
the target vector are indicated with the omarker while the components of the activation vector 
are indicated with the * marker. 
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Figure 7.4 Graph depicting target and activation vectors as percent 
                   released vs. time (hours). 
 
 
Having established that the neural network was not overtrained and that it was able to 
interpolate, it was then trained on the entire data set and the resulting neural network object was 
saved in order to be used for simulation. A simulation set, simp , consisting of 21 input patterns 
was generated. These vectors were such that the composition of CBZ CG varied from 9.5 to 29.5 
%w/w, while the CBZ FG composition was correspondingly varied from 40 to 20% w/w. The 
regression curves ( )rteMy −∞ −= 1  fitted to the corresponding activations indicated a clear trend 
as can be seen in Figure 7.5 
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         Figure 7.5 Trend in CBZ release profiles when CG:FG ratios are varied.  
                           This is presented as percent of drug released vs. time (hours). 
 
As the percentage composition of CBZ CG was increased, and the percentage 
composition of CBZ FG correspondingly decreased, the profiles flattened, showing a 
corresponding decrease in the release rate of CBZ from these dosage forms. This 
observation suggested that it might be possible to match the release profile of Tegretol® 
CR by finding the optimal balance between the CG and FG CBZ content in the test 
formulations. The formulation vector for which the resultant dissolution profile was 
most similar to that of Tegretol® CR was then found. This was achieved by comparing 
2f values of the activations and that of the reference formulation, Tegretol
® CR. This is 
the 2f similarity measure of Moore and Flanner introduced earlier in Section 3.9. It was 
considered vitally important to match the release of CBZ from the Tegretol® CR dosage 
form in the early stages of the dissolution test since most previous formulation release 
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profiles failed to match that of Tegretol® CR especially during the first hour dissolution 
testing.  
 
The release profile vector,T , for Tegretol® CR had been previously obtained. A 
normalised weighting vector, 
|||| v
vw = , where [ ]1,1,1,2,4,8=v  was generated and for 
each activation, a , from the simulation set, the weighted 2f value, as defined in 
Equation 7.3 was recorded. 
 
 
 
 
E 
     Eq 7.3 
 
 
 
 
The formulation vector, p , whose activation vector, a , was most similar (largest) in this sense 
to T was then found using the MATLAB functions max and find. The formulation predicted 
by the network (Batch C-120905-01) was manufactured and assessed using the USP Apparatus 3 
(Vankel, USA).   
 
Comparison of the dissolution profiles was done by visual inspection and regression analysis of 
the ANN predicted profiles versus the experimentally observed profile for the manufactured 
formulation as well as comparing the 1f  and 2f  difference and similarity factors where an 
1f value less than 15 and an 2f  value greater than 50 showed similarity between two profiles.  
Tegretol® CR served as the reference data set.  The release profiles are shown in shown in Figure 
7.6 and the difference and similarity factors are given in Table 7.5. 
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Table 7.5 Difference and similarity factors for Tegretol®, predicted and actual 
                 formulations. 
Formulation 1f  2f  
Tegretol® CR - - 
C-120905-01 (Network-predicted) 15.7 54.8 
C-160905-01 (Actual Test) 8.5 66.6 
              *Shaded value represents out-of-specification result. 
 
In an attempt to ensure that the similarity of the dissolution profile of the test formulation better 
matched that of the reference formulation, the proportions of the two particle size grades of CBZ 
were retained and the proportions of the two grades of HPMC used were varied.  The differences 
between the predicted and actual formulations that were manufactured, where adjustments of 2% 
were made to the percentage composition of  Emcompress®, Methocel® K4M and Methocel® 
K100M are summarized in Table 7.6.   
                       
 
                 Table 7.6 Predicted Formulation and Adjusted Formulation 
Formulation Component C-120905-01
(%) 
C-160905-01 
(%) 
CBZ CG 10.7 10.7 
CBZ  FG 38.8 38.8 
Emcocel® 90M 17.4 17.4 
Emcompress® 12.04 10.04 
Methocel® K4M 6.7 8.7 
Methocel® K100M 9 7 
lactose 5.36 5.36 
sodium lauryl sulphate 0.4 1.5 
Mg stearate 0.2 0.5 
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The rationale behind attempting these adjustments was to decrease the higher viscosity polymer 
so as to facilitate greater drug release early in the dissolution test.  Emcompress® contributes to 
tablet hardness and therefore the amount used in the formulation was reduced to enhance matrix 
dissolution and erosion, which in turn would facilitate or promote drug release.  The modified 
formulation was manufactured (Batch C-160905-01) and assessed and the resultant dissolution 
profile is also depicted in Figure 7.6.   The release data for the formulations shown in Figure 7.6 
is presented in Table 7.7. 
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Figure 7.6 Dissolution profiles of CBZ release from Tegretol® CR, the network- 
    predicted formulation (Batch C-120905-01) and the modified 
    formulation (Batch C-160905-01) 
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                  Table 7.7 Release data for the predicted and adjusted formulations. 
Time (Hours) C-120905-01 
(Predicted) 
C-160905-01 
(Adjusted) 
Tegretol® CR 
1i
t =1 15.065 14.917 15.779 
2i
t =2 21.265 21.087 28.361 
3i
t =6 35.354 37.128 42.475 
4i
t =10 46.872 50.930 56.237 
5i
t =14 56.973 63.984 67.158 
6i
t =22 68.928 76.162 78.320 
 
7.4 CONCLUSION 
 
ANN analysis is reasonably flexible as to the amount and form of the data required for training 
of a network, which makes it possible to use more informal experimental designs than those 
required with other statistical approaches, such as RSM [165] for formulation development.  The 
application of ANNs is a totally different approach in which all possible data are used for 
developing accurate models [165].  There is a need for historical and empirical data when using 
computing networks but this is an additional tool that can be used in the formulation 
development process, which can substantially reduce the time and the cost of formulation design 
and development. 
 
It is clearly evident, based on the difference and similarity factors as listed in Table 7.3 that the 
empirically modified formulation matched Tegretol® CR better than the composition predicted 
by the ANN.  The formulation parameters introduced to the ANN in this study did not include 
manufacturing process effects such as for example, direct compression or wet granulation 
methods manufacture and especially did not account for the effects of tablet hardness on drug 
release rates.  More comprehensive and tailored experimental studies would have to be 
conducted to create a network that would predict formulations for which consideration of these 
factors have been included. The lack of inclusion of these parameters in the ANN could account 
for the small differences observed in drug release rates predicted by the formulation composition 
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predicted by the ANN and the actual in vitro dissolution profile generated following manufacture 
of the formulation.   
 
In addition, the learning nature of ANNs determines that its ability to interpolate would be better 
with a large training data set and extensive internal mapping of the design space [165] and this 
would contribute to more accurate data prediction.  The size of the network training data set of 
36 input and output data pairs, can be considered small and this may account for the 
discrepancies observed between the ANN predicted and actual target results.  However, there is 
no definite rule to regulate how many data sets are sufficient for ANN training.  Furthermore, 
ANNs with a general structure may occasionally produce a poor estimation of some responses, 
which will lead to unreasonable predictions of results at some dissolution time points in the case 
of predicting drug release kinetics [165]. 
 
However, this ANN provided a rational basis from which a modification to a formulation 
composition could be made, to alter the drug release profile based on the knowledge of the 
physico-chemical properties of the formulation components.  The formulator is thus able to make 
rational decisions regarding formulation improvements based on ‘science’ rather than the ‘art’ of 
formulation.  Further studies with appropriate modifications to the network training data set may 
still yield better estimations of compositions and dissolution profiles.  Ultimately, ANNs provide 
a useful tool for the prediction of the in vitro performance of drug delivery systems [165]. 
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CHAPTER EIGHT 
IN VIVO ASSESSMENT OF 400MG CBZ SUSTAINED RELEASE POLYMERIC 
MATRIX TABLETS 
 
8.1 Introduction 
 
The Medicines Control Council (MCC) in South Africa is a statutory body that was established 
in terms of the Medicines and Related Substances Control Act (MRSCA), 101 of 1965, to 
oversee the regulation of medicines in South Africa.  The registration of generic drug products 
requires that an application be submitted to the MCC and guidelines have been prepared to serve 
as a recommendation to applicants wishing to submit data in support of the registration of such 
products [170]. 
 
Recent legislation requires that generic medicines registered in South Africa must be offered to all 
patients when a physician prescribes an innovator product.  More specifically, the amendment to the 
MRSCA [171] states the following: 
 
Subject to subsections (2), (3), and (4) of the Act, a pharmacist or a person licensed in terms of 
section 22C shall: 
 
a) Inform all members of the public who visit the pharmacy or any other place where 
dispensing takes place, as the case may be, with a prescription for dispensing, of 
the benefits of the substitution for a branded medicine by an interchangeable 
multi-source medicine; and 
 
b) Dispense an interchangeable multi-source medicine prescribed by a medical 
practitioner, dentist, practitioner, nurse or other person registered under the Health 
Professions Act, 1974, unless expressly forbidden by the patient to do so. 
 
Furthermore, subsection (4) states that “A pharmacist shall not sell an interchangeable multi-
source medicine 
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• if the retail price of the interchangeable multi-source medicine is higher than that 
of the prescribed medicine; or 
 
 • where the product has been declared not substitutable by the council” 
 
Therefore in the South African context the use of generic medicines is mandated, wherever 
possible. 
 
The main purpose of the MCC is to safeguard and protect the public through ensuring that all 
medicines that are sold and used in South Africa are safe, therapeutically effective, and 
consistently meet acceptable standards of quality. In this respect, all submissions must provide 
the necessary data for Quality, Safety, and Efficacy to register an interchangeable multi-source 
or generic pharmaceutical product (medicine) and thereby infer that it is therapeutically 
equivalent.  Furthermore, the intention of the new legislation is to make medicines more 
affordable and available to the wider South African public. 
 
In order to understand the implications for generic substitution, several important definitions and 
specific terms have been described in the relevant Act [171] as well as in the guidelines [170]. 
These considerations parallel the requirement for multisource interchangeability defined within 
the US and the European Union (EU).   
 
As defined in the Act, an interchangeable multi-source medicine means a medicine that contains 
the same active substance(s) as an approved drug product, and is identical in strength or 
concentration, dosage form and route of administration. An interchangeable multisource 
medication must meet the same or comparable standards that will confirm that the generic 
product complies with the requirements for therapeutic equivalence. Such demonstration may be 
accomplished via appropriate bioequivalence studies, pharmacodynamic studies, clinical 
endpoint studies or in vitro studies.  
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Consistent with conventional thinking [C,D,E and with the regulatory bodies in other 
jurisdictions, the Act [171] defines the term bioequivalence as follows: 
 
“Bioequivalence” means the absence of a significant difference in the rate and extent to which 
the active ingredient or active moiety in two pharmaceutically equivalent products becomes 
available at the site of drug action when administered at the same molar dose under similar 
conditions in an appropriately designed study. 
 
Regulation 2 of the Act [171] describes the requirements for therapeutic equivalence wherein “a 
medicine is regarded as therapeutically equivalent to another medicine if both medicines are 
pharmaceutically equivalent, i.e., contain the same amount of active substances in the same 
dosage form, meet the same or comparable standards and are intended to be administered by the 
same route, and that have essentially the same safety and efficacy profile.”  Consequently, a 
generic product is one that contains the same amount of and active compound delivered via the 
same route of administration as a specific type of dosage form, i.e., solid-oral or liquid-oral, as 
the innovator or marketed brand product.    
 
As part of the process of formulation development and testing, in vitro dissolution studies are 
conducted to assess the rate and extent of the release of and API in selected dissolution media 
[172].  Comparisons are made between the dissolution profile of the test product to that of an 
innovator or reference product and formulation adjustments are made to achieve a dissolution 
profile that is comparable to that of a reference product.  However, in order to prove 
bioequivalence, the evaluation of the in vivo behaviour of a generic product in comparison to that 
of an innovator product is a requirement for the registration of the generic formulation. 
 
Bioequivalence requirements may be imposed by Regulatory Agencies such as the MCC, FDA 
or EMEA on the basis of the physicochemical properties of an API, where such properties can 
have a significant impact on the in vivo availability of the API, from solid oral dosage forms.  
Compounds that have low water solubility and where particle size and polymorphism play a 
critical role in determining bioavailability are required to show bioequivalence to an appropriate 
innovator product [l73]. Drug products in which there is a high ratio of excipients to API and 
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where dose-dependant kinetics in or near the therapeutic range is evident and the rate and extent 
of absorption are important to bioequivalence, must undergo in vivo testing [173]. 
 
CBZ is a well-known and documented API, which is the drug of choice for all partial and tonic-
clonic seizures [174,175].  Therapeutic regiments in which conventional immediate-release CBZ 
tablets are used, often necessitates dosing three to four times daily to achieve optimum and 
sustained pharmacological responses with minimal variability [174].  Plasma concentration 
variability and dosing frequency can be reduced by the introduction of a twice-daily dosing 
regimen through the use of extended release products [174].  The advantages of a controlled 
release dosage form have been previously discussed in Section 5.1.  Controlled release CBZ 
products do not potentiate the anti-epileptic activity of CBZ, however can dramatically improve 
patient compliance and convenience, and therefore effect a reduction in the concentration-related 
side-effects, which can lead to improved anti-epileptic activity and improved patient adherence 
[176].  
 
All FDA approved generic CBZ tablet products are required to demonstrate bioequivalence to an 
innovator product in a single-dose crossover study conducted in health human volunteers [177]. 
In addition, bioequivalence-testing may also become important when comparing the in vivo 
behaviour between generic products.  The most important objective of bioequivalence testing is 
to guarantee that generic products are safe and clinically effective for patients, within the well-
established limits for bioequivalence testing [178]. 
 
8.2 Biopharmaceutics 
 
Biopharmaceutics is the study of the inter-relationship of the physicochemical properties of the 
drug, dosage form, route of administration and the rate and extent of systemic drug availability, 
i.e., bioavailability [173].  Pharmaceutical dosage forms can be precisely evaluated, controlled 
and corrected where necessary, whereas physiological factors cannot be controlled to the same 
extent. However, an awareness of impact of physiological factors on dosage form performance is 
important in determining a suitable and appropriate dosage regimen for a specific API [179]. 
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Knowledge of the physicochemical properties of a drug and the associated pharmacokinetic 
behaviour is essential and necessary when evaluating the potential bioavailability of an API from 
a particular dosage form [179].  Furthermore, the use of several excipients in combination in a 
formulation, to produce a specific delivery system may influence the in vivo performance of a 
drug [179]. 
 
The chemical structure of a drug will influence the rate and extent of dissolution and ultimately 
the bioavailability of the API [173,179]. It is important that an API has some degree of aqueous 
solubility to be effectively absorbed, when administered via the oral route [179].  Furthermore 
specific crystalline states, such as amorphicity, polymorphic structure and hydration, in addition 
to particle size may also influence the in vivo behaviour of an API [173,179]. 
 
As a general rule, a drug substance with an aqueous solubility < 1mg/ml may present a potential 
bioavailability challenge and therefore, methods to improve the aqueous solubility of such a 
compound,  such as micronisation of the API, complexation with cyclodextrins, salt formation 
and esterification should be explored during preformulation and formulation development studies 
[141,173,179].  The API should also have the potential to cross the lipid barriers of cell 
membranes in the region of the site of absorption in the GIT, in order to enter the systemic 
circulation [173,179].  The dissolution rate of a solid oral dosage form also plays a major role in 
controlling the rate and extent of absorption of an API from the GIT and is an important 
consideration when formulating sparingly or highly insoluble compounds such as CBZ 
[173,179]. 
 
Other biopharmaceutical factors that can influence bioavailability are related to dosage form 
design and the effects of various adjustments to a formulation during development [173,179].  
Excipients may be used as binders, diluents, disintegrants and lubricants, which are necessary 
components for tablet production and the type and amount of each of these adjuvants may affect 
the dissolution rate of a drug from such dosage forms and adversely impact its bioavailability 
[173,179].  In addition, the method of manufacture, viz., direct-compression, dry or wet 
granulation and processing controls such as humidity, temperature, storage time of in-process 
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material, may also adversely influence the in vitro and in vivo performance of a dosage form 
[179]. 
 
The physiology of the biological system also poses several challenges with respect to drug 
absorption and ultimately the pharmacokinetics of a specific drug compound.  In humans, the 
average pH range of GIT fluids extends from approximately a pH = 1 to pH = 2.5 in the stomach 
to between pH = 7 and up to pH = 8 in the lower ileum [183].  Drugs that show pH dependant 
dissolution and therefore, absorption, will be affected by the changing pH of the GIT fluids.  
Certain disease states or injury to the gut wall, such as duodenal ulcers as well as the presence of 
food or other substances in the GIT will also affect drug absorption.   
 
The role of the stomach mucosa is a relatively minor consideration in drug absorption due to its 
small surface area [179] and drugs such as CBZ are absorbed erratically whereas other 
compounds are not absorbed at all, from this organ [7,173,179].  Controlled-release dosage 
forms contain a greater quantity of drug than conventional immediate release formulations and 
are also dosed less frequently, therefore, a pronounced food effect food on bioavailability may 
result in a serious and/or long-lasting influence on plasma levels [180]. 
 
The aforementioned factors were taken into account when designing the controlled-release 
matrix delivery systems that were intended for administration of CBZ in vivo, where complex 
physiological processes affect dosage form performance and therefore, the therapeutic 
effectiveness of the API intended for pharmacological action.  
 
8.3 Pharmacokinetics 
 
The study of the kinetics of drug absorption, distribution and elimination is termed 
pharmacokinetics, whereas drug disposition is a general term that covers drug distribution 
controlled by the ability of the drug to partition into and between various biological 
compartments [173,179].  Drug disposition also describes any alteration in the chemical structure 
of the drug inside the body, viz., biotransformation as well as all the processes leading to the 
transfer or removal of a xenobiotic from the body, viz., drug excretion/elimination [173,179].  It 
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is important to have an understanding of pharmacokinetic principles in order to be able to 
interpret in vivo blood level data. 
 
In pharmacokinetics, the most common approach is to consider the body as comprising several 
hypothetical compartments, through which the drug can enter and exit according to first-order 
rate processes or kinetics [179]. The compartment itself is a mathematical concept, which is not 
easily visualised in anatomical or physiological terms [179].  The kinetics of most of the 
pharmacokinetic and drug disposition processes in the body can be described by hypothetical 
models that consist of one, two or at most three functional compartments arranged either in 
parallel or in series [179].   
 
The pharmacokinetic parameters of CBZ, i.e., absorption, distribution, metabolism and excretion 
are comprehensively described in Chapter 1.  CBZ is a lipid soluble compound, which is slowly 
and variably absorbed from the GIT [7,181].  The bioavailability of CBZ has not been directly 
determined but it is estimated to be in excess of 70% and may even approach 100% [7].     
 
The design of a dosage form and its subsequent composition may also significantly affect drug 
dissolution and therefore absorption [178,180]. Differences in the rate of absorption from 
different products may be responsible for the occurrence of side effects when patients switch 
from one product to another [178,182].   Studies have shown that there is a lack of food 
interaction for CBZ controlled-release formulations and patients may take the dosage form 
before or after a meal [180].  However, for long-term treatment a consistent dosing regimen is 
advocated and it has been suggested that CBZ generally taken after meals may minimise any 
possible GIT effects such as gastric irritation or nausea [180]. 
 
8.3.1 Volume of Distribution 
 
The apparent volume of distribution of a drug, Vd, is a guide to the extent of distribution of that 
drug in the body and is a mathematical and not a physiological constant. Consequently the 
calculated Vd of a drug may exceed the blood and body volume extensively [179]. The Vd of a 
drug following an extravascular dose may be estimated using Equation 8.1. 
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                                                                       Vd = 
kAUC
FD                                               Eq. 8.1 
 
where,  
 
 Vd = the volume obtained by extrapolation of the drug concentration 
 F = fraction of drug available to the systemic circulation 
 K = elimination rate constant 
 AUC = area under the curve represented by concentration as a function of time 
 
On average the volume of distribution of CBZ is approximately 1.4L/kg but a wide range of 
values have been reported as previously described in Chapter 1 [7].  CBZ is primarily bound to 
albumin with a free fraction of 20 to 30% [7]. 
 
8.3.2 Biological Half-Life (t½) 
 
The biological half-life of a drug can be expressed as the period of time required for the amount 
or concentration of unchanged drug in the plasma to reduce to one-half of the initial 
concentration under equilibrium conditions [173,179].  The biological half-life of a drug can be 
calculated as shown by Equation 8.2 
 
                         t
2
1  = 
k
693.0
                                                                                   Eq. 8.2 
 
where,  
  k = elimination rate constant of a drug 
 
Clinically, the elimination rate constant (k) and the biological half-life (t1/2) can be used to 
estimate the time to reach steady-state plasma concentration after initiation of change in 
maintenance dose [7]. Furthermore these parameters can be used to estimate the time required to 
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eliminate all or a fraction of an administered drug from the body once therapy has been 
discontinued [7].  These parameters are a significant consideration, when designing 
bioequivalence studies since it will allow the investigator the opportunity to determine the 
necessary sampling schedule and requisite washout period between each of the phases of that 
bioequivalence study. 
 
Although single dose studies suggest that the half-life of CBZ is approximately 30 to 35 hours, 
steady-state data suggest that the half-life is reduced to approximately 15 hours [7].  The 
decrease in the half-life observed on multiple dose therapy is more than likely due to the auto-
inductive effect of CBZ on its metabolism and which has been described in Chapter 1.  
Therefore, pharmacokinetic data derived from single-dose studies should not be used to calculate 
maintenance dose regimens for patients that have been prescribed CBZ for chronic conditions 
and patients must be monitored carefully when dose adjustments are made [7].   
 
8.3.3. Clearance 
 
Total body clearance (ClT) is a pharmacokinetic parameter that is used to describe the intrinsic 
ability of the body or its organs of elimination, i.e., kidneys and liver, to remove drug from blood 
or plasma and clearance is usually expressed as a volume cleared of drug per unit time [7].  The 
mathematical prediction of clearance is achieved using Equation 8.3. 
 
                                                         ClT = AUC
FD                                                                  Eq. 8.3 
where, 
 
  F = fraction of drug available in the systemic circulation 
 D = Administered dose 
AUC = area calculated under the curve and denoted by concentration as a 
function of time 
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8.3.4 One-Compartment Open Model 
 
The open-one compartment model is the simplest model that can be used in pharmacokinetics to 
describe the body [179]. The open-one compartment model is used to represent the body as a 
single compartment with no barriers to drug transfer [179].  The one compartment open model 
assumes that any changes that occur in the plasma levels of a drug reflect proportional changes in 
tissue drug levels, however this model does not assume that drug concentrations in each tissue 
are the same at any given point in time [173]. The pharmacokinetics of CBZ have been 
appropriately described by an open one-compartment linear model [1,175] and therefore the use 
of mathematical relationships that reflect the simple model to calculate pharmacokinetic 
parameters for CBZ can be considered appropriate. 
 
 
8.3.5 Zero and First-Order Kinetics 
 
The rate of drug absorption is constant and continues until the amount of the drug in the GIT is 
depleted, if the absorption process is best described by zero-order kinetics [179].  Once the 
amount of drug available for absorption has been depleted and no drug is available for further 
absorption from the GIT, first order rate processes then dominate the pharmacokinetics of the 
drug [179]. 
  
First-order elimination kinetics refers to a process in which the amount or concentration of drug 
in the body diminishes logarithmically over time and where total clearance and volume of 
distribution remain constant and do not vary with dose or concentration [7].  A mathematical 
equation to describe the plasma concentration versus time profile for a drug in which first-order 
elimination is dominant is shown in Equation 8.4. 
 
                                                                Cp = Cp0e-kt                                               Eq. 8.4 
where, 
  Cp = plasma concentration observed at time t 
  Cp0 = initial plasma concentration observed 
 194
   k = elimination rate constant 
   t = time 
 
 
8.4 Bioequivalence Testing of CBZ Matrix Tablets 
8.4.1 Ethical Approval 
 
The bioequivalence study undertaken to evaluate the in vivo performance of the test 
formulation was conducted in accordance with the recommendations and guidelines as set 
out in the Declaration of Helsinki (1964) and all its subsequent amendments of Tokyo 
(1975), Venice (1983), Hong Kong (1989), Somerset West (1996) and Edinburgh (2000) 
[187]. Furthermore, the study was conducted in accordance with the ICH Good Clinical 
Practice (GCP) guidelines [184] and in compliance with Standard Operating Procedures and 
requirements of the MCC [185].  
 
Ethical approval for the study was obtained from the Rhodes University Ethical Standards 
Committee (RUESC) before the study commenced. The Faculty of Pharmacy retained the 
original signed copy of the letter indicating that ethical approval has been granted to 
conduct the study. 
 
Prior to the commencement of the study, the nature, purpose and risk of participating in the 
study was explained to all volunteers.  If volunteers so desired, they were given time to 
consider the information or express any concerns regarding their participation in the study.  
Volunteers were also informed that they could withdraw from the study at any time without 
penalty to themselves, other than reduced remuneration, but that they should be committed 
to completing the study prior to their enrolment.  A signed consent form obtained in the 
presence of the person conducting the informed consent discussion was collected from each 
potential participant and all subjects received written, detailed instructions concerning the 
study performance and relevant restrictions. 
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8.4.2 Protocol and Study Design 
 
Carbamazepine exhibits simple simultaneous first-order and zero-order absorption kinetics 
and absorption is not significantly affected by the presence of food.  A pilot single-dose 
bioequivalence study in which the CBZ matrix formulation developed in these studies was 
compared to Tegretol® CR (Novartis, Quebec, Canada) in the fasted state in healthy male 
subjects, was undertaken. 
 
8.4.2.1 Test and Reference Products 
 
The batch of CBZ tablets that was used for in vivo bioequivalence testing was manufactured 
as described in Section 6.2.3.2.2, in accordance with GMP conditions and the batch 
manufacturing record has been included as Appendix III.  The test batch was also subjected 
to the necessary quality control tests such as, for example, dissolution testing, prior to 
administration as previously described in Chapter 3. 
 
The reference product Tegretol® was stored in a temperature controlled environment on 
receipt and for the duration of all the formulation and development studies. The test and 
reference products were dispensed twenty-four hours prior to each phase of the 
bioequivalence study. 
 
8.4.2.2 Study design 
 
A single oral dose of either Tegretol® CR (Novartis, Quebec, Canada) 400mg or 
carbamazepine 400mg sustained-release tablet was administered during each phase of the 
clinical studies.  Each phase was separated by a minimum washout period of 10 days. The 
randomisation schedule for administration of the test and reference products to healthy 
volunteers is shown in Table 8.1. 
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 Table 8.1 Randomisation schedule  
Sequence Number Phase 1 Phase 2 
1 Test Reference 
2 Reference Test 
 
 
The intake of food and fluid was standardized from check-in until the 24-hour post-dose 
sample had been taken. Subjects fasted for at least 10 hours prior to dosing and standard 
meals or snacks were served at 4, 8, 12 and 16 hours after dosing.  The intake of fluids was 
restricted from two hours prior to dosing until 4 hours after dosing. Water (240 mL) was 
administered at the time of dosing and subjects received an additional 240 mL of water 2 
hours after the dose.  Apart from the study restrictions the subjects were allowed to continue 
with their normal daily routine between phases 1 and 2. 
 
 
The ultimate objective of this bioequivalence study was to prove that the concept of 
administration of CBZ twice-daily in the form of HPMC matrix tablets would provide 
plasma drug levels equivalent to that of a commercially available product, viz., Tegretol® 
CR.  Therefore, it was decided to conduct the study with only two subjects as a ‘proof of 
concept’ pilot study to assess the in vivo potential of the sustained-release matrix tablets 
developed, assessed and manufactured during these studies.  Furthermore, it was decided to 
use only two subjects to reduce the costs associated with conduction a full-scale 
bioequivalence assessment of the test products.  
 
 
8.4.3 Pre-Study Screening 
8.4.3.1 Inclusion Criteria 
 
 
Only those subjects meeting the relevant inclusion criteria were included in the study. The 
inclusion criteria for the bioequivalence assessment of the CBZ tablets are summarized in 
Table 8.2.  
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Table 8.2 Inclusion criteria for the bioequivalence assessment of CBZ matrix tablets 
Criterion  Description 
1 Mentally competent subjects who are available for the entire study period and willing 
to adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form, which is also signed by the person performing the informed 
consent discussion. 
 
2 Males between the ages of 18 and 55 years of age. 
 
3 Volunteers with a body mass index (BMI) of between 19 and 30. 
 
4 Non-smoking volunteers who have not smoked for at least two months. 
 
5 Normal in terms of medical history at the pre-study screening medical, or in the case of 
an abnormality, the medical practitioner considers the abnormality to be clinically 
insignificant. 
 
6 Normal in terms of physical examination at the pre-study screening medical, or in the 
case of an abnormality, the medical practitioner considers the abnormality to be 
clinically insignificant. 
 
7 Normal in terms of laboratory test values for the pre-study screening medical within the 
laboratory’s stated normal range, or in the case of an abnormality, the medical 
practitioner considers the abnormality to be clinically insignificant 
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8.4.3.2 Exclusion Criteria 
The exclusion criteria used to eliminate subject participation in the bioequivalence 
assessment of the CBZ tablets are summarized in Table 8.3. 
Table 8.3 Exclusion criteria for the bioequivalence assessment of CBZ matrix tablets 
Criterion  Description 
1 Any history of hypersensitivity to carbamazepine or any other related anti-epileptic. 
2 Any history of cardiac, liver or renal dysfunction. 
3 Any history of adrenal or pituitary insufficiency. 
4 Any history of chronic asthma, bronchitis or other bronchospastic conditions. 
 
5 Any history of epilepsy or other convulsive disorders or of mania. 
 
6 Any history or other condition which the study physician regards as clinically 
significant to the study (including fainting upon blood sampling). 
 
7 Any history of drug or alcohol abuse, or the use of tobacco, within two months of the 
study start date. 
 
8 Treatment with any drug known to have a well-defined potential for toxicity to one of 
the major organs, particularly renal and hepatic toxicity, within 3 months of the study 
start date. 
9 Treatment with any drug, which could modify renal excretion of drugs (eg. probenicid) 
within 1 month of the study start date. 
 
10 The intake of a restricted or abnormal diet for longer than 1 week within 4 weeks of the 
study start date. 
 
11 Maintenance therapy with any drug or regular use of chronic medication. 
 
12 A major illness considered to be clinically significant by the study physician within 3 
months of the study start date. 
 
13 Participation in another study or the donation of one pint or more of blood within 1 
month of the study start date. 
 
14 A positive test for Hepatitis B surface antigen, Hepatitis C or HIV. 
 
15 Treatment with any prescription drug within one week of the study start date, unless the 
drug is considered to be clinically insignificant by the study physician. 
 
16 Treatment with any OTC drug within one week of the study start date, unless the drug 
is considered to be clinically insignificant by the study physician. 
 
17 The consumption of alcohol or other enzyme inducing agents within 96 hours of the 
start of the study (all barbiturates,corticosteriods, phenylhydantoins etc). 
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8.4.4 Concomitant Medication and Subject Restrictions 
 
No prescription or OTC medication such as cold remedies, vitamins and natural products 
used for therapeutic benefits or antacids were allowed for at least one week prior to the 
commencement of the study.  Any medication taken between the screening medical and 
dosing was assessed for its potential effects on the study and subjects were excluded if 
necessary.  With the exception of the study drugs, the subjects took no medication for the 
entire duration of the study. 
 
The consumption of alcohol was prohibited from 96 hours prior to dosing until the last 
sample of each phase had been taken and following phase two, until the post-study clinical 
investigations had been completed. 
 
Caffeine-containing beverages and foods such as tea, coffee, cola drinks and chocolate were 
restricted by the subjects from 48 hours before dosing until the last sample of each phase 
had been taken. 
 
Strenuous physical activity was not undertaken by the subjects from 24 hours prior to the 
commencement of each phase and was prohibited until the last sample of phase 1 had been 
taken, and until the post-study clinical investigations after phase two had been completed. 
Subjects were to have ceased smoking for at least 2 months prior to the commencement of 
the study and were to refrain from smoking until the end of the second phase after the last 
sample has been withdrawn. 
 
8.5 Pre- and Post-Study Medical Screening 
 
Pre-study screening was conducted not more than 30 days prior to the start of Phase 1 and 
post-study screening was conducted within 48 hours of the final sample of Phase 2 having 
been drawn or at the termination of the study. 
 
A full physical medical examination was conducted for each subject and the demographic 
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data documented.  The physical examination assessed height and weight to determine the 
Body Mass Index of each subject, vital signs such as BP, pulse and oral temperature, skin, 
head-neck, thyroid, eyes, ears-nose-throat, chest, lungs, heart, 10-lead ECG, neurological, 
musculoskeletal, abdomen, nutritional status and jaundice, anaemia, cyanosis, clubbing, 
oedema and lymphadenopathy (JACCOL). 
 
Haematological assessment included tests for haemoglobin, total and differential red cell 
count, haematocrit, total and differential white cell count, platelet count and sedimentation 
rate.  Blood chemistry assessments were also performed and included tests for sodium, 
potassium, chloride, urea, creatinine, cholesterol, random glucose,  total protein, albumin, 
total and conjugated bilirubin, alkaline phosphatase, GGT (glutamyl transpeptidase), ALT 
(alanine transaminase), AST (aspartate transaminase) and urate concentrations. 
 
Urine analysis was also undertaken and included checking the appearance of the urine and 
testing for glucose, ketones, blood, protein, nitrite, specific gravity, pH, leucocyte esterase, 
bilirubin,  urobilinogen and microscopic examination, if positive, for sediment. 
 
The subjects received counselling and provided informed consent documents for the 
purposes of HIV testing.  Blood analysis to detect the presence of antigens for Hepatitis B 
and C were also undertaken. 
 
 
8.6 Sample Collection 
 
Sample collection times were defined according to published pharmacokinetic data for CBZ 
in human subjects.  A summary of selected pharmacokinetic parameters that have been 
reported for CBZ sustained-release dosage forms and that was used to define the sampling 
protocol following drug administration for this study are listed in Table 8.4. 
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      Table 8.4 Pharmacokinetic data reported for CBZ  (Mean ±SD %). 
Reference Subjects n Dose 
mg 
Cmax 
μg/mL 
Tmax 
hr 
AUC0-t 
μg/mL/hr 
t½ 
hr 
176 Healthy male 30 Test 400 
Ref  400 
2.9±0.4 
3.1±0.5
23±5.8 
24±6.7 
236±53 
256±59 
38±7 
38±8 
187 Healthy male 
and female 
16 
4 
Test 400 
Ref  400 
2.32 13.8 
7.1 
157.4 
163.3 
 
180 Healthy male 24 Test 400 
Ref  400 
2.0±0.3 
2.3±0.2
23±8.4 
15.8±7.3
2.9±0.4 
3.1±0.5 
31.1±4.2 
30.8±4.4
 
Based on the information described in Table 8.4, blood samples were withdrawn and 
collected into Vacutainer® tubes (BD Vacutainer Systems, Blliver Industrial Estate, 
Plymouth, UK) containing EDTA as an anticoagulant, prior to dosing and subsequently at 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 24, 36, 48 and 72 hours after dosing.  A total of 15 
samples were collected from each subject for each phase, where the total volume of blood 
withdrawn from each subject, including pre- and post-study blood screening, did not exceed 
340ml for the duration of the study. 
 
Blood samples were stored in an ice-bath immediately after phlebotomy until centrifugation 
commenced. Centrifugation commenced within 30 minutes of sample withdrawal. Duplicate 
aliquots of plasma were placed in polypropylene tubes (Simport, Beloell, Canada), which 
were stored at –80°C ± 10°C until analysis. At the end of each phase, samples were stored 
on ice and couriered to the analytical facility within four hours of packing.  
 
 
8.7 Sample Analysis 
 
All CBZ concentrations were determined in plasma samples using a suitably sensitive and 
validated analytical method by Dr. Du Buisson and partners (East London, Eastern Cape, 
South Africa). 
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8.7.1 Reagents 
 
1% CBZ polyclonal sheep antiserum in phosphate buffer with protein stabilisers preserved with 
sodium azide was used for the analysis.  The sample pre-treatment solution consisted of 
surfactant in phosphate buffer preserved with sodium azide.  A 0.01% CBZ fluorescein tracer in 
phosphate buffer containing surfactant and preserved with sodium azide was used as the 
competing agent on the protein binding sites. 
 
8.7.2 Method 
 
CBZ plasma concentrations were measured according to a suitably sensitive, assay procedure 
using an Abbott AxSYM® (Abbott Diagnostics, Abbott Park, IL, USA) system. 
 
The AxSYM® CBZ assay is a reagent system for the quantitative measurement of CBZ in serum 
or plasma.  The method is based on Fluorescence Polaristation Immunoassay (FPIA) technology.  
The sample for analysis and all AxSYM® CBZ reagents required for one test were pipetted by 
sampling probe into various wells of a reaction vessel.  The sample and Solution 4, the line 
diluent, were pipetted into one well of the reaction vessel.  Thereafter, an aliquot of the 
predilution mixture, pretreatment solution and Solution 4 were transferred to the cuvette of the 
reaction vessel.  The reaction vessel was immediately transferred to the processing centre where 
further pipetting was performed with the processing probe. 
 
A second aliquot of the predilution mixture was transferred to the cuvette along with the CBZ 
antiserum antibody and the CBZ fluorescein tracer, in the Processing Centre.  CBZ from the 
sample and the CBZ fluorescein tracer compete for binding sites on the antibody molecule and 
the FPIA optical assembly measured the resultant intensity of the polarized fluorescent light. 
 
All plasma samples collected in these studies were analysed using this method of quantitation. 
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CBZ is metabolized to an active metabolite, the 10,11-epoxide, which was not measured for the 
purposes of these studies and the resultant concentrations reflect blood levels of the parent 
molecule only. 
 
 
8.8 Statistical Analysis 
 
Carbamazepine plasma concentration time profiles were constructed from the blood level 
data received from the analytical laboratory.  Pharmacokinetic and statistical parameters 
were calculated using the SAS (SAS Institute Inc., Cary, NC, USA) statistical package and 
the relevant parameters that were calculated are defined in Table 8.5. 
 
It was not possible to conduct an Analysis of variance (ANOVA) test for these data, as the 
power of the study was too low.   
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Table 8.5 Definitions of pharmacokinetic and statistical parameters used to analyse 
                CBZ blood level data 
 
Abbreviation Definition 
Cmax The maximum concentration of carbamazepine in a subject’s plasma 
Clast The last measurable concentration 
Tmax The sample time at which the Cmax was attained. If this occurs at more than one 
time point, it is defined as the first time point with this value (hour). 
 
Tlast The time of last quantifiable concentration (hour). 
TLin The time point where log linear elimination begins (hour). 
AUC0 - T The cumulative area under the plasma concentration vs. time curve from time zero 
to the last measured or measurable concentration, determined using the trapezoidal 
rule. 
 
AUC0 - ∞ The area under the extrapolated plasma concentration vs. time curve from time zero 
to infinity calculated as the sum of AUC 0 - T and Clast/kel. 
 
AUC0 - T/0 - ∞ The percent ratio of AUC 0 - T to AUC 0 - ∞ as a measure of the extent to which the 
elimination of the drug was followed. 
 
kel The apparent first-order terminal elimination rate constant calculated by linear 
regression of the terminal linear portion of a semi-logarithmic plot of plasma 
concentration vs. time using at least the last three measurable concentrations. 
 
T1/2el Mean elimination half-life (hour). 
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8.9 Results and Discussion 
 
Both subjects successfully completed both phases of the study.  The resultant mean plasma 
concentration versus time profiles following analysis of blood samples are depicted in Figure 8.1 
and a summary of the resultant plasma concentrations used to plot these curves are summarized 
in Appendix III. During the first phase, subject one, expressed signs of significant drowsiness at 
approximately twelve hours post-dose.  Similarly, subject two when administered the test 
product also reported sleepiness, however, at approximately fifteen hours post-dose.  The 
volunteers reported no other side effects and no adverse event occurred that, may or may not 
have been related to the conduct of the study.  In vivo, differences in absorption rates may be 
reflected by the occurrence of side effects, where central nervous system effects have been 
reported to be significantly more common when immediate release tablets that promote rapid and 
fast absorption are used [176,178,172].  
 
As is the norm for bioequivalence testing for the purposes of registration of generic drug 
products, the rate of absorption is reflected by evaluation of Cmax and the tmax [178].  The mean 
Cmax obtained for the test tablet formualtion and Tegretol® CR was to be 13.10µmol/l and 
9.45µmol/l, respectively.  The average time to reach maximum plasma levels was found to be 
35.00 and 29.50 hours for the test and reference formulations, respectively.  The time taken of 
approximately 35 hours to reach maximum concentration for CBZ from the test matrix tablet was 
found to be similar for both subjects.  Point estimate ratios for the log-transformed data are 
shown in Table 8.6 and both values fall between the margin of 0.8 and 1.25. The 
pharmacokinetic parameters determined for both subjects for Phases one and two, are 
summarised in Tables 8.7 and 8.8 respectively. 
 
Table 8.6 Point estimate ratios for Cmax and AUCT using log transformed data 
Mean AUCT Ratio Mean Cmax Ratio 
1.23 1.16 
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In order for a generic product to be approved by the FDA or other regulatory agency and rated 
therapeutically equivalent, the 90% confidence limits for the ratio of the mean of the log-
transformed data for AUClast or AUCT and Cmax of the generic and reference product must 
usually fall within 80 – 120% or 0.8-1.25  [178,186-188].  The three classic pharmacokinetic 
parameters used to assess bioequivalence are AUCT or area under the curve to the last 
measurable concentration, Cmax and Tmax [8,176,178,180,182,189] and these were the 
parameters that were calculated to compare the test and reference formulations in these studies.  
It has been reported that Cmax should be the characteristic of choice for the rate of absorption in 
single-dose studies with CBZ products [178].  Consequently evaluation of the point estimate 
ratio for Cmax would be of importance in assessing equivalence. Notwithstanding the small 
sample and low power of this study, it is evident that the point estimates of the ratio of AUCT 
and Cmax fall within the conventional 0.8 –1.25 90% confidence interval. These results provide 
evidence that the test formulation has the potential to be developed further to produce a generic 
sustained release CBZ product. Further, it must be noted that Cmax and Tmax are single-point 
observed parameters, and may be misleading when comparing flat, plateau like or multiple-peak 
concentration-time curves obtained after dosage of sustained-release formulations [176,190].  
Furthermore, the values obtained for these parameters are also dependant on the sampling 
schedule used during a study and that may introduce significant experimental error if the 
maximum plasma concentrations and/or time to reach that concentration are not appropriately 
characterized [176]. 
 
Table 8.7 Pharmacokinetic and statistical results for the Test formulation for both 
                 subjects. 
ID Seq Period Cmax Tmax AUCT AUCI kel TLin T1/2el 
1 BA 2 14.60 35.00 764.75 1364.80 0.0136 24.0 50.94 
2 AB 1 11.60 35.00 591.45 925.64 0.0168 24.0 41.33 
          
Mean - - 13.10 35.0 678.10 1145.20 0.015 24.00 46.14 
SD - - 2.12 - 12.54 310.51 0.02 - 6.8 
CV - - 16.19 - 18.07 27.11 14.74 - 14.74 
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   Table 8.8 Pharmacokinetic and statistical results for Tegretol® CR for both 
                    subjects. 
ID Seq Period Cmax Tmax AUCT AUCI kel TLin T1/2el 
1 BA 1 9.80 35.00 573.00 3321.90 0.03 24.00 238.2 
2 BA 2 9.10 24.00 526.35 996.75 0.01 24.00 59.86 
          
Mean - - 9.45 29.50 549.68 2159.30 0.01 24.00 149.00 
SD - - 0.50 7.78 32.99 1644.10 0.01 - 126.10 
CV - - 5.24 26.37 6.00 76.14 84.61 - 84.61 
 
                                     
The coefficient of variability (CV) of CBZ for AUCT was approximately 12% higher for the test 
tablets than that observed for the Tegretol® CR tablets.  Notwithstanding the small sample size, 
these results suggest that CBZ may be delivered more consistently and predictably from the 
commercially available Tegretol® CR tablets than the test matrix tablets [174]. These results may 
be a consequence of the differences in the technology used to deliver CBZ or an artefact of the 
small population used in the bioequivalence study. Consistency of drug release and subsequent 
absorption is highly desirable for sustained-release dosage forms to ensure consistent blood 
levels and this is particularly critical for conditions where clinically important blood level 
concentration ranges have been established such as for CBZ, which is known to function within a 
narrow therapeutic index [174].  However, the results of these findings provide the formulation 
scientist with insight into the predictability of the in vivo performance of these dosage forms.  
 
The average blood level profiles for both products are depicted on a Cartesian plot in Figure 8.1.  
Visual assessment of these profiles reveals that both the test and reference products released 
CBZ at equivalent rates as indicated by the similar blood levels achieved, for the first twelve 
hours after dosing.  A key feature of this assessment is the attainment of measurable blood levels 
for the test formulation, which provides confidence in the ability and potential of these dosage 
forms to deliver the API in controlled and sustained manner. 
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Figure 8.1 Cartesian plot of the mean blood level profiles of both the test and the  
reference products 
 
  
Low peak to trough variability is also important for sustained-release dosage forms to ensure that 
the lowest attained levels are in the therapeutic range while the peak levels do not exceed the 
limits of toxic drug concentration [174].  The effective therapeutic range as previously reported 
in Section 1.5.6 is 16 to 50µmol/l or 4 to 12µg/ml on chronic therapy to maintain seizure control.  
Peak to trough levels ratios of 50% or more are less desirable [174].  The mean Cmax for the 
matrix test formulation and Tegretol® CR were 13.1 and 9.7 μmol/l, respectively (Appendix III), 
and the mean Cmin values for the test matrix tablets and Tegretol® CR were 1.35 and 2.6 µmol/l.  
The variation between peak and trough levels is higher for the matrix tablets and this 
corresponds with the higher CV for matrix tablets.  However, these variations are based on a 
single dose and further investigative studies must be conducted to determine the extent of peak to 
trough fluctuations following chronic dosing. 
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The Cartesian plasma drug level concentration profiles for subjects 1 and 2, for both test and 
reference products are depicted in Figures 8.2 and 8.3, respectively.  Both subjects showed 
symptoms of extreme drowsiness approximately 12 - 14 hours following administration.  The 
subjective assessment by the subjects are substantiated by the plasma profiles where drug levels 
show a dramatic increase in concentration after twelve hours and this effect appears to be 
consistent for this product in both subjects. 
 
CBZ has significant CNS effects and neuron activity is decreased as a result of its physiological 
effects as has been mentioned in Chapter 1.  The decreased neuronal activity could account for 
the onset of decreased mental alertness in both subjects as the plasma levels of CBZ increased 
dramatically, twelve hours following administration. 
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Figure 8.2  Resultant plasma concentration versus time profiles for subject 1 following  
                        administration of the test (Phase 1) and reference (Phase 2) products  
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Figure 8.3  Resultant plasma concentration versus time profiles for subject 2  
following administration of the test (Phase 2) and reference (Phase 1)  
products  
 
A mean semi logarithmic plot of CBZ plasma concentration versus time profiles for both the test 
and reference products is depicted in Figure 8.4. It is clearly evident from a visual assessment of 
these profiles that the two products appear to perform similarly in vivo. For the purposes of 
comparison, point estimates of the mean log transformed data for Cmax and AUCT were 
calculated and are listed in Table 8.6. However, as the study population was small such 
comparisons must be made with caution. 
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Figure 8.4  Semi-logarithmic plot of the mean (n=2) plasma concentration of CBZ  
for both test and reference products. 
 
 
CBZ is very sensitive to moisture and the degree of hydration will affect in vitro and in vivo 
dissolution rates and the altered dissolution rate may result in the incidence of adverse side-
effects such as, for example, sedation.  The altered dissolution rates could account for the 
seemingly erratic plasma profile observed for the reference product for both subjects depicted in 
Figure 8.5, where the sustained-release beads in the dosage form may release CBZ at varying 
rates which, may account for the erratic plasma profile seen for subject one at twelve hours 
following administration of Tegretol® CR.  Tegretol® CR uses coated beads compressed into a 
tablet and this may pass through the pyloric sphincter in a random manner further complicating 
the in vivo release and absorption patterns of CBZ. The use of different controlled-drug release 
technologies between the test and reference products may account for individual differences 
observed between the two subjects, for both products. 
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Figure 8.5 Plasma CBZ concentrations obtained following administration of the reference 
                   product, Tegretol® CR to subjects 1 and 2. 
 
 
 
The blood level profiles for the test formulations in both subjects are depicted in Figure 8.6. It is 
obvious that there is a significant increase in the amount of CBZ that is absorbed approximately 
12 hours after dosing.  The steep rise in drug levels may be a consequence of the physical 
collapse of the dosage form due to peristaltic forces present within the GIT.  Therefore, a large 
dose of the API becomes readily available for absorption.  Since this phenomenon seems to have 
occurred in both subjects, it is highly likely to be a function of the dosage form design rather 
than due to physiological factors that can affect dosage form performance.  Furthermore this 
increased release of CBZ corresponds closely, with the onset and report of drowsiness 
experienced by the subjects during these studies. 
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Figure 8.6 Plasma CBZ concentrations obtained following administration of the test 
                  matrix tablets for subjects 1 and 2  
 
 
The reference product, Tegretol® CR disintegrates within fifteen minutes during in vitro 
dissolution testing, to release beads that deliver CBZ in a controlled manner thereafter. 
Therefore, the transport and integrity of the beads may not be significantly affected when passing 
through the pyloric sphincter and thus the sharp rise in CBZ levels is not observed in the plasma 
profiles obtained following the oral administration of the reference product, Tegretol® CR.   
Furthermore the dramatic increase in CBZ blood levels observed at approximately 12 hours after 
oral administration of the test matrix tablets corresponds closely, with the onset and report of 
drowsiness experienced by the subjects during these studies. 
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8.10 CONCLUSION 
 
The primary purpose of this bioequivalence study was to show via ‘proof of concept’ that the 
sustained release test formulations, viz., the HPMC matrix tablets administered to two subjects 
clearly released sufficient CBZ, such that it was bioavailable and blood levels could be 
monitored. The results revealed that the formulation has the potential for further testing in a 
larger study population and clearly has commercial potential and ability of these dosage forms to 
effectively deliver CBZ in a sustained manner.  
 
It was not possible to conduct an ANOVA assessment of the blood level data since only two 
subjects were used in this study and in order to conduct an appropriate statistical analysis with 
sufficient power a larger study population would be required.   
 
The ultimate purpose of these studies was to provide a dosage form that could effectively control 
the release of CBZ at a rate comparable to that of Tegretol® CR.  The matrix tablets tested in the 
two subjects showed similar release rates to that of Tegretol® CR especially over the first twelve 
hours of after dosing.  
 
The use of different drug release technologies for the same route and form of delivery can show 
variations between test and reference products.  The ultimate objective is to achieve an overall 
release rate comparable to that of the reference product and to ensure that the extent of 
absorption as reported by AUCT become useful for the comparison of two seemingly dissimilar 
plasma profiles.  The dramatic increase in the plasma levels observed at approximately twelve 
hours after administration was observed for both subjects and this is more than likely a function 
of dosage form design and in vivo performance than to the influence of physiological conditions.    
 
The tablets produced for in vivo testing were large biconvex tablets weighing approximately 
800mg.  To avoid the sharp increase in drug levels that was observed, it may be possible to 
reduce the size of the dosage form or alter the shape of the dosage form to allow for easier transit 
through the GIT and thus avoid disruption to the integrity of the dosage form where dose 
dumping may become an issue during the latter stages of a dosing interval during drug therapy.  
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These tablets have shown release rates similar to that of Tegretol® CR during the first twelve 
hours which strongly suggests that these tablets may be a potential generic equivalent to 
Tegretol® CR for the treatment of epileptic patients. However, further comprehensive 
investigations must be undertaken to establish such equivalence. 
 
The formulation components of the matrix tablets produced by the direct compression method of 
manufacture as described in Section 6.2.3.2.2, effectively release CBZ in a controlled and 
sustained manner.  As mentioned previously, adjustments to the dosage form configuration may 
reduce the possibility of dose dumping from these matrix tablets but may affect the rate and 
mechanism of drug release and therefore, further assessments would be necessary. 
 
Ultimately, the availability of generic equivalent products for patients requiring anti-epileptic 
therapy will reduce the cost of chronic therapy and may in some cases, enhance therapy through 
the availability of dosage forms that perform better than the innovator product. 
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CHAPTER 9 
CONCLUSIONS 
 
The objectives of these studies were to develop and assess sustained-release formulations 
of a hydrophobic API, viz., CBZ.   Sustained-release drug delivery systems are designed 
to deliver a constant amount of drug in the GIT, which in turn allows for the controlled 
absorption and subsequent maintenance of relatively constant plasma concentrations, 
which is vital for a drug such as CBZ that has a narrow therapeutic range.   In the case of 
CBZ, a reduction of plasma level fluctuations will decrease the incidence and severity of 
associated side effects such as drowsiness, general obtundity, ataxia, nystagmus, diplopia 
and headache, in particular, since these side effects are dose-dependent. 
 
The clinical use of sustained-release dosage forms can enhance anti-epileptic therapy 
through a combination of improving patient compliance by reducing the dosing 
frequency and optimizing drug delivery through the controlled and predictable release of 
CBZ. Therefore the development of a generic CBZ sustained release dosage form that 
would be equivalent to a commercially available sustained release CBZ dosage form, viz., 
Tegretol® CR, was undertaken. 
 
A modular HPLC system was used for the development and validation of an isocratic 
method for the analysis and quantitation of CBZ in pharmaceutical dosage forms and was 
applied to the assessment of dosage form performance. The analytical method was 
developed and validated according to scientifically established acceptability criteria and 
was found to be selective, sensitive, precise and accurate for the evaluation of the in vitro 
performance of test and reference products. 
 
The moisture content of the CBZ, excipients and selected batches was accurately 
determined using a standard Karl Fischer titration method. DSC  thermograms revealed 
no significant thermal shifts for CBZ, when it was assessed in combination with the  
excipients intended for use in tablet production.  Furthermore, XRPD studies revealed 
that CBZ did not show polymorphic transitions during blending, granulation and  
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and tableting and therefore, it was concluded that CBZ release rates were a function of 
dosage form design and composition rather than transformation to a low solubility 
polymorph during production. 
 
Dissolution testing using USP Apparatus 3 was found to be more applicable than USP 
Apparatus 2, for the characterization of in vitro dissolution rate profiles of the hydrophilic 
matrix sustained release dosage forms. It is likely that exposure of test tablets to fresh 
dissolution media, at predetermined times, prevented the formation of saturation 
conditions and enabled greater discrimination when testing formulations of different 
composition, than that achieved using USP Apparatus 2.   Furthermore, the use of USP 
Apparatus 3 is a more stringent test procedure that has a high degree of precision, and 
facilitates the use of a more realistic dissolution environment, through simulation of the 
GIT pH range and peristalsis.  In addition, the exposure of dosage forms to a range of 
media of different pH was considered valuable and more meaningful for assessing dosage 
form performance than exposure to a single dissolution medium, as is the case if USP 
Apparatus 2 were used to assess the dissolution rates of CBZ from the test and reference 
products, used in these studies. 
 
Dissolution rate profiles were compared using the f1 and f2 difference and similarity 
factors and the use of these factors allowed for effective and objective assessment of the 
release rate profiles.  In addition, the fit factors were used as a key criterion when 
designing and developing the ANN and were integral when attempting to find appropriate 
solutions during the application of the ANN to optimise formulation compositions. 
 
Matrix tablets were initially manufactured by wet granulation and the resultant percent 
CBZ released in vitro was found to be less than 65% of the total content. Residual 
content analysis undertaken on tablet cores that remained following dissolution testing 
revealed that the low percent CBZ released was more than likely due to the design and 
composition of the formulation and not due to low CBZ content. Therefore, direct 
compression manufacture was considered as an alternate method of production and was 
investigated for its potential to produce batches of these tablets. 
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The conversion of a wet granulation formulation to a direct compression composition 
proved successful and the direct compression method of manufacture was adopted for all 
future manufacture.  Several excipients and associated factors of potential formulations 
were assessed for their impact on CBZ release rates and adjustments were made to the 
formulations based on the resultant dissolution profiles, where drug release was either 
enhanced or prolonged through manipulation of the specific variable being assessed.  The 
effects of the factors evaluated, served as a reference to determine whether these 
variables significantly affected CBZ release rates from the early test formulations.  The 
effect of using fine particle size grade CBZ on release performance from these dosage 
forms was also ascertained and further optimisation of formulations was achieved by use 
of the fine and coarse grade CBZ in different combinations. Variation of the proportions 
of the different particle size grades of CBZ, yielded more defined drug release rate 
profiles that could be modified depending on the content of the respective particle size 
grade of CBZ used. 
 
The effects of tablet components such as the type, grade and proportion of the HPMC 
polymer used during formulation, significantly influenced drug release rates from these 
matrix tablets where the use of a lower viscosity grade HPMC revealed a greater rate and 
extent of CBZ release from tablets.  The incorporation of a surfactant in the formulation 
composition even at low concentrations further enhanced the rate and extent of drug 
release from these dosage forms. 
 
Test tablets from the batch produced for in vivo testing and stored under accelerated 
conditions showed the greatest increase in moisture content compared to tablets from the 
same the batch stored under ambient conditions, had a moisture content well within 
specification.  The results of preliminary stability testing provided insight into the 
potential long term viability of these tablets and revealed that the packaging would be a 
critical consideration during future formulation development studies and where the use of 
a protective non-functional aesthetic coating may also be required to maintain the 
physical integrity and acceptability of tablets for an extended period of time, in particular 
in high humidity climates. 
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The mechanisms by which drug was released from the formulations produced during 
these studies was found to be diffusion controlled or to occur via a process termed 
anomalous transport, when evaluating the release exponent n, derived from the 
Korsmeyer-Peppas model. Several of the formulations studied showed evidence of 
diffusion controlled release as square root of time plots for the first six hours and in a 
number of cases over the entire 22-hour dissolution test period were found to be linear 
following least squares linear regression analysis. However matrix dissolution or erosion, 
which is an important feature of swellable and erodible systems, is not considered in the 
Higuchi model and therefore mechanistic information about drug release that is derived 
using this model should be viewed and assessed with caution [103].   
 
Values of n , derived following modelling of drug release data, that are suggestive of 
diffusion-controlled release are more than likely reflective of polymeric erosion rates that 
are slower than the rate of release of CBZ from the tablets and therefore diffusion of CBZ 
within the dosage form is a far more significant than the effects of polymeric dissolution, 
at that stage of the release process.  These effects become formulation specific since 
different formulations produced different results following assessment of their dissolution 
profiles using modelling techniques.  
 
A ‘first-order decay’ model was developed and applied to the assessment of the resultant 
dissolution data. The model is able to describe drug release for the entire dissolution 
profile whereas the ‘power law’ as described by Peppas et. al. is only applicable to the 
first 60% of drug release.  The parameters of the ‘first-order decay’ model were also 
related to the ‘power law’ and strong correlations were found to exist between the n 
values derived from the ‘power law’ and the r values derived from the ‘first-order decay’ 
model. The correlations that have been derived, suggest that the r values can be used to 
gain insight into mechanistic information pertaining to CBZ release when using model. 
Consequently the ‘first-order decay’ model provides another mathematical tool to predict 
and describe drug release from the HPMC based matrix tablets. 
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Polymer erosion and dissolution may become more significant in affecting drug release 
where the concentration and viscosity grade of the polymer become relevant in 
determining gel layer thickness and degree of erosion during extended dissolution testing. 
 
Synchronisation of the swelling and erosion fronts during the release process is 
associated with zero-order drug release and this is true for drug release from surface 
erodible systems with flat sheet geometry.  CBZ release from tablets produced during 
these studies did not show zero-order drug release ( n  = 1), more than likely as a result of 
the geometry of these dosage forms. The biconvex shape of the tablets produced during 
these studies makes it theoretically impossible for CBZ to be release via a zero-order 
release process, since as the system erodes, which is the case with most polymers the 
surface area exposed to the dissolution fluid continually decreases, i.e., the diffusion path 
for drugs increases in length. 
 
The resultant values of n  = 1 for the matrix devices developed and assessed during these 
studies emphasize that release from these dosage forms is not Fickian controlled and 
implies large contributions to drug release kinetics by erosion of the polymer. 
 
An ANN was designed and developed based on the existing CBZ release rate data that 
had been obtained during the early phases of these studies. The ANN was trained and 
applied to the prediction of formulation compositions and associated dissolution rate 
profiles.  The ANN that as developed added to the versatility of dosage form design and 
provided another tool to predict formulation composition to match specific drug release 
rate profiles, such as for example that of the reference product, Tegretol® CR.  The 
parameters introduced to the ANN and subsequently used to train the network did not 
include manufacturing process effects, such as for example, method of manufacture and 
the effects of tablet hardness on drug release rates.  Additional comprehensive and 
tailored experimental studies would have to be conducted to create a network that would 
predict formulations for which consideration of these factors have been included.  The 
formulation that was ultimately adopted for in vivo analysis, was an empirically modified 
version of a formulation predicted by the ANN.  The formulations developed prior to the 
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application of the ANN were not comparable to that of the Tegretol® CR tablets, during 
the first hour of dissolution testing. However, although the neural network predicted 
formulation had to be further adjusted, the resultant in vitro dissolution profile of CBZ 
from the tablets produced from the predicted formulation, matched that of CBZ from 
Tegretol® CR, especially during the first hour of the test.  The ANN was designed such 
that the highest weighting for the f1 and f2 fit factors were applied to the release rate data 
for the first hour of dissolution testing, so as to match more precisely the release rate of 
CBZ from the Tegretol® CR tablets during this time. 
 
The size of the network training data set of 36 input and output data pairs, can be 
considered small and in conjunction with insufficient weight allocation may account for 
the discrepancies observed between the ANN predicted and actual target results.   
 
The resultant sustained-release matrix tablets were designed with the intention for use in 
human subjects. Therefore, since the test and reference product dissolution rate profiles 
were similar, additional tablets were produced and assessed in vivo.  The primary purpose 
of the in vivo study was to show that the sustained release test formulation, viz., the 
HPMC matrix tablets released sufficient CBZ, such that it was bioavailable and that 
blood levels could be monitored. Furthermore, the same subjects were administered 
Tegretol® CR tablets for comparative purposes. The results following analysis of plasma 
samples revealed that the test formulation has potential for further testing in a larger 
study population and is clearly a commercial prospect. Furthermore the test product can 
effectively deliver CBZ in a sustained manner over a 24-hour period and may be further 
assessed for its potential to be used as a once-daily delivery system. 
 
Although bioequivalence could not be established due to the small study population and 
low power of the study, the results of the in vivo testing in two human subjects were 
considered adequate to show that these dosage forms produced plasma concentration 
versus time profiles for CBZ that are comparable to that obtained when Tegretol® CR 
tablets were administered.  The ultimate purpose of these studies was to provide a dosage 
form that could effectively control the release of CBZ at a rate comparable to that of 
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Tegretol® CR.  The matrix tablets tested in the two subjects showed similar release rates 
to that of Tegretol® CR especially over the first twelve hours following oral 
administration.  It is clear that the potential exists for these dosage forms to release their 
drug load in a sustained and controlled fashion without ‘dose-dumping’ immediately 
following administration and that would have become evident by subjects presenting with 
severe and adverse side effects. 
  
The availability of generic products for patients requiring anti-epileptic therapy will 
reduce the cost of chronic therapy and may in some cases, enhance therapy through the 
availability of dosage forms that perform in vivo such that they are equivalent to the 
innovator product.  
 
Further development and assessment of the aforementioned dosage forms are required to 
ascertain whether improvements to the formulation can be made such that stability, in 
vitro and in vivo performance can be enhanced. In addition, the results of the in vivo 
study revealed that the HPMC based polymeric tablets produced in these studies have the 
potential for being developed into a product that performs better than the innovator 
product. Furthermore, it may be possible to achieve similar plasma concentration time 
profiles to that obtained for CBZ from the Tegretol® CR tablets using a lower dose of 
CBZ, which would reduce the possibility and incidence of unwanted side effects that may 
reduce patient compliance. 
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